CLINICAL STUDY PROTOCOL  
NCT Number:  
Study  Title:  
Study  Number:  [STUDY_ID_REMOVED]  
A Phase 1/1b Study of Pevonedistat in Combination With Select 
Standard of Care Agents in Patients With Higher -Risk 
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, 
Acute Myelogenous Leukemia, or Advanced Solid Tumors With Severe Renal Impairment  or Mild or Moderate Hepatic Impairmen t
 
Pevo
nedistat- 1016
Protocol  Version and Date: 
Version 4.0: 01-June-2 021 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
1.0 TITLE PAGE
PROTOCOL
A Phase 1/1b Study of Pevonedistat in Combination With Select Standard of Care Agents in 
Patients With Higher -Risk Myelodysplastic Syndromes, Chronic Myelomonocytic 
Leukemia, Acute Myelogenous Leukemia, or Advanced Solid Tumors With Severe Renal 
Impairment or Mild or Moderate Hepatic Impairment
Pevonedistat Plus Select Standard of Care Agents Administered in Cancer Patients
With Renal or Hepatic Impairment
Sponsor: Takeda De velopment Center Americas, Inc. 
95 Hay den Avenue
Lexington, MA 02421
Study Number: Pevonedistat -1016
EudraCT Number: 2018-004049-17
Compound: Pevonedistat (TAK -924/MLN4924) 
Date: 27 May  2021 Version/Amendment 
Number:4
Amendment History:
Date Amendment No. Amendment Type Region
27 May  2021 4 Substantial Global
04 November 2020 3 Substantial Global
29 June 2020 2 Substantial Global
25 February 2019 1 Substantial Global
07 November 2018 Initial protocol Not applicable Global
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement by 
the recipient that no information contained herein will be published or disclosed without written authorization from 
Takeda except to the extent necessary to obtain informed consent from those persons to whom the drug may be 
administered. Furthermore, the information is only meant for review and compliance by the recipient, his or her staff, 
and applicable institutional review committee and regulatory agencies to enable conduct of the study.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 2of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL1.0 ADMINISTRATIVE INFORMATION
1.1 Contacts
A separate contact informat ion list will be provided to each site.
Serious adverse event (SAE) and pregnancy reporting informat ion is presented in Secti on10.0, as 
is informat ion on reporting product complaints.
Takeda Development Center–sponsored invest igators per individual country requiremen ts will be 
provi ded wi th emergency  medical  contact inform ation cards to be carried by  each subject.
General advice on protocol procedures should be obtained through the monitor assigned to the 
study  site. Inf ormation on service providers is given in Sect ion3.1and relevant guidelines 
provi ded to the si te.
Contact Type/Role North America Europe
Serious adverse event and pregnancy reporting See Section 10.0 See Section 10.0
Medical Monitor
(medical advice on protocol and compound)Refer to Study Manual Refer to Study Manual
Responsible Medical Officer
(carries overall responsibility for the conduct of the 
study)Refer to Study Manual Refer to Study Manual
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 3of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL1.2 Approval
REPRESENTATIVES OF TAKEDA
This study  will be conducted with the highest respect for the individual part icipants in accordance 
with the requi rements of this clinical study  protocol and also in accordance wit h the fo llowing:
The ethical principles that have their origin in the Declarati on of  Helsinki.
International Council for Harmonisat ion (ICH) E6 Good Clinical Pract ice (GCP): 
Conso lidated Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws, clinical 
trial discl osure l aws, and r egulations.
SIGNATURES
The signature of the responsible Takeda medical officer (and other signatories, as applicable) can 
be found on the signature page.
Electronic Signatures may  be found on the l ast page of thi s docum ent.
 MD
(or designee)Date  PhD
(or designee)Date
 PhD
(or designee)Date  PhD
(or designee)Date
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 4of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALINVESTIGATOR AGREEMENT
I confirm that I have read and that I understand this protocol, the Invest igator’s Brochure, 
prescribing information, and any other product information provided by the sponsor. I agree to 
conduct thi s study  in accordance wit h the requirements of this protocol  and also to protect the 
rights, safet y, privacy, and well -being of study  subjects in accordance wit h the fo llowing:
The ethical principles that have their origin in the Declaration of Helsinki.
International Council for Harmonisat ion, E6 Good Clinical Practice: Conso lidated Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serious adverse events (SAEs) defined in Section 10.0
of this protocol .
Terms outlined in the clinical study  site agreement.
Responsibilit ies o f the invest igator (Appendix C).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Cof this protocol .
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provi nce)
Locati on of  Facilit y (Country )
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 5of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL1.3 Protocol Amendment 4 Summary of Changes
Protocol Amendment 4 Summary and Rationale :
This sectiondescribes the changes in reference to the protocol incorporating Amendment 4.The 
primary  reason for this amendment is to update the name of the legal ent ity to Takeda 
Development Center Americas, Inc. and to update its address. In addit ion, the text on the posttrial 
access (PTA) program and its durati on are clarified, a cl arificat ion in the schedule o f events is 
provi ded, and a corrected study  diagram is provi ded.
In thi s amendment, minor grammat ical, editorial, formatting, and administrative changes not 
affect ing the conduct of the study  are included for clarification and administrative purposes only.
Protocol Amendment 4
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Change Description of Each Change and Rationale
Location Description Rationale
1. Title page
Section 2.0STUDY 
SUMMARY
Section 3.4Corporate 
IdentificationUpdated the name and address 
of legal entity to Takeda 
Development Center Americas, 
Inc., 95 Hayden Avenue, 
Lexingto n, M A 02421Update to name of the legal entity 
and its address.
2. Section 6.3.5 P TA Updated and clarified text on 
the posttrial access program 
and its duration.Change made to include the current 
approach by the sponsor.
3. Section 7.2Exclusion 
Criteria Item 20.Added multigated acquisition scan 
for the determination of left 
ventricular ejection fraction
(LVEF) at screening.Change made to increase flexibility 
of measurements.
4. Appendix ASOE
SOE for Part A: Single Agent 
Pevonedistat and PK (All 
Patients) FootnotesUpdated Schedule of Events 
(SOE) table to include (LVEF) 
screening timing.Clarified timing of LVEF in the SOE 
previously included in the Exc lusion 
Criteria.
5. Appendix BStudy Diagrams Replaced Study Diagram for 
patients with hematologic 
malignanciesCorrection of an error in the 
designation of study days in Part A of 
the Study  Diagram (no change made 
to study conduct/asses sments).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 6of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALTABLE OF CONTENTS
1.0 ADMINISTRATIVE INFOR MATION ........................................................................... 2
1.1 Contacts ..................................................................................................................... 2
1.2 Approval .................................................................................................................... 3
1.3 Protocol  Amendment 4 Summary  of Changes ............................................................ 5
2.0 STUDY SUMMARY .................................................................................................... 12
3.0 STUDY REFERENCE INFO RMATION ...................................................................... 20
3.1 Study -Related Responsibilit ies................................................................................. 20
3.2 Principal Invest igator/Coordinating Invest igator ...................................................... 20
3.3 List of Abbreviat ions............................................................................................... 21
3.4 Corp orate Identificat ion........................................................................................... 23
4.0 INTRODUCTION ......................................................................................................... 24
4.1 Background ............................................................................................................. 24
4.1.1 Study  Drug ...................................................................................................... 24
4.1.2 Nonclinical Background .................................................................................. 25
4.1.3 Clinical Background Information ..................................................................... 25
4.1.4 Potenti al Risks and Benefits ............................................................................. 28
4.1.5 Potenti al for DDIs ............................................................................................ 33
4.1.6 Summary  of Risks and Benefits ....................................................................... 33
4.2 Rationale for the Proposed Study ............................................................................. 34
4.3 Rationale for the Dose ............................................................................................. 35
5.0 STUDY OBJECTIVES AND ENDPOINTS .................................................................. 38
5.1 Object ives................................................................................................................ 38
5.1.1 Primary Obje ctives.......................................................................................... 38
5.1.2 Secondary  Object ives...................................................................................... 39
5.1.3 Safety Objective .............................................................................................. 39
5.1.4 Exploratory  Objectives .................................................................................... 39
5.2 Endpoints ................................................................................................................. 39
5.2.1 Primary Endpo ints........................................................................................... 39
5.2.2 Secondary  Endpo ints....................................................................................... 40
5.2.3 Exploratory  Endpo ints..................................................................................... 40
5.2.4 Safety Endpo ints.............................................................................................. 40
6.0 STUDY DESIGN .......................................................................................................... 40
6.1 Overview of Study  Design ....................................................................................... 40
6.2 Number of Patients .................................................................................................. 42
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 7of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL6.3 Durati on of  Study .................................................................................................... 42
6.3.1 Durati on of  an Individual Pat ient’s Study  Parti cipati on.................................... 42
6.3.2 End of Study /Study  Com pletion Definit ion and Pl anned Reporting .................. 43
6.3.3 Timeframes for Primary and Secondary  Endpo ints to Support Disclosures ......43
6.3.4 Total  Study  Durati on....................................................................................... 44
6.3.5 PTA ................................................................................................................. 45
7.0 STUDY POPULATION ................................................................................................ 45
7.1 Inclusio n Cri teria................................
..................................................................... 45
7.1.1 All Patients...................................................................................................... 45
7.1.2 Patients Wi th Hematol ogic Malignancies ......................................................... 46
7.1.3 Patients Wi th Advanced Solid Tumors ............................................................. 47
7.2 Exclusio n Cri teria.................................................................................................... 48
7.2.1 All Patients...................................................................................................... 48
7.2.2 Patients Wi th Hematol ogic Malignancies ......................................................... 50
7.2.3 Patients Wi th Advanced Solid Tumors ............................................................. 50
8.0 STUDY DRUG ............................................................................................................. 51
8.1 Study  Drug Administration ...................................................................................... 51
8.1.1 Instructi ons for Pevonedistat and Azacit idine Dosing ....................................... 54
8.1.2 Instructi ons for Pevonedistat and Docetaxel Dosing ......................................... 55
8.1.3 Instructi ons for Pevonedistat and Carbop latin Plus Paclitaxel Dosing .............. 55
8.2 Reference/Control Therapy ...................................................................................... 56
8.3 Dose Modificat ion Guidelines .................................................................................. 56
8.3.1 Dose Modificat ions for Hematologic Toxicit ies............................................... 56
8.3.2 Dose Modificat ions for Nonhematologic Toxicit ies......................................... 58
8.3.3 Intrapatient Dose Escalation (Part B)............................................................... 60
8.4 Excluded Conco mitant Medi cations and Procedures ................................................ 61
8.5 Permi tted Concomitant Medications and Procedures ................................................ 62
8.6 Precauti ons and Restri ctions.................................................................................... 63
8.7 Management of Clinical Events ............................................................................... 65
8.7.1 Combinat ion Pevonedistat Plus Standard of Care Agents .................................65
8.8 Blinding and Unblinding .......................................................................................... 66
8.9 Descript ion of Invest igational Agents ...................................................................... 67
8.9.1 Azacit idine...................................................................................................... 67
8.9.2 Pevonedistat .................................................................................................... 67
8.9.3 Docetaxel, Carboplatin, and Paclitaxel ............................................................. 67
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 8of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL8.10 Preparati on, Reconstitution, and Dispensat ion.......................................................... 67
8.11 Packaging and Labeling ................................
........................................................... 68
8.12 Storage, Handling, and Accountabilit y..................................................................... 68
8.13 Other Protocol -Specified Materials .......................................................................... 68
9.0 STUDY CONDUCT ...................................................................................................... 69
9.1 Study  Personnel and Organizations .......................................................................... 69
9.2 Arrangements for Recruit ment of Patients ................................................................ 69
9.3 Treatment Group Assignments ................................................................................. 69
9.4 Study  Procedures ..................................................................................................... 71
9.4.1 Inform ed Consent ............................................................................................ 71
9.4.2 Inclusio n/Exclusio n Confirmat ion.................................................................... 71
9.4.3 Patient Dem ographi cs...................................................................................... 72
9.4.4 Medical History ............................................................................................... 72
9.4.5 Physical Examinat ion...................................................................................... 72
9.4.6 Patient Hei ght.................................................................................................. 72
9.4.7 Patient Weight .................................................................................................72
9.4.8 ECOG PS ........................................................................................................ 73
9.4.9 Vital Signs....................................................................................................... 73
9.4.10 Pregnancy Test ................................................................................................ 73
9.4.11 Concomitant Medications and Procedures ........................................................ 73
9.4.12 AEs ................................................................................................................. 74
9.4.13 Enrollment ....................................................................................................... 74
9.4.14 ECG ................................................................................................................ 74
9.4.15 Clinical Laboratory  Evaluat ions....................................................................... 74
9.4.16 Assessment of Hepatic and Renal Funct ion for Treatm ent Group Assignment .76
9.4.17 Disease Assessment ......................................................................................... 77
9.4.18 Biomarker, Pharmacodynamic, and PK Samples .............................................. 78
9.4.19 PK Measurements ............................................................................................ 78
9.4.20 Pharmacodynamic Measurements .................................................................... 79
9.4.21 DNA Measurements ........................................................................................ 79
9.4.22 Banked Tum or Specimen Measurements ......................................................... 79
9.5 Com pletion of Study  Treatm ent (f or Individual Patients) ......................................... 80
9.6 Com pletion of Study  (for Individual Pat ients).......................................................... 80
9.7 Discontinuati on of  Treatment Wi th Study  Drug and Pati ent Repl acement ................ 80
9.8 Withdrawal o f Patients From  Study ......................................................................... 81
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 9of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL9.9 Study  Com pliance .................................................................................................... 82
10.0 ADVERSE EVENTS .................................................................................................... 82
10.1 Definit ions............................................................................................................... 82
10.1.1 Pretreatment Event Definit ion.......................................................................... 82
10.1.2 AE Definit ion.................................................................................................. 82
10.1.3 SAE D efinit ion................................................................................................ 82
10.2 Procedures for Recording and Reporting AEs and SAEs .......................................... 83
10.3 Moni toring of AEs and Period of Observat ion......................................................... 84
10.4 Procedures for Reporting Drug Exposure During Pregnancy and Birth Events ......... 84
10.5 Procedures for Reporting Product Complaints or Medicat ion Errors (Including 
Overdose) ................................................................................................................ 85
10.6 Safety Reporting to Invest igators, IRBs or IECs, and Regulatory  Authori ties........... 85
11.0 STUDY -SPECIFIC COMMITTEES ............................................................................. 85
12.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 86
12.1 eCRFs ................................
...................................................................................... 86
12.2 Record Retention ..................................................................................................... 86
13.0 STATIST ICAL METHODS .......................................................................................... 87
13.1 Statistical and Analyt ical Plans ................................................................................ 87
13.1.1 Analysis Sets ................................................................................................... 87
13.1.2 Dem ographics and Other Baseline Characterist ics........................................... 88
13.1.3 Efficacy Analysis ............................................................................................. 88
13.1.4 PK Analysis ..................................................................................................... 88
13.1.5 Pharmacodynamic Analysis ............................................................................. 89
13.1.6 PK/Pharmacodynamic Analysis ................................ ....................................... 89
13.1.7 Immunogenicit y Analyses ................................................................................ 89
13.1.8 Safety Analysis ................................................................................................ 89
13.2 Inter im Analysis ...................................................................................................... 90
13.3 Determinat ion of Sample Size .................................................................................. 90
14.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 91
14.1 Study  Site Moni toring Visits .................................................................................... 91
14.2 Protocol  Deviat ions.................................................................................................. 91
14.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 91
15.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 92
15.1 IRB and/or IEC Approval ........................................................................................ 92
15.2 Subject Informat ion, Inform ed Consent, and Subject Authorizat ion......................... 93
15.3 Subject Confidentialit y............................................................................................ 94
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 10of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL15.4 Publicat ion, Di sclosure, and Clinical Trial Registration Po licy.................................94
15.4.1 Publicat ion....................................................................................................... 94
15.4.2 Clinical Trial Registration ................................
................................................ 95
15.4.3 Clinical Trial Result s Disclosure ...................................................................... 95
15.5 Insurance and Co mpensation for Injury .................................................................... 96
16.0 REFERENCES .............................................................................................................. 96
LIST OF IN -TEXT TABLES
Table 6.a Primary and Secondary  Endpo ints for Di sclosures ............................................. 44
Table 8.a Starti ng Doses for Patients Wit h Mild Hepat ic Impairment ................................ 52
Table 8.b Starti ng Doses for Patients Wit h Moderate Hepatic Impairment ......................... 53
Table 8.c Starti ng Doses for Pati ents Wi th Severe Renal Impai rment................................ 54
Table 8.d Dose Modificat ion Guidelines for Specific Hematologic Toxicit ies in Pat ients
With Advanced Solid Tumors ............................................................................ 58
Table 8.e Dose Modificat ion Guidelines for Specific Nonhematologic Toxicit ies in 
Patients Wi th Advance d Solid Tum ors............................................................... 60
Table 8.f Concomitant Medications Excluded While Receiving Study  Treatm ent: 
Combinat ion Pevonedistat Plus SOC agen ts....................................................... 62
Table 8.g Concomitant Medications and Procedures Permitted During the Study ............... 63
Table 9.a Laboratory  Value Requirements per Treatment Arm for eGFR, Total Bilirubin, 
and ALT (Patients Wit h Hematol ogic Malignancies Only) .................................69
Table 9.b Laboratory  Value Requirements per Treatment Arm for eGFR, Total Bilirubin, 
and ALT (Patients Wit h Advanced Solid Tumors Only) ..................................... 70
Table 9.c Hem atology Tests .............................................................................................. 74
Table 9.d Com plete Serum  Chemistry  Panel ...................................................................... 75
Table 9.e Select Serum  Chemistry  Panel ........................................................................... 75
Table 9.f Coagulation Panel .............................................................................................. 75
Table 9.g Urinalysis Wit h Microscopic Analysis ............................................................... 76
Table 9.h Primary Specimen Collection ............................................................................. 78
LIST OF APPENDICES
Appendix ASOE ................................................................................................................... 99
Appendix BStudy  Diagrams ............................................................................................... 112
Appendix CResponsibilit ies o f the Invest igator ................................................................... 113
Appendix DECOG Scal e for Perf ormance Status ................................................................ 115
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 11of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALAppendix EDefinit ion of Postmenopausal .......................................................................... 116
Appendix FAcceptable Methods of Contracepti on Considered Hi ghly Effective ................. 117
Appendix GNew York Heart Associat ion Classificat ion of Cardi ac Disease ........................ 118
Appendix HBSA Calculat ion................................
.............................................................. 119
Appendix IForm ula for ANC Calculat ion.......................................................................... 120
Appendix JResponse Criteria for MDS, CMML, AML, and Solid Tumors ......................... 121
Appendix KDrugs Associated Wit h Nephrotoxicit y............................................................ 126
Appendix LHem atologic Toxi city of Carbopl atin Alo ne and in Combinat ion Wit h 
Paclitaxel ......................................................................................................... 127
Appendix MExcluded Stro ng CYP3A Inhibitors and Inducers ............................................. 129
Appendix NProtocol  History............................................................................................... 130
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 12of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL2.0 STUDY SUMMARY
Name of Sponsor(s) :Takeda Development Center 
Americas, Inc.Compound: Pevonedistat
(TAK -924; MLN4924)
Title of Protocol: A Phase 1/1b Study of Pevonedistat in 
Combination With Select Standard of Care Agents in 
Patients With Higher -Risk Myelodysplastic Syndromes, 
Chro nic Myelom onocytic Leukemia, Acute Myelogenous 
Leukemia, or Advanced Solid Tumors With Severe Renal 
Impairment or Mild or Moderate Hepatic ImpairmentEudraCT No.: 2018 -004049 -17
Study Number: Pevonedistat -1016 Phase: 1/1b
Study Design:
This study is an open -label, multicenter, 2-part study. The study has been designed to characterize the 
pharmacokinetics (PK) of pevonedistat and assess the safety of pevonedistat in combination with select standard of 
care (SOC) agents in patients with myelodysplastic syn dromes (MDS), chronic myelomonocytic leukemia (CMML), 
acute my elogenous leukemia (AML), or advanced solid tumors who also have severe renal impairment or 
mild/moderate hepatic impairment. Patients will be assigned to 1 of 4 arms based on their renal and/or hepatic 
function: normal renal and hepatic function (Control Arm), severe renal impairment (Renal Arm), mild hepatic 
impairment (Mild Hepatic Arm), and moderate hepatic impairment (Moderate Hepatic Arm).
Part A of the study will be a single -agent PK asses sment period with pevonedistat. All eligible patients will be 
administered a single dose of pevonedistat 20 mg/m2via an approximately 1 -hour intravenous (IV) infusion on Day 1. 
Plasma PK samples will be collected at a series of predetermined time points u p to 72 hours (Day 4) following the 
single dose of pevonedistat. There will be an approximate 4 -to 7-day washout period before the start of Part B.
In Part B, patients will receive pevonedistat in combination with SOC agents (azacitidine, docetaxel, or 
carboplatin plus paclitaxel).
Patients with hematologic malignancies (MDS, CMML, or AML) may receive pevonedistat on Days 1, 3, and 5 in 
combinatio n with azacitidine (75 mg/m2,) on Days 1 through 7 or Days 1 through 5, 8, and 9 in 28-day cycles. Patients 
will receive azacitidine subcutaneously (SC) in Cycle 1. Azacitidine will be given SC or IV during Cycle 2 and 
beyond. During Cycle 1 of Part B, plasma and urine PK samples for measurement of pevonedistat and azacitidine will 
be collected at predetermined tim e points or intervals on Day 3. Plasma PK samples for measurement of pevonedistat 
will also be collected on Days 4 and 5 of Cycle 1.
Patients with advanced solid tumors may receive pevonedistat in combination with docetaxel or carboplatin plus 
paclitaxel o n Day 1 and pevonedistat alone on Days 3 and 5 in 21
-day cycles. During Cycle 1 of Part B, plasma PK 
samples for measurement of pevonedistat will be collected on Days 3, 4, and 5.
Following sponsor and investigator discussion of safety data from Cycle 1, patients in the organ impairment arms who 
tolerate pevonedistat well at a low starting dose may be eligible for intrapatient dose escalation starting in Cycle 2 of 
Part B or soon thereafter. Patients who tolerate treatment well at low starting doses of SOC agents may also be eligible 
for intrapatient dose escalation of those agents, per United States Prescribing Information/Summary of Product 
Characteristics recommendations.
Patients may continue to receive the combination treatment (in 28 -day cycles in comb ination with azacitidine or in 
21-day  cycles in combination with docetaxel or carboplatin plus paclitaxel) in Part B until they experience 
symptomatic deterioration or disease progression, treatment is discontinued for another reason, or until the study is
stopped by the sponsor.
Treatment with the study drug will be discontinued early if a patient experiences study drug –related toxicities. Patients 
may discontinue therapy at any time. Patients will attend the end of study (EOS) visit 30 (+10) days after re ceiving 
their last dose of study drug or before the start of subsequent antineoplastic therapy, if that occurs sooner.
Adverse events (AEs) and Eastern Cooperative Oncology Group performance status (ECOG PS) will be assessed, and 
electrocardiograms, clinic al laboratory values (with select chemistry panel during Part B), and vital signs will be 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 13of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALobtained, to evaluate the safety and tolerability of the study drug treatments. Toxicity will be evaluated according to 
Natio nal Cancer Institute Common Terminology C riteria for Adverse Events, version 5.0, effective date 27 November 
2017 [1]. Guidelines for dose modifications are provided as per the study protocol.
Measures of disease response (complete response [CR] or partial response [PR] for AML and solid tumo rs; CR, PR, or 
hematologic improvement [HI] for MDS and CMML), including response rate and duration of response, will be based 
on the investigator’s assessment (Part B only).
Primary Objectives:
The primary objectives (Part A) are as follows:
To characterize the PK of pevonedistat in patients with severe renal impairment.
To characterize the PK of pevonedistat in patients with mild hepatic impairment.
To characterize the PK of pevonedistat in patients with moderate hepatic impairment.
Secondary Objectives:
The secondary objectives (Part B) are as follows:
To evaluate disease response in patients with severe renal impairment or mild or moderate hepatic impairment 
that may  be obs erved in the combination of pevonedistat with chemotherapy (azacitidine, docetaxel, or 
carboplatin plus paclitaxel).
To characterize the PK of pevonedistat and azacitidine in the combination setting in patients with hematologic 
malignancies and severe renal impairment or mild or moderate hepatic impairment.
To characterize the PK of pevonedistat in combination with docetaxel or carboplatin plus paclitaxel in patients 
with advanced solid tumors and severe renal impairment or mild or moderate hepatic impairme nt.
Safety Objective:
The safety objective (Part A and Part B) is as follows:
To evaluate the safety of pevonedistat following a single dose or in combination with chemotherapy (azacitidine, 
docetaxel, or carboplatin plus paclitaxel) in patients with normal organ function and in patients with organ 
impairment.
Patient Population: Male or female patients aged 18 years or older with higher -risk (HR) MDS, HR CMML, AML, 
or advanced solid tumors, with various degrees of renal or hepatic function.
Number o f Patients:
Approximately 42 patients will be enrolled in the study.Number of Sites:
There will be approximately 25 to 30 sites in the 
United States and European Union.
Dose Level(s):
Part A
Single dose of pevonedistat 20 mg/m2via a 1 -hour IV 
infusion.
Part B
After completion of Part A, all patients will be given an 
opportunity to continue treatment in Part B.
Patients with hematologic malignancies may receive 
pevonedistat on Days 1, 3, and 5 in combination with 
azacitidine (75 mg/m2) on Days1 through 7 or Days 1 
through 5, 8, and 9 in 28 -day cycles. Patients will receive 
azacitidine SC in Cycle 1. Azacitidine will be given SC or 
IV during Cycle 2 and beyond.
Starting doses: pevonedistat 20 mg/m2and azacitidine 
75mg/m2(Control Arm and Mild Hepatic Arm ); Route of Administration:
Pevonedistat, docetaxel, carboplatin, and 
paclitaxel: IV
Azacitidine: IV or SC
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 14of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALpevonedistat 10 mg/m2 and azacitidine 75 mg/m2 (Moderate 
Hepatic Arm); pevonedistat 15 mg/m2 and azacitidine 
75mg/m2(Renal Arm).
Based on available safety data, patients who tolerate 
treatment well at the initially assigned dose of pevonedistat 
may beallowed to increase their dose of pevonedistat in 
increments of 5 mg/m2per cycle.
Maximum doses: pevonedistat 20 mg/m2and azacitidine 
75mg/m2.
Patients with advanced solid tumors may receive 
pevonedistat in combination with docetaxel or carboplatin 
plus paclitaxel on Day 1 and pevonedistat alone on Days 3 
and 5 in 21 -day cycles. Only  patients in the Renal Arm will 
receive treatment with pevonedistat in combination with 
docetaxel.
Starting doses: pevonedistat 20 mg/m2and carboplatin area 
under the pl asma concentration -time curve (AUC)4 plus 
paclitaxel 135 mg/m2(Mild Hepatic Arm); pevonedistat 
10mg/m2and carboplatin AUC4 plus paclitaxel 90 mg/m2
(Moderate Hepatic Arm); pevonedistat 15 mg/m2and 
docetaxel 75 mg/m2or carboplatin AUC4 plus paclitaxel 
135mg/m2(Renal Arm).
Maximum doses: pevonedistat 20 mg/m2and carboplatin 
AUC5 plus paclitaxel 135 mg/m2(Mild Hepatic Arm);
pevonedistat 20 mg/m2and carboplatin AUC5 plus 
paclitaxel 90 mg/m2(Moderate Hepatic Arm); pevonedistat 
25mg/m2and docetaxel 75 mg/m2; pevonedistat 20 mg/m2
and carboplatin AUC5 plus paclitaxel 175 mg/m2(Renal 
Arm).
Duration of Treatment:
Part A: Approximately 4 to 7 days, including the 
pevonedistat single -dose PK assessment and washout.
Part B: The maximum duration of treatment with 
pevonedistat in combination with SOC agents (azacitidine, 
docetaxel, or carboplatin plus paclitaxel) is 12 cycles 
(28-day  cycles for patients w ith hematologic malignancies 
and 21- day cycles for patients with advanced solid tumors), 
unless the investigator and sponsor (or designee) agree that 
a patient would benefit from continued treatment.Period of Evaluation:
Screening: Within 28 days before t he first dose of 
study drug in Part A.
Part A:
Pevonedistat single -dose for PK assessment: 
Days 1to4.
Washout: 4 to 7 days.
Part B:Patients may continue to receive the 
combinatio n treatment in Part B until they experience 
symptomatic deterioration or di sease progression, 
treatment is discontinued for another reason, or until 
the study  is stopped by the sponsor.
Follow -up: Patients will attend an EOS visit 30 days 
(+10 days) after the last dose of study drugs or before 
the start of subsequent alternative anticancer therapy , if 
that occurs sooner.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 15of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALMain Criteria for Inclusion:
All Patients:
Male and female patients aged 18 years or older.
Expected survival of at least 3 months from the date of enrollment in the study.
ECOG PS of 0, 1, or 2.
Recovered (ie, Grade≤1 toxicity) from the reversible effects of prior anticancer therapy.
Prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤1.5 ×upper limit of the normal range 
(ULN) at screening or within 7 days before the first dose of study dru g.
Female patients who:
–Are postmenopausal for at least 1 year before the screening visit, OR
–Are surgically sterile, OR
–Agree, if they are of childbearing potential, to practice 1 highly effective method of contraception and 
1additional effective (barrie r) method, at the same time, from the time of signing the informed consent 
through 6 months after the last dose of study drug, OR
–Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject.
Male patients, even if surgically sterilized (ie, status postvasectomy), who:
–Agree to practice effective barrier contraception during the entire study treatment period and through 
4months after the last dose of study drug, OR
–Agree to practice true abstinence, when thi s is in line with the preferred and usual lifestyle of the subject.
Suitable venous access for the study -required blood sampling (ie, PK sampling).
Voluntary written consent must be given by the patient or the patient's legally acceptable representative be fore 
performance of any study -related procedure not part of standard medical care, with the understanding that consent 
may be withdrawn by the patient or the patient’s legally acceptable representative at any time without prejudice to 
future medical care.
Patients with Hematologic Malignancies:
Previously untreated hematologic malignancies not suitable for induction therapy.
Morphologically confirmed diagnosis of MDS or nonproliferative CMML (ie, with white blood cells [WBC] 
<13,000/µL) at study entry, base d on one of the following:
French -American -British Classifications [2]:
–Refractory anemia with excess blasts (RAEB), defined as having 5% to 20% myeloblasts in the bone marrow.
–CMML with 10% to 19% myeloblasts in the bone marrow and/or 5% to 19% blasts in the blood.
OR
World Health Organization (WHO) Classifications [3]:
–RAEB -1, defined as having 5% to 9% myeloblasts in the bone marrow.
–RAEB -2, defined as having 10% to 19% myeloblasts in the bone marrow and/or 5% to 19% blasts in the 
blood.
–CMML -2, defined as having 10% to 19% myeloblasts in the bone marrow and/or 5% to 19% blasts in the 
blood.
–CMML -1 (although CMML -1 is defined as having <10% myeloblasts in the bone marrow and/or <5% blasts 
in the blood, these patients may enroll only if bone marrow blasts ≥5%).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 16of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALAll patients with MDS or CMML must also have one of the following Prognostic Risk Categories at study entry, 
based on the Revised International Prognostic Scoring System [4]:
–Very  high (>6 points).
–High (>4.5 -6 points).
–Intermediate (>3 -4.5 points): A patient determined to be in the Intermediate Prognostic Risk Category is only 
allowable in the setting of ≥5% bone marrow myeloblasts.
Patients with WHO -defined AML at study entry , including leukemia secondary to prior chemotherapy or 
resulting from an antecedent hematologic disorder, w ho have failed to achieve CR or who have relapsed after 
prior therapy and are not candidates for potentially curative treatment.
Patients with relapsed or refractory MDS at study entry, who have previously been treated with an 
hypomethy lating agents.
For patients with hematologic malignancies, laboratory value requirements per study arms for estimated glomerular 
filtration rate (eGFR), total bili rubin, and alanine aminotransferase (ALT) are provided in the table, below:
Treatment Arm eGFR (mL/min/1.73 m2) Total Bilirubin ALT
Control ≥90 ≤ULN ≤ULN
Renal <30 ≤ULN ≤2.5 ×ULN
Mild Hepatic ≥60 ULN <bilirubin ≤1.5 ×ULN
(not secondary to 
transfusions)Any
Moderate Hepatic ≥60 1.5×ULN <bilirubin 
≤3.0 ×ULN
(not secondary to 
transfusions)Any
Patients with Advanced Solid Tumors:
Adult patients who have a histologically or cytologically confirmed metastatic or locally advanced solid tumor
that is appropriate for treatment with pevonedistat in combination with either docetaxel or carboplatin plus 
paclitaxel in Part B of this study, or have progressed despite standard therapy, or for whom conventional therapy 
is not considered effective.
Forpatients with advanced solid tumors, clinical laboratory values as specified below:
–Hemoglobin ≥8 g/dL. Patients may be transfused to achieve this value.
–For patients to be treated with pevonedistat plus docetaxel in Part B, total bilirubin must be ≤ULN.
–ALT, aspartate aminotransferase (AST), and alkaline phosphatase ≤2.5 ×ULN.
For patients to be treated with pevonedistat plus docetaxel in Part B, AST and ALT must be 
≤1.5 ×ULN. Only patients with severe renal impairment may be considered for this combination.
–Absolute neutrophil count ≥1,500/mm3.
–Platelet count ≥100,000/mm3.
–Albumin ≥2.7 g/dL.
Computerized tomography scan or magnetic resonance imaging (MRI) of the chest, abdomen, and pelvis within 
28days of the first dose of study drug.
For patien ts with advanced solid tumors, laboratory value requirements per study arms for eGFR, total bilirubin, and 
ALT are provided in the table, below:
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 17of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALTreatment ArmeGFR 
(mL/min/1.73 m2) Total Bilirubin ALT
Renal <30 ≤ULN ≤1.5 ×ULN (for 
pevonedistat plus docetaxel)
≤2.5 ×ULN (for 
pevonedistat plus carboplatin 
plus paclitaxel)
Mild hepatic ≥60 ULN <bilirubin ≤1.5 ×ULN Any
Moderate hepatic ≥60 1.5×ULN <bilirubin ≤3.0 ×ULN Any
Main Criteria for Exclusion:
All Patients:
Any serious medical or psychiatric illness that could, in the investigator’s opinion, potentially interfere with the 
completion of study procedures or could limit expected patient survival to less than 6 months.
End-stage renal disease requiring hemodialysis at study entry.
Gilbert syndrome.
Treatment with any investigational products or participation in any interventional studies within 21 days before 
the first dose of any study drug.
Known hypersensitivity to pevonedistat or its excipients.
Active uncontrolled infection or seve re infectious disease, such as severe pneumonia, meningitis, or septicemia. 
Prophy lactic treatment with antibiotics is allowed.
Major surgery within 14 days before first dose or a scheduled surgery during study period; insertion of a venous 
access device ( eg, catheter, port) is not considered major surgery.
Life-threatening illness unrelated to cancer.
Known HIV seropositive.
Known hepatitis B surface antigen seropositive, or known or suspected active hepatitis C infection.
Known hepatic cirrhosis or severe pre-existing hepatic impairment.
Known cardiopulmonary disease defined as unstable angina, clinically significant arrhythmia, congestive heart 
failure (New York Heart Association Class III or IV), and/or myocardial infarction within 6 months before first 
dose.
Prolonged rate corrected QT interval ≥500 msec, calculated according to institutional guidelines.
Treatment with strong cytochrome P450 (CYP3A) inducers within 14 days before the first dose of pevonedistat.
Female patients who are lactating and breastfeeding or have a positive serum pregnancy test during the screening 
period or a positive urine pregnancy test on Day 1 of Part A, before first dose of study drug.
Female patients who intend to donate eggs (ova) during the course of this study or for 6months after receiving 
their last dose of study drug(s).
Male patients who intend to donate sperm or father a child during the course of this study or for 4 months after 
receiving their last dose of study drug(s).
Diagnosed or treated for a different malignancy within 2years before randomization or previously diagnosed with 
a different malignancy with any current evidence of residual disease.
High blood pressure that cannot be controlled by standard treatments.
Left ventricular ejection fraction <50% wi thin 6 months prio r to study  enrollment.
Severe uncontrolled ventricular arrhythmias or torsade de pointes; electrocardiographic evidence of acute 
ischemia or active conduction system abnormalities; or clinically significant arrhythmia.
Severe symptomatic pulmonary hypertension requiring pharmacologic therapy or patients with chronic 
respiratory  disease that require continuous oxygen.
Patients with Hematologic Malignancies:
Acute promyelocytic leukemia as diagnosed by morphologic examination of bone marrow, by fluorescent in situ 
hybridization o r cytogenetics of peripheral blood or bone marrow, or by other accepted analysis.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 18of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALPatients with AML with a WBC count ≥50,000/ μL. Patients who are cytoreduced with leukapheresis or with 
hydroxy urea may  be enrolled if t hey otherwise meet the eligibility criteria.
Patients with either clinical evidence of or history of central nervous system (CNS) involvement by AML.
Known hypersensitivity to azacitidine or its excipients.
For patients with hematologic malignancies, PT or aPTT >1.5 ×ULN or active uncontrolled coagulopathy or 
bleeding disorder. Patients therapeutically anticoagulated with warfarin, direct thrombin inhibitors, direct factor 
Xa inhibitors, or heparin are excluded from enrollment.
Patients with Advanced Solid Tumors:
Prior treatment with radiation therapy involving ≥25% of the hematopoietically active bone marrow.
Known hypersensitivity or history of severe intolerance or toxicity to chemotherapeutic agents, including known 
history  of severe hy persensitivity r eactions to docetaxel (polysorbate 80 -based formulations) for patients to be 
treated with pevonedistat in combination with docetaxel; histor y of hy persensitivity to carboplatin for patients to 
be treated with pevonedistat plus carboplatin plus paclitaxel; or history of severe hypersensitivity to paclitaxel 
(Cremophor -based formulations) for patients to be treated with pevonedistat with carboplatin plus paclitaxel.
CNS metastasis, except for patients who have received prior treatment (radiation or resection) and have stable 
CNS disease (eg, stable MRI, no steroid requirement).
Main Criteria for Evaluation and Analyses:
Primary Endpoints:
Area under the plasma concentration -time curve from time zero to infinity (AUC ∞) following a single dose of 
pevonedistat in patients with normal renal and hepatic function, severe renal impairment, or mild or moderate 
hepatic impairment.
Area under the plasma concentration -time curve from time zero to the time of the last quantifiable concentration 
(AUC last) following a sing le dose of pevonedistat in patients with normal renal and hepatic function, severe renal 
impairment, or mild or moderate hepatic impairment.
Maximum observed plasma concentration (C max) of pevonedistat following a single dose of pevonedistat in 
patients wi th normal renal and hepatic function, severe renal impairment, or mild or moderate hepatic 
impairment.
Secondary Endpoints:
Terminal disposition phase half -life (t 1/2z) of pevonedistat following single -and multiple -dose administration.
Cmaxof pevonedista t following multiple -dose administration.
Fraction of unbound drug in plasma (f u) of pevonedistat.
Cmaxof azacitidine following multiple -dose administration.
Time of first occurrence of maximum observed concentration of azacitidine following multiple -dose
administration.
t1/2z of azacitidine following multiple -dose administration.
Area under the concentration -time curve from time zero to the end of the dosing interval of pevonedistat and 
azacitidine following multiple -dose administration.
Clearance of pevonedistat and apparent clearance of azacitidine.
Renal clearance of pevonedistat and azacitidine.
Volume of distribution at steady -state (V ss) of pevonedistat and apparent V ssof azacitidine.
Measures of disease response (CR, complete remission with inc omplete blood count recovery [CRi] or PR for 
AML; CR, PR, or HI for MDS and CMML; CR or PR for solid tumors using the Response Evaluation Criteria In 
Solid Tumors [RECIST] version 1.1 criteria); including response rate and duration of response, based on th e 
investigator’s assessment ( PartB only ).
Safety Endpoints:
AEs, serious AEs, assessments of clinical laboratory values, vital signs measurements, and ECOG PS.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 19of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALStatistical Considerations:
Analy ses will be primarily descriptive in nature. No formal statistical hypothesis testing will be performed. A 
statistical analysis plan will be prepared and finalized before database lock. This document will provide further details 
regarding the definition of analysis variables and analysis methodology to address all study objectives.
Summary tabulations will be presented to display the number of observations, mean, standard deviation, median, 
minimum, and maximum for continuous variables along with the number and percentage (calculated using 
nonmissing values) pe r category for categorical data, unless specified otherwise.
PK: Individual and mean pevonedistat plasma concentration -time data following a single dose of pevonedistat during 
the PK assessment in Part A will be plotted and listed by organ function group. Individual and mean pevonedistat 
and/o r azacitidine plasma concentration -time data following multiple -dose administration during Cycle 1 of Part B 
will be plotted and listed by organ function group and by dose levels. Plasma pevonedistat and/or azacitidine PK 
parameters for each patient will be calculated using noncompartmental analysis methods.
The analy sis for the effects of organ impairment on pevonedistat PK will be based on unbound pevonedistat plasma 
exposure (AUC) following a single dose of pevonedis tat in Part A. To assess the effects of severe renal impairment or 
mild or moderate hepatic impairment on pevonedistat PK (unbound AUC lastand AUC ∞), an analysis of variance 
(ANOVA) on the natural log -transformed PK parameters will be performed for severe renal impairment (Renal Arm) 
versus the normal group (Control Arm), mild hepatic impairment (Mild Hepatic Arm) versus the normal group 
(Control Arm), and moderate hepatic impairment (Moderate Hepatic Arm) versus the normal group (Control Arm). 
The ANOVA re sults will be used to estimate the ratios of LS geometric means (severe renal impairment vs normal, 
and mild or moderate hepatic impairment vs normal) and corresponding 90% CIs for pevonedistat unbound AUC. The 
PK-evaluable population will be used for thes e analyses.
Efficacy: Efficacy measures will include disease response and duration of disease response. Analysis of all efficacy 
measures will be descriptive. Disease response in AML will be based on the overall response rate (CR +PR) using the 
Revised Re commendatio ns of the International Working Group (IWG) for Diagnosis, Standardization of Response 
Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in AML [5]. For AML patients, all CR 
includes both CR and CRi. Disease response in patients with MDS or CMML will be based on the best overall 
response (CR +PR+HI) as determined by the investigator using the revised IWG respons e criteria for MDS [6].
Disease response to pevonedistat in combination with docetaxel or carboplatin plus paclitaxel will be based on the best 
overall response as determined by the investigator using RECIST version 1.1 guidelines. 
The duration of response will be defined in all patients with disease response as the time between the first 
documentation of response and the first documentation of PD or death if no prior PD is documented. Responders 
without disease progression will be censored at the last clinical asses sment of response.
Safety:
A safety analysis will be conducted separately for Part A and Part B. The safety population will be used for the safety 
analy sis. Safety will be evaluated on the basis of the incidence of AEs, severity and type of AEs, and by cha nges from 
baseline in the patient’s vital signs, weight, and clinical laboratory values using the safety population. Exposure to the 
study drugs and reasons for discontinuation will be tabulated.
Sample Size Justification: The sample size calculation is based on the number of patients required to adequately 
characterize the PK of pevonedistat in the organ impairment arms (severe renal impairment or mild or moderate 
hepatic impairment) in comparison to the control group. Bas ed on these considerations, the expected sample size is 
approximately 9 for the Control Arm (normal renal and hepatic function) and 9 to 12 patients in each of the 3 organ 
impairment arms. Patients who are considered nonevaluable may be replaced. The sampl e size of approximately 
9patients specified as being required for the PK -evaluable population in each group in Part A is based on typical 
sample sizes utilized in organ impairment PK studies in cancer patients, rather than on specific statistical 
consider ations. With a sample size of 9 patients per group, if the ratio of geometric means (impaired organ function vs 
control) of AUC ∞is X, the associated 90% CI is expected to be (0.688X, 1.45X) based on the percent coefficient of 
variation in pevonedistat AUC ∞of 43.8% (Study C15011).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 20of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL3.0 STUDY REFERENCE INFORMATION
3.1 Study -Related Responsibilities
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
Clinical Study  Supplier List. The i dentified vendors will perform specific study -related activit ies 
either in full or in partnership with the sponsor.
3.2 Principal Investigator/Coordinating Investigator
Takeda will select a signatory  coordinat ing invest igator from the invest igators who participate in 
the study . Selection criteria for thi s investi gator will include significant knowledge of the study  
protocol , the study  medicat ion, thei r experti se in the therapeutic area and the conduct of clinical 
research, and study  parti cipat ion. The signatory  coordinating investigator will be required to 
review and sign the clinical study report (CSR) and by doing so agrees that it accurately describes 
the resul ts of the study .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 21of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL3.3 List of Abbreviations
AE adverse event
ALP alkaline phosphatase
ALT alanine aminotransferase
AML acute myelogenous leukemia
ANC absolute neutrophil count
ANOVA analy sis of variance
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
AUC area under the plasma concentration -time curve 
AUC last area under the plasma concentration -time curve from time zero to the time of the last quantifiable 
concentration
AUC ∞ area under the plasma concentration -time curve from time 0 to infinity
AUC τ area under plasma concentration -time curve from time zero to the end of the dosing interval
BCRP breast cancer resistance protein
BDC bile in bile duct –cannulated
BSA body surface area
CDLs cullin -dependent ubiquitin E3 ligases
CL total clearance
CL/F apparent clearance
CL R renal clearance
CMML chronic myelomonocytic leukemia
Cmax maximum observed plasma concentration
CNS central nervous system
COVID -19 coronavirus disease 2019
CR complete response/remission
CRi complete remission with incomplete blood count recovery
CrCL creatinine clearance
CRO contract research organization
CSR clinical study report
CT computerized tomography
CYP cytochrome P450
DDI drug-drug interaction
DLT dose-limiting toxicity
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF electronic case report form
EDC electronic data capture
eGFR estimated glomerular filtration rate
EOS end of study
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 22of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALET early  termination
EU European Union
FDA [United States] Food and Drug Administration
fu fraction of unbound drug in plasma
FSH follicle stimulating hormone
GCP Good Clinical Practice
G-CSF granulocyte -colon y stimulating factor
GFR glomerular filtration rate
HI hematologic improvement
HR CMML higher -risk chro nic my elomonocytic leukemia
HR MDS higher -risk my elodysplastic syndromes
IB investigator’s brochure
ICF informed consent form
ICH International Council for Harmonisation
IEC independent ethics committee
IPSS -R Revised International Prognostic Scoring System
IRB institutional review board
ITT intent -to-treat
IV intravenous(ly)
IWG International Working Group 
LVEF left ventricular ejection fraction 
MDRD Modification of Diet in Renal Disease
MDS myelodysplastic syndromes
MHRA Medicines and Healthcare products Regulatory Agency
MedDRA Medical Dictionary for Regulatory Activities
MRI magnetic resonance imaging
MTD maximum tolerated dose
NAE NEDD8 -activating enzyme
NCI CTCAE Natio nal Cancer Institute Common Terminology Criteria for Adverse Events
NEDD8 neural precursor cell expressed, developmentally down -regulated 8
ORR overall response rate
PBPK physiologically based pharmacokinetic(s)
PD progressive disease
P-gp P-glycoprotein
PK pharmacokinetic(s)
PMDA Pharmaceuticals and Medical Devices Agency
PR partial response/remission
PS performance status
PT prothrombin time
PTA posttrial access
PTE pretreatment event
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 23of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALRAEB refracto ry anemia with excess blasts
RBC red blood cells
RECIST Response Evaluation Criteria in Solid Tumors
RP2D recommended phase 2 dose
SAE serious adverse event
SmPC Summary of Product Characteristics
SOC standard of care
SOE schedule of events
SC subcutaneous(ly)
SUSAR suspected unexpected serious adverse reaction
t1/2z terminal disposition phase half -life
TEAE treatment -emergent adverse event
Tmax time of first occurrence of maximum observed concentration
UK United Kingdom
ULN upper limit of the normal range
US United States
USP United States Pharmacopeia
USPI US Prescribing Information
Vss volume of distribution at steady -state
WBC white blood cell
WHO World Health Organization
3.4 Corporate Identification 
TDC Americas Takeda Development Center Americas, Inc.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 24of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL4.0 INTRODUCTION
4.1 Background
As of 22 January 2020, an est imated 794patients received active treatment with pevonedistat, 
either as a single agent or in combinat ionwith other therapeutic agents in hematologic 
malignancies (N =508) or in so lid tumors (N =286).
Pevonedistat is current ly in phase 2/3 of clinical development for higher -risk myelodysplast ic 
syndro mes (HR MDS), HR chronic myelo monocy tic leukemia (HR CMM L), and l ow-blast acute 
myelogenous leukemia (AML). The recommended phase 2 dose (RP2D) of pevonedistat 
administered as a single agent in pat ients with advanced hematologic malignancy  is 50 mg/m2on 
Days 1, 3, and 5 in 21 -day cycles.
Pevonedistat is curren tly under development as a component of regimens with azacit idine. Two 
clinical studies wit h pevonedistat and azacit idine are ongoing as of 22 January 2020; 
Pevonedistat -2001 (P2001), a phase 2 study , and Pevonedistat -3001 (P3001), a phase 3 study , are 
both in pat ients with HR MDS, HR CMML, or low- blast AML. Preliminary data from interim 
analysis 2 of Study P2001 suggest potential clinical benefit in terms of longer overall survival and 
event -free survival amo ng patients with HR MDS/CMML or low -blast AML re ceiving the 
combinat ion treatment of pevonedistat plus azacit idine versus azacit idine alo ne.
Pevonedistat is also being evaluated in co mbinat ion therapy  with standard of care (SOC) agents 
(eg,pevonedistat plus docetaxel  or pevonedistat plus carbopl atin/pa clitaxel) f or pati ents wi th 
solid tumors. Addit ive/synergist ic effects of docetaxel and carboplat in/ paclitaxel in co mbinat ion 
with pevonedistat have been studied in a number of in vitro and in vivo models by  the sponsor 
[7,8] . In patients with so lid tumors, the maximum tolerated dose (MTD) and RP2D of pevonedistat 
in co
mbinat ion with docetaxel is 25 mg/m2pevonedi stat dosed on Days 1, 3, and 5, and 75 mg/m2 
docetaxel on Day 1 in 21- day cycles. The MTD and RP2D of pevonedistat in co mbinat ion with 
carbopl atin/paclitaxel is 20 mg/m2pevonedistat dosed on Day s1, 3, and 5 and 175 mg/m2
paclitaxel plus area under the plasma concentration -time curve (AUC)5 carboplat in on Day 1 in 
21-day cycles.
4.1.1 Study Drug
Pevonedistat is a first -in-class, small  molecule inhibi tor of  neural precursor cell expressed, 
developmentally down -regul ated 8 (NEDD8) -activating enzyme (NAE) under development for 
the treatment of malignancies. NAE, an E1 activating enzyme, is an essent ia
l component of the 
NEDD8 conjugat ion pathway, which controls the activit y of cullin -dependent ubiquit in E3 ligases 
(CDLs). Once activated, CDLs are able to transfer ubiquit in to specific protein substrates, which 
targets them for proteasomal degradat ion. CDLs thereby control the timely  ubiqui tination and 
degradation of many proteins with important roles in cell cycle progression a nd signal transduct ion. 
Inhibitors of NAE activit y may be of therapeuti c val ue in the treatm ent of various cancers, by  
prevent ing neddylat ion and act ivation of the CDLs, thus disrupt ing proteasomal degradat ion of a 
variet y of critical regulatory  proteins i ntegral  to tum or cell growth, proliferat ion, and survival.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 25of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL4.1.2 Nonclinical Background
Pevonedistat is a potent and selective inhibitor of NAE activit y. Pevonedistat also inhibits human 
carbonic anhydrase II, which may  explain the extensive part itioning of pevo nedistat in red blood 
cells (RBCs) that has been observed in animal species and humans.
Pevonedistat showed medium permeabilit y in Caco -2 cells.
Plasma clearance ranged fro m relatively low in chimpanzees, to moderate in dogs and monkeys, to 
relatively high in rats. The plasma terminal disposition phase half -life (t 1/2z), cal culated as ln(2)λ z
varied fro m 1hour in rats to approximately 15 hours in mo nkeys.
The m ajor eliminat ion pathway  of pevonedistat in animals is through the hepat ic route. Urinary 
excret ion of unchanged pevonedistat was negligible in rats, monkeys, and chimpanzees. After an 
intravenous (IV) dose of [14C]pevonedistat, radioactivit y was primarily  excreted in the feces in 
intact rats and in bile in bile duct–cannulated (BDC) rats; excret ion was almost com plete by  
24hours postdose. Similar to results in intact rats, IV infusion of [14C]pevonedistat to intact beagle 
dogs resulted in most of the administered dose being eliminated in the feces. In BDC beagle dogs, 
however, most of the dose was e liminated in the urine and bile. In both intact and BDC beagles, 
most of the radi oactivi ty in the excreta was recovered over 24 hours after the start of infusio n.
Detailed informat ion regarding the nonclinical pharmaco logy and toxico logy of pevonedistat ma y 
be found in the current invest igator’s brochure (IB).
4.1.3 Clinical Background Information
4.1.3.1 Clinical Pharmacokinetics
Popul ation pharmacokinet ic (PK) analysis was conducted using data fro m pevonedistat 
single
-agent studi es (Studi esC15001, C15002, C15003, and C15005) and pevonedistat in 
combinat ion wit h SOC chemotherapy (Studies C15009, C15010, Pevonedistat -1012 [P1012], and 
P2001) in patients with so lid tumor or hematologic malignancies. As of 22 January 2020, the 
database contained 416 evaluable pat ients cont ributing 4689 PK observations. Pevonedistat 
plasma concentration -time profiles were well described by a 2 -compartm ent m odel with linear 
eliminat ion. Coadministration with azacit idine or docetaxel did not appear to affect the total 
clearance (CL) of pevoned istat, whereas concurrent administration of carboplat in and paclitaxel 
decreased the CL of pevonedistat by  approximately  50%, transl ating to an approximately 100% 
higher pevonedistat exposure (AUC) during coadministration with carboplatin and paclitaxel, 
consistent with pevonedistat concentration data observed in Study C15010. Race, sex, age, tumor 
type (hematol ogic vs so lid), mild or moderate renal impairment (creatinine clearance [CrCL] 
≥30mL/min), and mildly impaired liver funct ion, to the extent repres ented in this dataset (ie, total 
bilirubin ≤upper limit of the normal range [ULN] and alanine aminotransferase [ALT]/aspartate 
aminotransferase [AST] ≤2.5 ×ULN), had no impact on pevonedistat PK.
An open -label drug -drug interaction (DDI) Study C15011 eval uated the cy tochrom e 
P450 (CYP)3A -mediated inhibitory effects of fluconazole and itraconazo le on pevonedistat PK in 
patients wi th advanced so lid tumors. The results indicated that itraconazole, a strong CYP3A/ 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 26of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALP-glycoprotein (P-gp) inhibi tor, and fluconazo le, a moderate CYP3A inhibitor, had no clinically 
meaningful effects on pevonedistat PK.
Study Pevonedistat -1015 (P1015) indicated that rifampin, a strong CYP3A inducer, had no 
clinically meaningful impact on pevonedistat systemic exposures. Despite result s of 
Studi esC15011 and P1015, in the current study , use of strong CYP3A inducers and inhibitors 
remains prohibited in order to interpret the effects of organ impairment on pevonedistat PK 
without other confounding factors.
Study P1012 is a phase 1/1b, ope n-label study  of pevonedistat as single agent and in combinat ion 
with azaci tidine in adult East Asian pat ients with AML or MDS enrolled in Japan, South Korea, 
and Taiwan. Pevonedistat 20 mg/m2in combinat ion with 75mg/m2azacit idine was determined to 
be the MTD/RP2D in Asian patients. The analysis indicated that the systemic exposure of 
pevonedistat was similar amo ng m ajor East Asian races, i e, Japanese, Korean, and Chinese. 
Furtherm ore, the sy stemic exposures of pevonedistat was comparable between East As ian and 
Western patients. These results support the same RP2/3D of pevonedistat in co mbinat ion with 
azacit idine in glo bal pat ient populat ion.
4.1.3.2 Clinical Experience
As of 22 January 2020, an est imated 794 patients received active treatment with pevonedistat, 
including 508 patients wit h hematologic indicat ions and 286 patients with so lid tumor indicat ions. 
These include 227 patients di agnosed wi th advanced malignancies, including solid tumors, AML, 
melano ma, lympho ma, multiple myelo ma, HR MDS, and acute lymphoblast ic leukemia, who 
participated in studies of single- agent pevonedistat.
In com pleted combinat ion studies in pat ients with hematol ogic malignancies, 64 elderly patients 
with treatm ent-naïve AML (Study C15009) were treated with pevonedistat plus azacit idine [9]; 
and 23 East Asian patients with Worl d Heal th Organizat ion (WHO) -defined AML or HR MDS 
have received a single IV dose of pevonedistat alone and in co mbinat ion with azaci tidine 
(Study P1012).
In com pleted combinat ion studies in pat ients with solid tumors, 64 patients have re ceived 
combinat ion treatments with docetaxel, gemcitabine, or a combinat ion of carboplatin and 
paclitaxel (Study C15010); and 51 patients have received a single IV dose of pevonedistat alone 
and in co mbinat ion with the CYP3A inhibitor probes itraconazole o r fluconazo le (36 of these 
51patients then continued receiving pevonedistat plus SOC, either docetaxel, or carboplat in plus 
paclitaxel) (Study C15011).
Eight pati ents wi th advanced so lid tumors have received a single dose of [14C]-pevonedistat (7 of 
these8patients then continued receiving pevonedistat plus SOC, either docetaxel, or carboplat in 
plus paclitaxel) (Study Pevonedistat -1013 [P1013]).
In ongoing co mbination studies, 58 patients with HR MDS, CMML, or low -blast AML have 
received co mbinat ion treat ment with azaci tidine and pevonedistat (Study P2001), and it is 
estimated that 222 patients with HR MDS, CMML, or low
-blast AML have received co mbinat ion 
treatm ent wi th azaci tidine and pevonedistat in Study P3001.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 27of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALPevonedistat has reported single -agent cli nical act ivity in a phase 1 study  (Study C15003) in 
patients wi th relapsed/refractory  AML. In Study C15003, a total  of 66patients wi th AML were 
treated in a variet y of patient settings, including after relapse fo llowing allogeneic transplant as 
well as wi th therapy -related AML, and primary refractory  AML. In the phase 1 trial, 7 responses 
(2 com plete remissio ns [CR] and 5 partial remissions [PR]) were observed among 
55response -evaluable patients with AML who received pevonedistat monotherapy . Invest igator s 
shoul d note that som e pat ients may benefi t from continued treatm ent even though their bone 
marrow bl ast counts m ay fluctuate over the course of the first 4 cycles. For example, 2 of the 
7responders to pevonedistat given as a single agent in Study C15003 had asymptomat ic, transient 
increases in bone marrow blasts after achieving a response. In these 2 cases, bone marrow blasts 
increased from less than 5% to more than 20%, and then went down. In addit ion, another 
responder i n that study  had an asymptomat ic, transient increase in bone marrow blasts before 
achieving a response. In that case, bone marrow blasts almost doubled before response. These 
3patients were allowed to remain on study  because thei r invest igators felt they  were clinically 
benefit ing from continued treatment despite changes in their bone marrow blast counts.
Pevonedistat has clinical act ivity when administered in co mbinat ion with azaci tidine. 
Study C15009 evaluated the combinat ion of escalating doses of pevonedistat plus azacit idine in 
64 treatment -naïve pat ients with AML. The MTD was determined to be 20 mg/m2pevonedistat in 
combinat ion with 75mg/m2azacit idine. A total of 61 patients were treated at the MTD. Overall 
response rate (ORR) in the 64 -patient intent -to-treat (ITT) cohort was 50 % (20 CR, 5 complete 
remission wit h incomplete blood count recovery  [CRi ], 7 PR); m edian durati on of  remissi on was 
8.3months. Pevonedistat PK was not altered by the addit ion of azacit idine. The nature and 
frequency  of the reported toxi cities (excluding do se-limiting toxicit ies [DLTs]) were similar to 
previous reports for azacit idine alo ne [9]. Addi tional efficacy  and safet y informat ion from 
Study C15009 i s provi ded in Secti on4.1.4.2 .
Pevonedistat has clinical act ivity when administered in co mbinat ion therapy  with docetaxel or 
carbopl atin plus paclitaxel. In Study C15010, the ORR for patients treated with pevonedistat in 
combinat ion with docetaxel was 16% (3 PRs in a respons e
-evaluable population o f 19patients) [7]. 
For pati ents treated with pevonedistat in combinat ion with carboplat in plus pac litaxel the ORR 
(CR + PR) was 35% (2 CRs and 6 PRs in a response -evaluable populat ion of 23 patients). In 
Study C15011, the ORR (CR +PR) among 28 patients who received treatment with pevonedistat 
in combinat ion with chem otherapy  was 14.3% (10.5% in the pe vonedistat plus docetaxel arm and 
22.2% in the pevonedistat plus carboplatin plus paclitaxel arm; 2 patients in each arm). A total of 
4patients (14.3%) achieved PR and 16 patients (57.1%) had stable disease (SD); 8 patients 
(28.6%) had a best response of progressive disease (PD). Ongoing studies that include pat ients 
with solid tum ors (Studi esPevonedistat -1014 and P1015) have not resulted in any new safet y 
signals for the combinat ion of pevonedistat with docetaxel or carboplat in plus paclitaxel.
Refer to the IB, which will be updated regularly throughout the duration of this study , for further 
details on the clinical development program for pevonedistat.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 28of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL4.1.4 Potential Risks and Benefits
4.1.4.1 Azacitidine
In clinical studies, adverse react ions to azacit idine were qua litatively  similar between the IV and 
subcutaneous (SC) routes of administration [10]. In clinical studies with SC administration of 
azacit idine, adverse reac tions of neutropenia, thrombocy topenia, anemia, nausea, vomit ing, 
diarrhea, consti pation, and inject ion site ery thema/reacti on tended to increase in incidence with 
higher doses of azacit idine. Adverse reactions that tended to be more pronounced during the first 1 
to 2cycles of SC treatment compared with later cycles, and included thrombocytopenia, 
neutropeni a, anemia, nausea, vo miting, inject ion site ery thema/pain/bruising/react ion, 
constipation, petechiae, dizziness, anxiet y, hypokalemia, and inso mnia. Th ere did not appear to be 
any adverse react ions that increased in frequency over the course of treatment.
Adverse reactions that appeared to be specifically associated with the IV route of administration 
included infusio n site reactions (eg, ery thema or pai n) and catheter site reactions (eg, infect ion, 
erythema, or hem orrhage).
Adverse reactions ident ified during postmarketing use of azacit idine include interst it
ial lung 
disease, tum or lysis syndrome, i nject ion site necrosis, Sweet’s syndro me (acute febrile 
neutrophilic dermatosis), and necrotizing fasciit is (including fatal cases).
Refer to the VIDAZA (azacit idine) United States Prescribing Informat ion (USPI) [10], or the 
European Unio n (EU) Summary  of Product Characterist ics (Sm PC) [
11], as applicable, for the 
most recent information regarding the anticipated risks and benefits of azacit idine.
4.1.4.1.1 Anemia, Neutropenia, and Thrombocytopenia
Azacit idine causes anemia, neutropenia, and thrombocy topeni a. Moni tor com plete bl ood counts 
frequently for response and/or toxicit y, at a min imum , before each dosing cycle. After 
administration of the reco mmended dosage for the first cycle, adjust dosage for subsequent cycles 
based on nadir counts and hematologic response (see Section 8.3)
.
4.1.4.1.2 Severe Pre -existing Hepatic Impairment
Cauti on is needed in pat ients with liver disease when administering azacit idine. Patients with 
extensive tumor burden due to metastatic disease have been reported to experience progressive 
hepat ic co ma and death during azacit idine treatm ent, especi ally in such pat ients with baseline 
albumin <30 g/L [12]. Azacit idine is contraindicated in patients with advanced malignant hepatic 
tumors.
4.1.4.1.3 Renal Abnormalities
Patients with renal impairment should be closely monitored for toxicity because azacit idine and its 
metabo lites are primarily  excreted by  the kidneys. Renal abnormalit ies ranging fro m elevated 
serum  creat inine to renal failure and death have been reported in patients treated with IV 
azacit idine in combinat ion with other chemotherapeutic agents for non -MDS condit ions. Renal 
tubul ar aci dosis, defined as a fall in serum bicarbonate to <20 mEq/L in associat ion with an 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 29of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALalkaline urine and hypokalemia (serum potas sium <3 m Eq/L), developed in 5 patients wi th 
CMML treated with azacit idine and etoposide.
4.1.4.2 Pevonedistat Plus Azacitidine
Study C15009 was a phase 1b study  that evaluated the MTD of pevonedistat on Days 1, 3, and 5 in 
combinat ion with 75mg/m2azacit idine (a dministered on a 5 -on/2-off [weekend]/2- on schedule) 
in a 28 -day treatm ent cycle in pat ients aged 60 years or older wit h treatment -naïve AML who were 
unlikely  to benefi t from standard induction therapy. A total o f 64patients were treated (ITT 
popul ation) at 2dose levels . Pevonedistat dosing started at 20 mg/m2(n=6) and increased to 
30mg/m2 (n=3) in the absence o f DLTs. During dose escalat ion, at the 30 mg/m2dose l evel, 2 of 
the 3patients experienced a DLT: 1 patient had persistent Grade 2 bilirubi n elevat ion, and 
1patient had reversible Grade 4 AST elevat ion. Transaminase and bilirubin elevat ions were 
transi ent and clinically inconsequential in both patients (resolving to Grade 1 or baseline levels 
within 1 week after wi thdrawal  from study ). The M TD was determined to be 20 mg/m2
pevonedistat in co mbination wit h 75 mg/m2azacit idine. An addit ional 55 patients were treated at 
the MTD, for a total of 61 patients treated at the MTD.
Patients in the ITT cohort (n =64) received a median of 4 cycles (ran ge, 1 -37), and 23 of 
64patients (36%) received ≥6cycles of pevonedistat plus azacit idine. The most commo n adverse 
events (AEs) were constipat ion (48%), nausea (42%), fat igue (42%), and anemia (39%). 
Fifty-three pati ents (82%) experi enced Grade ≥3 AEs; th e most frequent ( ≥15%) were anemia, 
febrile neutropenia (each 30%), thrombocy topeni a (23%), neutropeni a (20%), and pneumo nia 
(17%). AST/ALT elevat ions Grade ≥3 were reported in 6% of patients. Forty -four patients (69%) 
experienced serious adverse events (S AEs); the most frequent ( ≥10%) were febrile neutropenia 
(25%) and pneumo nia (14%). In addit ion to the 2 patients who wi thdrew because of DLTs, 
2patients withdrew fro m the study because o f therapy -related toxicit y (febrile neutropenia). In the 
MTD expansio n cohort (n =55), 2 addit ional patients experienced DLTs (Grade ≥3transaminase 
elevation) and were successfully rechallenged with a reduced dose of pevonedistat. Both patients 
remained on study  without further hepat ic toxicit y. There were 11 on-study  deaths unrelated to 
study  therapy . Pevonedistat PK was not altered by  the addi tion of  azaci tidine.
The m ost detailed informat ion on risks is provided in the IB and the Developmental Core Safety 
Inform ation located wi thin the IB.
Overall ident ified risks of pe vonedistat include increased heart rate, diarrhea, nausea, vo miting, 
abnorm al liver funct ion tests, py rexia, myalgia, and musculoskeletal pain.
Hepatotoxicity : Hepatotoxicit y has been noted follo wing administration of pevonedistat in patients 
with advanced malignancy, including elevations of liver transaminases (up to Grade 4), alkaline 
phosphatase (ALP; up to Grade 3), and bilirubin (up to Grade 3). Grade 1 through Grade 4 
increases in ALT and AST have been observed in patients receiving single -agent pevon edistat for 
relapsed and/or refractory  AML. The pati ents experi encing these changes in laboratory  values 
have been asymptomatic. This type o f elevat ion in transaminases had been observed previously in 
patients treated with pevonedistat. The elevat ions in laboratory  values have been reversible wit h 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 30of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALdose m odificat ion including dose delay and reduct ion. Patients with elevated transaminases have 
been successfully rechallenged at lower doses.
Some events are considered potential risks of pevonedistat because of the occurrence of these 
events in phase 1 clinical  studi es in which single -agent pevonedistat was administered at doses 
substant ially higher than those being used in current clinical trials. Those events included 
multiorgan failure that could result in dea th, renal  failure, myel osuppressi on with increased 
suscept ibilit y to infect ion, bleeding, anemia, acute phase response, gastrointest inal toxicit y 
including or resulting in dehydrat ion, electroly te imbalance, and hypophosphatemia. Reported 
instances of card iac arrhyt hmias were all supraventricular in origin, and all except 1 were deemed 
unrelated: the case of atrial fibrillat ion assessed by the investigator as related occurred in a pat ient 
with cardi ovascular ri sk factors.
Other events, such as fat igue, chil ls, decreased appetite, febrile neutropenia, and gastrointestinal 
bleeding (all events assessed by an investigator as unrelated, the majorit y occurring in the setting 
of thrombocy topeni a), are considered potential risks that are confounded by underlying di sease or 
malignancy.
Potenti al risks that are derived fro m findings in animal studies in rats and dogs include myocardia l 
degeneration and thrombosis; cardiovascular changes that could result in tachycardia; decreased or 
increased systolic blood pressure; increased diastolic blood pressure; pulmo nary hypertensio n; 
enteropathy  (including dehydration and electroly te loss) wi th secondary  sepsis; effects on testes 
and ovaries that represent a reproductive hazard, including sterilit y and increased developmental 
risk to fetus or embryo. Decreased trabecular bone (graded minimal to moderate) was noted in the 
femur and in the sternum in rats at all dose groups (low, medium, high); this finding was 
considered adverse in the high -dose group, but no bone fractures were noted at any  of the doses. 
Prolongati on of the act ivated partial thromboplast in time (aPTT) and potential risk for local t issue 
injury  are also associated with pevonedistat SC administration. Addit ional details may be found in 
the current IB.
Based on the known individual safet y profiles of pevonedistat and azacit idine, the following 
potenti al risks of combinati on therapy  may apply: myelosuppressio n, gastrointestinal events, 
electroly te imbalances, hypophosphatemia, decreased renal funct ion, hepatotoxicit y, cardi ac 
arrhy thmias, cardi omyopathies, m uscul oskeletal  pain, bleeding, and inject ion site reactions.
In Study C15009, patients received azacit idine as eit her an IV infusio n or SC inject ion. Data fro m 
Study C15009 indicate that the route of azacit idine ad ministration has no apparent effect on the 
safet y profile of pevonedistat plus azacit idine.
4.1.4.3 Docetaxel
Treatment -related mortalit y increases with abnormal liver funct ion, at higher doses, and in patients 
with non‒small  cell lung cancer who received prior pl atinum -based therapy receiving docetaxel at 
100mg/m2.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 31of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALSevere hypersensit ivity, including very rare, fatal anaphylaxis, has been reported in patients who 
received dexamethasone premedication. Severe reactions require immediate discont inuat ion of 
docetaxel and administrati on of  appropri ate therapy .
Docetaxel is contraindicated if the patient has a history  of severe hypersensit ivity react ions to 
docetaxel or to drugs formulated with polysorbate 80.
Severe fluid retention may  occur despi te dexamethasone premed ication.
For m ore details, refer to the docetaxel SmPC [13] or USPI [1].
4.1.4.3.1 Hepatotoxicity Warning
Docetaxel should not be given if total bilirubin is >ULN or if AST or ALT is ≥1.5 ×ULN. Patients 
with elevations of bilirubin or abnormalit ies of transaminase concurrent with ALP are at increased 
risk for the development of Grade 4 neutropenia, febrile neutropenia, infect ions, severe 
thrombocy topenia, severe stom atitis, severe skin toxicit y, and toxi c death. Pati ents wi th isolated 
elevations of transaminase >1.5 ×ULN also had a higher rate of Grade 4 febrile neutropenia but 
did not have an increased incidence of toxic death. For this reason, patients with mild or mo derate 
hepat ic impairment will not be enrolled in the Part B arm incorporating docetaxel. Bilirubin, AST 
or ALT, and ALP values should be obtained prior to each cycle of docetaxel therapy and reviewed 
by the investigator.
4.1.4.3.2 Hematologic Warning
Docetaxel shou ld not be given if the abso lute neutrophil count (ANC) is less than 1500 cells/mm3.
4.1.4.4 Pevonedistat Plus Docetaxel
The fo llowing potenti al risks, based on the known individual safet y profiles of pevonedistat 
plusdocetaxel , of combinati on therapy  may apply: death, hy persensi tivity, hepatotoxicit y, 
neutropeni a, and fluid retention (cardiac/pulmo nary).
4.1.4.5 Carboplatin
Anaphylaxis -like react ions to carboplat in have been reported and may occur within minutes of 
carbopl atin administration. Epinephrine, corticosteroids , and ant ihistamines have been emplo yed 
to alleviate symptoms.
Vomit ing is another frequent drug –related side effect.
Carbopl atin injection is contraindicated in pat ients with a history  of severe allergic reactions to 
cisplatin or other plat inum -containing compounds.
Carbopl atin injection should not be emplo yed in patients with severe bone marrow depression or 
significant bleeding.
For m ore details, refer to the carboplatin USPI [
14]or Sm PC [15].
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 32of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL4.1.4.5.1 Nephrotoxicity Warning
The m ajor route of  eliminat ion for carbopl atin is renal excret ion. Renal effects of nephrotoxic 
compounds [16] (see  Appendix K) may  be potentiated by  carbopl atin. For patients with impaired 
renal funct ion, carboplatin is given at 200 mg/m2or at a dose determined using t he Calvert formula 
based on the glo merular filtration rate (GFR) of the patient. Treatment with carboplat in for patients 
with hepatic or renal impairment is administered at no higher than AUC5 based on safet y profile of 
pevonedistat plus carbopl atin plus p aclitaxel in Study C15010.
4.1.4.5.2 Hematologic Warning
Bone m arrow suppressi on is dose rel ated and may  be severe, resul ting in infect ion or bleeding. 
Peripheral  blood counts shoul d be frequent ly monitored during carboplat in treatment and, when 
appropriate, until r ecovery  is achieved.
Anemia may  be cum ulative and may require transfusion support.
4.1.4.6 Paclitaxel
Anaphylaxis and severe hypersensit ivity react ions characterized by  dyspnea and hypotension 
requi ring treatm ent; angioedema; and generalized urticaria have occurre d in 2% to 4% of patients 
receiving paclitaxel in clinical studies. Fatal react ions have occurred in pat ients despite 
prem edicat ion. All patients should be pretreated with corticosteroids, diphenhydramine, and 
H2antagonists. Patients who experience severe hypersensit ivity reactions to paclitaxel should not 
be rechallenged with the drug.
Severe conduct ion abnormalit ies have been documented in less than 1% of patients during 
paclitaxel therapy and, in so me cases, require pacemaker placement. If patients deve lop significant 
conduction abnormalit ies during paclitaxel infusio n, appropriate therapy  shoul d be administered, 
and cont inuous cardiac monitoring should be performed during subsequent therapy with 
paclitaxel.
Paclitaxel is contraindicated in patients who have a history o f hypersensit ivity react ions to 
paclitaxel or other drugs formulated in Cremophor EL (polyo xyethylated castor oil).
For m ore details, refer to the paclitaxel USPI [16] or Sm PC [ 17] .
Paclitaxel inject ion the rapy shoul d not be given to patients with so lid tumors who have baseline 
neutrophil counts of less than 1500 cells/mm3. To m onitor for the occurrence of bone marrow 
suppressio n and primarily neutropenia, which may be severe and result in infect ion, it is 
recommended that frequent peripheral blood cell counts be performed on all pat ients receiving 
paclitaxel inject ion.
There i s limit ed evidence that the myelotoxicit y of paclitaxel may be exacerbated in patients with 
serum  total  bilirubin >2 ×ULN. For patien ts wi th total  bilirubin levels o f 1.26 to 2 ×ULN, 
paclitaxel should be given at 135 mg/m2over a 3 -hour infusio n peri od.
The effect of renal dysfunct ion on the di sposi tion of  paclitaxel has not been invest igated.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 33of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL4.1.4.7 Pevonedistat and Carboplatin Plus Paclitax el
The fo llowing potenti al risks of combinat ion therapy  with pevonedistat and carboplat in plus 
paclitaxel may  apply: bone marrow suppression, hypersensit ivity/anaphylaxis react ions, and 
hepatotoxicit y. A summary  of hematol ogic toxi city of carbopl atin alone and in co mbinat ion with 
paclitaxel is provided in Appendix L.
4.1.5 Potential for DDIs
No formal clinical assessments of DDIs between azacit idine and other a gents have been conducted. 
Please consult the VIDAZA USPI (Clinical Pharmacology [Section 12.3], Drug -Drug Interactions) 
for addit ional informat ion [10]. Urin ary excret ion is the primary route of eliminat ion of azacit idine 
and its metabolites. Pevonedistat is not a strong inhibitor or inducer for major CYP enzymes and 
drug transporters. The concomitant administration of pevonedistat is not expected to have 
clinically meaningful impact on azacit idine PK.
Pevonedistat concentration
-time data were obtained from 64 treatment -naïve pat ients with AML 
who were administered pevonedistat in co mbination with azacit idine in Study C15009. 
Pevonedistat systemic exposures wer e not altered in the presence of azacit idine when compared 
with histori cal pevonedistat single- agent data (Study C15003), indicat ing that coadministration of 
azacit idine has no effects on pevonedistat PK.
Concurrent administration of carboplat in and paclit axel decreased the CL of pevonedistat by 
approximately  50%, translat ing to an approximately 100% higher pevonedistat exposure (AUC).
The potential risk of DDIs between pevonedistat and conco mitantly administered drugs is 
currently informed by  available non clinical and clinical data (see IB). Study C15011 assessed the 
effect of mult iple doses of fluconazo le (a moderate CYP3A inhibitor) as well as the effect of 
multiple doses of itraconazole (a strong CYP3A/P -gp inhibitor) on pevonedistat PK. The result 
indic ated that fluconazo le or itraconazole has no clinically meaningful impact on pevonedistat PK. 
In Study P1015, co-administration of rifampin, a strong CYP3A inducer, with pevonedistat did not 
resul t in clinically  meaningful al terati on of  pevonedi stat system ic exposures [18]. Despi te resul ts 
of Studi esC15011 and P1015, in the current study , use of  strong CYP3A inducers and inhibitors 
remains prohibited in order to interpret the effects of organ impairment on pevonedistat PK 
without other confounding factors. As a general precauti on, pati ents receiving concomitant 
medicat ions, particularly  those wi th narrow therapeuti c indices, shoul d be carefully mo nitored as 
the DDI potential between pevonedistat and other drugs has not been formally studied in humans. 
Patients shoul d also be instructed to consult with the invest igator before taking any new 
medicat ions, including over -the
-counter products and herbal supplements.
See Section 8.4for informat ion on concomitant medicat ions that are prohibited and Section 8.5for 
inform ation on m edicat ions that are permitted durin g this study .
4.1.6 Summary of Risks and Benefits
Analyses of safet y data fro m mo re than 130 patients treated with pevonedistat plus azacit idine at 
the dose and schedule to be used in this phase 1/1b study  dem onstrate that pevonedistat adds little 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 34of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALtoxicity to azacit idine alone and that toxicit ies are manageable. Efficacy data fro m a phase 1 study 
using this combinat ion demonstrated a 50% ORR based on an ITT analysis (20 CR, 5 CRi, 7 PR), 
with an 8.3 -month median duration of remissio n in untre ated, older patients with AML for whom 
intensive induct ion chemotherapy  was considered inappropriate. In patients receiving ≥6cycles o f 
therapy  (n=23, 44%), ORR was 83%. In total, 6 out of 8 patients wi th a TP53 m utation achieved 
CR/CRi/PR, and 4 of 6 r emained on study for >10 cycles. Baseline bone marrow blast percentage 
or cy togenetic/m olecular risk di d not influence ORR [9]. Thus, the benefit -risk rati o supports 
further study o f the combinat ion of pevonedistat and azacit idine in a rando mized controlled trial in 
patients wi th HR MDS or CMML, or AML.
A number of patients with so lid tumors treated with pevonedistat as a single agent demonstrated 
clinical benefit based primarily on prol onged SD. In addit ion, pevonedistat has clinical activit y 
when administered in co mbinat ion therapy  with docetaxel or carboplat in plus paclitaxel. On the 
basis of findings from Study C15010 and Study C15011, these combinat ions have shown evidence 
of clinica l benefit in the form of mult iple PRs, limited CRs, and extended durations o f SD. 
Therefore, it is considered that docetaxel and carboplat in plus paclitaxel may serve as reasonable 
partners in co mbinat ion with pevonedistat for investigat ions in patients wi th various advanced 
solid tumors in this study .
4.2 Rationale for the Proposed Study
Pevonedistat is being developed in co mbination with azacit idine for the treatm ent of HR MDS, HR 
CMML, and AML and in co mbinat ion with docetaxel or carbopl atin plus paclitaxel for treatm ent 
of advanced so lid tumors. Based on the preliminary results fro m the clinical radio labeled mass 
balance study  (Study P1013), pevonedistat undergoes extensive biotransformat ion with 41% and 
53% of administered radioactivit y recovered in urine a nd feces, respectively . Oxidative 
biotransformat ion pathways represented the major clearance mechanisms for pevonedistat, as 
inferred fro m metabolite profiling studies of excreta.
A population PK analysis of pevonedistat has been conducted with a wide rang e of renal functio n 
represented in the analysis populat ion of cancer patients (CrCL, 26.3 -
301mL/min; estimated 
glomerular filtration rate [eGFR] 24-267 mL/min/1.73 m2). The analysis dataset included patients 
with renal impairment ranging fro m mild (N = 114 wi th CrCL of 60 - 89mL/min; N =157 wi th 
eGFR o f 60-89 mL/min/1.73 m2) or m oderate (N =57 with CrCL of 30 - 59mL/min; N =75 with 
eGFR o f 30-59 mL/min/1.73 m2). Renal funct ion was not i dentified as a covariate in the 
popul ation PK model, and it was conclu ded that mild or moderate renal impairment had no 
clinically meaningful impact on the PK of pevonedistat. Although renal clearance o f parent drug is 
only a minor (2.5%) contributor to overall pevonedistat clearance, the possibilit y of severe renal 
impairme nt altering drug m etabo lism and impact ing pevonedistat PK cannot be ruled out.
Azacit idine and its metabo lites are primarily  excreted by  the ki dneys. Azacit idine exposures 
increase (70% following single -dose and 40% following mult iple-dose administration) in patients 
with severe renal impairment. This increase in azacit idine exposure was not correlated with an 
increase in AEs in the single -agent setti ng. Therefore, a Cy cle1 dose m odificat ion of azacit idine 
for pati ent wi th severe renal impairment is not re commended [10]in its single -agent setting of 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 35of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALapproved use. This study  will also evaluate the safety  of pevonedistat in combinat ion with 
azacit idine in patien ts wi th severe renal impairment.
The effects of severe renal impairment or mild or moderate hepat ic impairment on pevonedistat 
PK will be evaluated in this study . The resul ts of this study  will guide development of posology  
adjustm ents that m ay be needed f or pevonedistat in these special pat ient popul ations. In Part A, 
administration of a single dose of pevonedistat will allow for the characterization of the effects of 
severe renal impairment or mild or moderate hepatic impairment on pevonedistat PK. In Par tB, 
the safet y and PK of pevonedistat in combinat ion with SOC agents will be assessed. For patients 
with hematol ogic malignancies, the PK of both pevonedistat and azacit idine in the co mbinat ion 
setting will be assessed. For patients with solid tumors, the PK of pevonedistat will be assessed in 
the combination setting.
Patients wi th advanced so lid tumors will be eligible for enrollment in the organ impairment arms 
of the study . Based on the popul ation PK analysis in 416 patients wi th advanced malignancies, 
tumor type (hematol ogic vs so lid tumor) did not impact the PK of pevonedistat. Therefore, it is 
appropriate to broaden participat ion in this study  to incl ude pati ents wi th solid tum ors. After 
completing Part A (single dose of pevonedistat), patients with a dvanced so lid tumors will have the 
option to continue into the second part of the study (Part B), in which they will receive 
combinat ion treatment with pevonedistat and docetaxel or carboplat in plus paclitaxel.
The cho ice of the above chemotherapy  agents i n combinat ion with pevonedistat in this study  is 
based on the fo llowing considerat ions:
These chemotherapy agents have been well recognized as SOC in a number of malignancies in 
first-line (carboplat in plus paclitaxel) or in various relapse settings (both regimens).
The safet y profiles, risks, and benefits have been widely studied and reported.
Addit ive/synergist ic effects of these agents in co mbinat ion with pevonedistat have been 
studi ed in a number of in vitro and in vivo models by  the sponsor.
4.3 Rationale for the Dose
Single dose of pevonedistat (Part A)
The recommended clinical dose of pevonedistat as a single agent is 50 mg/m2or higher on Days 1, 
3, and 5 in 21- day cycles.
In thi s study , all eligible pati ents will  receive a singl e dose of 20 mg/m2pevone distat i n Part A. A 
single dose of 20 mg/m2pevonedistat in pat ients with severe renal impairment or mild or moderate 
hepat ic impairment is considered to be safe and is expected to be well -tolerated, as i t is at l east 
2.5-fold below the upper end of the to lerated dose range of single -agent pevonedistat.
Based on the population PK analysis in 416 patients receiving pevonedistat over a dose range of 10 
to 278 mg/m2, levels of ALT and AST did not have meaningful impact on pevonedistat exposures. 
Tumor type (hematol ogic vs so lid) showed no impact on pevonedistat systemic exposure. In 
addition, renal  clearance plays a minor role in pevonedistat eliminat ion pathways. Pa tients will  be 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 36of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALclosely  monitored for toxicities. After administration of the first dose of pevonedistat, there will be 
a period of 4 to 7 days (washout period) without further dosing wit h pevonedistat.
Multiple dosing of pevonedistat in combination with st andard of care agents (Part B)
After complet ion of Part A, patients will have the opportunit y to parti cipate in Part B and receive 
pevonedistat in co mbination wit h SOC agents.
In pati ents wi th hematol ogic m alignancies (MDS, CMML, or AML), pevonedistat is b eing 
developed in co mbinat ion with azacit idine. The RP2D is determined to be 20 mg/m2on Days 1, 3, 
and 5 pl us 75 mg/m2azacit idine on Days 1 through 5, 8, and 9 in 28 -day cycles (Study C15009).
In pati ents wi th advanced so lid tumors, pevonedistat is being devel oped in combinat ion with 
carbopl atin plus paclitaxel or docetaxel. The RP2D in co mbinat ion with carboplat in plus paclitaxe l 
is determined to be 20 mg/m2on Days 1, 3, and 5 with 175 mg/m2pacli taxel  plus AUC5 
carbopl atin on Day 1 in 21- day treatm ent cycles (Study C15010). The RP2D of pevonedistat in 
combinat ion with docetaxel is 25 mg/m2on Day s1, 3, and 5 with 75 mg/m2docetaxel on Day 1 in 
21-day treatm ent cy cles (Study C15010).
Forpatients with normal renal and hepatic function
In pati ents wi th hematol ogic m alignancies and normal renal and hepat ic function, starting in 
Cycle 1 of Part B, patients will receive 20 mg/m2pevonedistat on Days 1, 3, and 5 in combinat ion 
with 75mg/m2azacit idine on Days 1 through 5, 8, and 9 in 28 -day cycles.
As of Ame ndment 02, the Control Arm of the study completed enro llment. Patients with advanced 
solid tumors with normal renal and hepat ic function will not be enro lled in the Control Arm.
Forpatients with mild hepatic impairment
Three patients with hematologic malignancies and mild hepat ic impairment have been enro lled in 
Study Pevonedistat -1016 and received 10 mg/m2pevonedistat in combinat ion with azacit idine. No 
new safet y signals were reported. Therefore, as of Amendment 02, pati ents wi th mild hepatic 
impairment and hematol ogic malignancies or solid tumors will receive 20 mg/m2 pevonedistat in 
combinat ion therapy  in Part B.
Starti ng in Cycle 1 of Part B, patients with hematologic malignancies and mild hepat ic impairment 
will receive 20 mg/m2pevonedistat on Days 1, 3, and 5 in co mbinat ion with 75 mg/m2azacit idine 
on Day s1 through 7 or Days 1 through 5, 8, and 9 in 28 -day cycles. The starting doses for 
pevonedistat and azacit idine in co mbinat ion are not to be escalated in this cohort.
Patients wi th advanced so lid tumors and mild hepatic impairment who are considered to benefit 
from treatment wi th pevonedistat in co mbinat ion with carbopl atin plus paclitaxel will receive 
20mg/m2pevonedistat on Days 1, 3, and 5 in co mbinat ion with 135 mg/m2paclitaxel plus AUC4 
carbopl atin on Day 1 of each 21 -day treatment cy cle.
The dose of paclitaxel (135 mg/m2) selected for patients with mild hepat ic impairment is based on 
USPI recommendat ions in pat ients with bilirubin <2 mg/dL [19] and is not to be escalated.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 37of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALThe l ower starti ng dose of carboplat in (AUC4) is selected to provide a window of safety for 
patients with mild hepat ic impairment. Starting in Cycle 2 or in subsequent cy cles, intrapatient 
dose escalat ion of carbopl atin to AUC5 will be allowed if treatment with AUC4 in Cycle 1 is 
judged to be safe and tolerable.
According to the docetaxel USPI, patien ts wi th bilirubin >ULN or AST or ALT ≥1.5 ×ULN 
shoul d not receive docetaxel. Docetaxel will therefore not be dosed in pat ients with mild or 
moderate hepat ic impairment.
For patients with moderate hepatic impairment
For pati ents wi th moderate hepati c impai rment, a lower starti ng dose of pevonedistat (10 mg/m2) 
is selected to provide an adequate safet y window for potentially increased pevonedistat exposures 
in this pat ient popul ation.
Starti ng in Cycle 1 of Part B, patients with hematologic malignancies and moderate hepatic 
impairment will receive 10 mg/m2pevonedistat on Days 1, 3, and 5 in combinat ion with 75 mg/m2
azacit idine on Days 1 through 7 or Days 1 through 5, 8, and 9 in 28 -day cycles.
Patients wi th advanced so lid tumors and moderate hepat ic impair ment who are considered to 
benefit from treatment with pevonedistat in combinat ion with carbopl atin plus paclitaxel will 
receive a starting dose of 10 mg/m2pevonedistat on Days 1, 3, and 5 in combinat ion with 
90mg/m2paclit axel plus AUC4 carbopl atin on Day 1 of each 21 -day treatm ent cy cle.
Following sponsor and invest igator discussio n of safet y data fro m Cycle 1, pati ents with moderate 
hepat ic impairment who tolerate pevonedistat well at lower doses may be eligible for intrapatient 
pevonedistat dose escal ation in dose increments of 5 mg/m2 per cycle starting in Cycle 2 (eg, 
pevonedistat may be increased to 15 mg/m2on Days 1, 3, and 5 of Cycle 2) and in subsequent 
cycles, to a m aximum  dose of 20 mg/m2.
The dose of paclitaxel (90 mg/m2) selected for patient s with moderate hepatic impairment is based 
on USPI recommendations in pat ients with bilirubin >2 ×ULN [19] and is not to be escalated.
As in patients with mild hepat ic impairment, carboplat in dosing will begin at AUC4 for patient 
safet y. Starting in Cycle 2 or in subsequent cy cles, intrapat ient dose escalat ion of carbopl atin to 
AUC5 will be allowed if t reatm ent with AUC4 in previous cycles is judged to be safe and tolerable. 
Dose escalat ion of carbopl atin is not to take place during the same cycle in which pevonedistat 
dose i s escalated.
For patients with severe renal impairment
Renal clearance of pevone distat i s a minor route of eliminat ion. Three patients with hematologic 
malignancies and severe renal impairment have been enrolled in Study Pevonedistat -1016 and 
received 10 mg/m2pevonedistat in co mbinat ion with azacit idine. No new safet y signals were 
reported. The safet y and preliminary  PK data from these 3 patients support a starti ng dose of 
15mg/m2pevonedistat. Therefore, patients with severe renal impairment and hematologic 
malignancies or solid tumors will receive a starting dose of 15 mg/m2 pevone distat in combinat ion 
therapy  in Part B.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 38of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALStarti ng in Cycle 1 of Part B, patients with hematol ogic malignancies and severe renal impairment  
will receive 15 mg/m2pevonedistat on Days 1, 3, and 5 in co mbinat ion with 75 mg/m2azacit idine 
on Day s1 through 7 o r Days 1 through 5, 8, and 9 in 28 -day cycles.
Patients wi th advanced so lid tumors and severe renal impairment who are considered to benefit 
from treatment wi th pevonedistat in co mbinat ion with carbopl atin plus paclitaxel will receive 
15mg/m2pevonedistat on Days 1, 3, and 5 in co mbinat ion with pacli taxel 135 mg/m2plus 
carbopl atin AUC4 on Day 1 of each 21 -day treatm ent cy cle.
Patients wi th advanced so lid tumors and severe renal impairment may receive pevonedistat in 
combinat ion with docetaxel . For pati ents considered to benefit from treatment with pevonedistat 
plus docetaxel , the starting pevonedistat dose in Cycle 1 will be 15 mg/m2in combinat ion with 
docetaxel 75 mg/m2.
Following sponsor and invest igator discussio n of safet y data from  Cycle 1, pati ents with severe 
renal impairment who tolerate pevonedistat well at lower doses may be eligible for intrapatient 
pevonedistat dose escalat ion. Starti ng in Cycle 2 or in subsequent cycles, patients treated with 
pevonedistat in co mbination wit h azacit idine or car boplatin plus paclitaxel may  be eligible for 
intrapat ient pevonedistat dose escalation to a maximum dose of 20 mg/m2.
For pati ents receiving pevonedistat in co mbinat ion with docetaxel  who tol erate pevonedistat well 
at lower doses, intrapatient dose escalat ion of pevonedistat in dose increments of 5 mg/m2per 
cycle is allowed starting in Cycle 2 (eg, pevonedistat may be increased to 15 mg/m2on Day s1, 3, 
and 5 of Cycle 2) and in subsequent cycles, to a maximum dose of 25 mg/m2.
The dose of paclitaxel (135 mg/m2) is selected for patient safet y, however, as paclitaxel is cleared 
through the hepat ic route, patients with severe renal impairment may be eligible for intrapatient 
dose escalation to 175 mg/m2 pacli taxel in Cycle 2 or bey ond if the lower dose is well -tolerated in 
Cycle 1.
The starting dose of carboplat in will be AUC4 to provide a window for patient safet y. Starti ng in 
Cycle 2 or in subsequent cy cles, intrapatient dose escalat ion of carboplat in to AUC5 will be 
allowed if treatment with AUC4 in Cycle 1 is judged to be safe and tolerable.
Dose escalat ion of any  SOC agent i s not permitted in the same cycle as dose escalat ion of other 
SOC agents or of pevonedistat.
5.0 STUDY OBJECTIVES AND ENDPOINTS
5.1 Objectives
5.1.1 Primary Objectives
The primary  object ives (Part A) are as follows:
To characterize the PK o f pevonedistat in pat ients with severe renal impairment.
To characterize the PK o f pevonedistat in pat ients with mild hepat ic impairment.
To characterize the PK o f pevonedistat in pat ients with moderate hepati c impairment.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 39of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL5.1.2 Secondary Objectives
The secondary  objectives (Part A and Part B) are as follows:
To evaluate disease response in pat ients with severe renal impairment or mild or moderate 
hepat ic impairment that may be observed in the combinat ion of pevonedist at wi th 
chemotherapy (azacit idine, docetaxel, or carboplatin plus paclitaxel).
To characterize the PK o f pevonedistat and azacit idine in the co mbination setting in pat ients 
with hematol ogic malignancies and severe renal impairment or mild or moderate hepat ic 
impairment.
To characterize the PK o f pevonedistat in co mbination with docetaxel or carboplat in plus 
paclitaxel in pat ients with advanced solid tumors and severe renal impairment or mild or 
moderate hepat ic impairment.
5.1.3 Safety Objective
The safet y objective (Part A and Part B) is as fo llows:
To evaluate the safet y of pevonedistat following a single dose, or in combinat ion with 
chemotherapy (azacit idine, docetaxel, or carboplatin plus paclitaxel), in pat ients with normal  
organ funct ion and in patients with organ impairment.
5.1.4 Exploratory Objectives
Not applicable.
5.2 Endpoints
5.2.1 Primary Endpoints
The primary  endpoints are as follows:
Area under the plasma concentration -time curve from t ime zero to infinit y (AUC ∞) following a 
single dose of pevonedistat in pat ientswith norm al renal  and hepat ic function, severe renal 
impairment, or mild or moderate hepat ic impairment.
Area under the plasma concentration -time curve from time zero to the time of the last 
quant ifiable concentration (AUC last) following a single dose of pevonedistat in patients with 
norm al renal and hepatic funct ion, severe renal impairment, or mild or moderate hepatic 
impairment.
Maximum observed plasma concentration (C max) of pevonedistat fo llowing a single dose of 
pevonedistat in pat ients with normal  renal  and hepati c function, severe renal impairment, or 
mild or moderate hepatic impairment.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 40of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL5.2.2 Secondary Endpoints
The secondary  endpoints are as follows:
t1/2z of pevonedistat following single -and m ultiple-dose administration.
Cmaxof pevonedistat followin g multiple-dose administrati on.
Fract ion of unbou nd drug in plasma (f u) of pevonedistat.
Cmaxof azaci tidine fo llowing m ultiple-dose administrati on.
Time o f first occurrence of maximum observed concentration (T max) of azaci tidine fo llowing 
multiple-dose ad ministration.
t1/2z of azaci tidine fo llowing mul tiple-dose administrati on.
Area under the concentration -time curve from t ime zero to the end of the dosing interval 
(AUC τ) of pevonedistat and azacit idine fo llowing mul tiple-dose administration.
CL of pevonedistat and apparent clearance (CL/F) of azacit idine.
Renal clearance (CL R) of pevonedistat and azacit idine.
Volume of distribut ion at steady -state (V ss) of pevonedistat and apparent V ssof azaci tidine.
Measures of disease response, including response rate and duration of response, based on the 
investigator’s assessment (Part B only) using the following responses for each disease t ype:
–CR, CRi, or PR for AML.
–CR, PR, or hematologic improvement (HI) for MDS and CMML.
–CR or PR in patients with so lid tumo rs using the Response Evaluation Criteria in Solid 
Tumors (RECIST) versi on1.1 cri teria.
5.2.3 Exploratory Endpoints
None.
5.2.4 Safety Endpoints
The safet y endpo ints are:
AEs, SAEs, assessments of clinical laboratory  values, vi tal signs m easurements, and Eastern 
Cooperative Onco logy Group (ECOG) performance status (PS).
6.0 STUDY DESIGN
6.1 Overview of Study Design
This study  is an open -label, mult icenter, phase 1/1b, 2 -part study  of pevonedistat pl us select SOC 
agents in adult patients with hematologic malignancies (HR M DS, HR CMML, AML) or solid 
tumors wi th various degrees of renal or hepatic function. Eligible pat ients include those with 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 41of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALrelapsed/refractory  MDS, nonproliferat ive CMML, AML, and metastatic or advanced so lid 
tumors for whom  treatment wi th pevonedistat and SOC agents is appropriate. Patients with 
previously untreated hematologic malignancies not suitable for induct ion therapy  will also be 
eligible for enrollment. The study has been designed to characterize the PK and assess the safet y of 
pevonedistat in co mbination wit h SOC agents in patients with hematologic malignancies or solid 
tumors who al so have severe renal impairment or mild or moderate hepatic impairment. As of 
Amendment 02, pati ents will be assigned to 1 of 4 arms based on their renal and/or hepatic
funct ion: normal renal and hepat ic function (Control Arm), severe renal impairment (Renal Arm), 
mild hepatic impairment (Mild Hepat ic Ar m), and moderate hepat ic impairment (Moderate 
Hepati c Arm ).
It is expected that approximately 42 patients will  be enrol led in this study . As of Amendment 02, 
Part A of the study  will be a single -agent pevonedistat PK assessment, fo llowed by  Part B 
treatm ent wi th pevonedistat in combinat ion with SOC agents (azaci tidine, docetaxel , or 
carbopl atin plus paclitaxel).
Once enro lled into the study, all eligible patients will be administered a single dose of pevonedistat 
20mg/m2via approximately  1-hour IV infusio n on Day 1 of Part A. Plasma PK samples will be 
collected at a series of predetermined t ime points up to 72 hours follo wing the single dose of 
pevonedistat. There will be an approximate 4- to 7-day washout peri od before the start of Part B. 
The schedules of events and study  schema for the study  are provi ded in Appendix Aand 
Appendix B,
 respectively .
After complet ion of Part A, all pat ients will have the opportunit y to continue into Part B of the 
study .
In Part B, patients with hematologic malignancies may receive pevonedistat on Days 1, 3, and 5 in 
combinat ion with azaci tidine (75 m g/m2) on Days 1 through 7 or Days 1 through 5, 8, and 9 in 
28-day cycles. Pati ents will receive azaci tidine SC in Cycle 1. Azacit idine will be given SC or IV 
during Cycle 2 and beyo nd. During Cycle 1 of Part B, pl asma and urine PK samples for 
measurement of both pevonedistat and azacit idine will be co llected at predetermined time po ints 
or intervals on Day 3. Plasma PK samples for measurement of pevonedistat will also be collected 
on Day s4 and 5 of Cycle 1.
Patients wi th advanced so lid tumors may receive pevonedistat in co mbination wit h docetaxel or 
carbopl atin plus paclitaxel on Day 1 and p evonedistat al one on Day s3 and 5 in 21 -day cycles. 
During Cycle 1 of Part B, plasma PK samples for measurement of pevonedistat will be collected 
on Day s3, 4, and 5.
The schedule of sample co llection for PK assessments is provided in Appendix A .
Following sponsor and invest igator discussio n of safet y data from  Cycle 1, pati ents in the organ 
impairment arms who tolerate pevonedistat well at a low starting dose m ay be eligible for 
intrapat ient dose escalat ion of pevonedistat starting in Cycle 2 of Part B or soon thereafter. 
Patients who tol erate treatm ent well at low starting doses of SOC agents may also be eligible for 
intrapat ient dose escalat ion of those agents, per USPI/SmPC reco mmendat ions.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 42of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALDetails for dosing, study  drug administration, and intrapatient dose escalat ion are provi ded in 
Secti on8.1
Patients m ay continue to receive combinat ion treatment with pevonedistat in 28 -day cycles (in 
combinat ion with azaci tidine) or i n 21-day cycles (in combinat ion with docetaxel or carboplat in 
plus paclitaxel) in Part B un til they  experi ence symptom atic deter ioration or disease progression, 
treatm ent is di scontinued for another reason, or until the study  is stopped by  the sponsor.
Treatment with the study  drug will  be discont inued early if a pat ient experiences study  
drug-related toxicities. Patients may discontinue therapy at any t ime. Patients will attend the end of 
study  (EOS)/early terminat ion (ET) visit 30 (+10) days after receiving their last dose of study drug 
or before the start of subsequent antineoplast ic therapy, if that occurs sooner.
AEs and E COG PS will be assessed, and electrocardiograms (ECGs), clinical laboratory values 
(with select chemistry panel during Part B), and vit al signs will be obtained, to evaluate the safet y 
and tol erabilit y of the study  drug treatm ents. Toxi city will be eval uated according to National 
Cancer Inst itute Common Termino logy Cri teria for Adverse Events (NCI CTCAE), version 5.0, 
effect ive date 27 November 2017 [1]. Dose modification gu idelines are presented in Sect ion8.3.
Measures of disease response (CR or PR for AML and so lid tumors; CR, PR, or HI for MDS and 
CMML), including response rate and duration of response, will be based on the invest igator’s 
assessment (Part B only).
6.2 Number of Patients
Approximately  42patients will be enrolled at 25 to 30 study centers located in the United States 
(US) and EU. Enrollment is achieved w hen the first dose of any study drug has been administered.
Patients will  be assigned to 1 of 4 arms based on their renal and/or hepatic function: normal renal 
and hepat ic function (Control Arm), severe renal impairment (Renal Arm), mild hepatic 
impairment (Mild Hepat ic Ar m), and moderate hepatic impairment (Moderate Hepatic Arm). 
Patients who are wi thdrawn from  treatm ent during Part A of the study , will be replaced. Patients 
who are nonevaluable for PK during Part A may also be replaced.
6.3 Duration of Study
6.3.1 Duration of an Individual Patient’s Study Participation
Part A:Patients will part icipate in the assessment of pevonedistat PK fo llowing a single -dose 
administration of pevonedistat (4 to 7 days).
Part B:Eligible pat ients who opt to continue into Part B of the study  will receive pevonedistat in 
combinat ion with SOC agents (azacit idine, docetaxel, or carboplat in plus paclitaxel). Patients ma y 
receive co mbinat ion therapy  until they  experience symptom atic deterioration or PD, 
discontinuat ion for any other rea son outlined in Section 9.7,
 or the study is stopped by the sponsor 
(eg, if a PTA study  becom es available). The maximum durat ion of treatment is 12 cycles, unless 
the invest igator and sponsor (or designee) agree that a patient would benefit fro m continued 
treatm ent. Pati ents who continue on treatment after 12 cycles will be permitted to take treatment 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 43of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALbreaks, at the invest igator’s discretion, that ar e no longer than 4 weeks in durat ion; treatment 
breaks may not be taken consecut ively. The invest igator will confirm pat ient eligibilit y for 
continued treatment upon return from a treatment break (Section 8.3). Pati ents wi th hematol ogic 
malignancies may be allo wed to continue study  treatm ent even if they  meet the cri teria for PD 
based only on bone marrow blast counts if, in the clinical judgment of th e invest igator, the patient 
is still receiving clinical benefit fro m this treatm ent, and the continuat ion is endorsed by  the 
sponsor’s project clinician (or designee). Patients who continue on study  under these condit ions 
must be reconsented before continu ing study  treatment (see Secti on9.4.1 ).
Patients wi th advanced solid tumors who have achieved clinical benefit fro m combinat ion therap y 
(chemothera pyplus pevonedistat) and who have developed into lerance that is reasonably 
attributable to the chemotherapy after 2 or more cycles may cont inue on single -agent pevonedistat 
upon request by  the invest igator and agreement by the sponsor.
Patients will  be followed for 30 (+10) days after the last dose of study drugs or the start of 
subsequent alternative ant icancer therapy  to permi t detecti on of  any delayed treatm ent-related 
AEs.
6.3.2 End of Study/Study Completion Definition and Planned Reporting
The final analyse s for the CSR may  be conducted when all pat ients have had the opportunit y to 
complete Part A and Cycle 1 of Part B of the study. Patients will be fo llowed unt il they are no 
longer receiving study  drug or the study  has been terminated by  the sponsor.
6.3.3 Timefr ames for Primary and Secondary Endpoints to Support Disclosures
Refer to Table 6.afor disclosures informat ion for all primary  and secondary  endpoints.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 44of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALTable 6.a Primary and Secondary Endpoints for Disclosures
EndpointMaximum Time Frame Per Individual 
Patient
AUC ∞following a single dose of pevonedistat in patients with 
normal renal and hepatic function, severe renal impairment, or 
mild or moderate hepatic impairment (Part A).Up to 72 hours following single dose of 
pevonedistat.
AUC lastfollowing a single dose of pevonedistat in patients 
with normal renal and hepatic function, severe renal 
impairment, or mild or moderate hepatic impairment (Part A).Up to 72 hours following single dose of 
pevonedistat.
Cmaxof pevonedistat following a single dose of pevonedistat in 
patients with normal renal and hepatic function, severe renal 
impairment, or mild or moderate hepatic impairment (Part A).Up to 72 hours following single dose of 
pevonedistat.
t1/2zof pevonedis tat (Parts A and B). Up to 72 hours following pevonedistat dosing.
fuof pevonedistat. Up to 48 hours following pevonedistat dosing.
t1/2z of azacitidine (Part B). Up to 8 hours following azacitidine dosing.
AUC τof pevonedistat and azacitidine
(Part B).Up to 48 hours following azacitidine and 
pevonedistat dosing.
CL of pevonedistat (Parts A and B). Up to 72 hours following pevonedistat dosing.
CL/F of azacitidine. Up to 8 hours following azacitidine dosing.
CL R, pevonedistat (Part B). Up to 8hours following pevonedistat dosing.
CL R, azacitidine (Part B). Up to 8 hours following azacitidine dosing.
Vssof pevonedistat (Parts A and B). Up to 72 hours following pevonedistat dosing.
Vssof azacitidine (Part B). Up to 8 hours following azaciti dine dosing.
Measures of disease response (CR or PR for AML and solid 
tumors; CR, PR, or HI for MDS and CMML); including 
response rate and duration of response, based on the 
investigator’s assessment (Part B).Cycle2, and then every 3rd cycle thereafter, or 
otherwise as clinically indicated per the 
discretio n of the investigator. After completion 
of 11 cycles, disease response will be assessed 
every 6th cy cle, or otherwise as clinically 
indicated. a
AML: acute myelogenous leukemia; AUC ∞: area under the plasma concentration -time curve from time zero to 
infinity ; AUC last: area under the plasma concentration -time curve from time zero to the time of the last quantifiable 
concentration; AUC τ: area under plasma concentration -time curve from time zero to the e nd of the dosing interval ; 
CL: total clearance; CL/F: apparent clearance; CL R: renal clearance; C max: maximum observed plasma concentration; 
CMML: chronic myelomonocytic leukemia; CR: complete response/remission; f u: fraction of unbound drug in 
plasma; HI: hematologic improvement; MDS: myelodysplastic syndromes; PR: partial response/remission; t 1/2z: 
terminal disposition phase half -life; V ss: volume of distribution at steady -state.
aThe maximum duration of treatment will be 12 cycles; however, if it is determined after discussion between the 
investigator and the sponsor that a patient would derive benefit from continued treatment, the patient may remain on 
the current combination the rapy.
6.3.4 Total Study Duration
It is ant icipated that overall this study  will last for approximately  3.5years for Part A and Part B 
combined.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 45of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL6.3.5 PTA
6.3.5.1 PTA
If a PTA program should beco me an option for a patient, and if the responsible invest igator and the 
sponsor agree that the patient would derive benefit  from or woul d be harm ed wi thout continued 
treatm ent, then pevonedistat may be provided through the PTA program (where permitted by loca l 
regul ations).
6.3.5.2 Duration of PTA
If a PTA program  shoul d beco me an option for a patient, as described in Sect ion6.3.5.1 , the 
sponsor may cont inue to provide pevonedistat to that patient through the PTA program . Continued 
acces s to pevonedistat for participants will be terminated for those individuals who no longer 
benefit from treatment (eg, their disease has progressed or treatment is no longer tolerable), the 
benefit -risk no l onger favors the individual, an appropriate altern ative therapy beco mes available, 
or pevonedistat beco mes available eit her commercially or via another access mechanism. PTA 
may be terminated in a country  or geographi c region where the development of pevonedistat has 
been suspended or stopped by  the spons or or where pevonedistat can no longer be supplied.
7.0 STUDY POPULATION
7.1 Inclusion Criteria
7.1.1 All Patients
Each patient must meet all the fo llowing inclusio n criteria to be enro lled in the study :
1.Male and female patients aged 18 y ears or ol der.
2.Expected survival of at least 3 months from  the date of enrollment in the study .
3.ECOG PS of 0, 1, or 2 ( Appendix D).
4. Recovered (ie, Grade ≤1 toxicit y) fro m the reversib le effects of prior anticancer therapy .
5.Prothrombin t ime (PT) and aPTT ≤1.5 ×ULN at screening or within 7 days before the first 
dose of study  drug.
6.Female pat ients who:
Are postm enopausal  (see Appendix E)  for at l east 1 year before the screening visit, OR
Are surgically  sterile, OR
Agree, if they are of childbearing potential, to practice 1 highly effect ive method of 
contraception and 1 addit ional effect ive (barrier) method (see Appendix F) , at the sam e 
time, fro m the time of signing the informed consent through 6 months after the last dos e of 
study  drug, OR
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 46of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALAgree to practice true abst inence, when this is in line wit h the preferred and usual lifest yle 
of the subject. Periodic abst inence (eg, calendar, ovulat ion, symptothermal, postovulat ion 
methods), withdrawal, spermicides only, and lactat ional amenorrhea are not acceptable 
methods of contraception. Female and male condoms should not be used together.
7.Male patients, even if surgically  sterilized (ie, status postvasectomy), who:
Agree to practice effective barrier contraception during the en tire study  treatm ent peri od 
and through 4 months after the last dose of study  drug, OR
Agree to practice true abst inence, when this is in line wit h the preferred and usual lifest yle 
of the subject. Periodic abst inence (eg, calendar, ovulat ion, symptotherma l, postovul ation 
methods), withdrawal, spermicides only, and lactatio nal amenorrhea are not acceptable 
methods of contraception. Female and male condoms should not be used together.
8.Suitable venous access for the study -requi red bl ood sam pling (i e, PK sampl ing).
9.Voluntary  written consent must be given by the patient or the patient’s legally  acceptable 
representative before performance of any study -related procedure not part of standard medical 
care, with the understanding that consent may  be withdrawn by the patient or the patient’s 
legally acceptable representative at any  time without prejudice to future medical care.
7.1.2 Patients With Hematologic Malignancies
In addit ion to the inclusio n criteria in Sect ion7.1.1 , each patient with hematologic malignancies 
must al so m eet the following inclusio n criteria, as they apply  to thei r specific malignancy , to be 
enrolled in the study :
10.Previously  untreated hem atologicmalignancies not suitable for induct ion therapy .
11.Morphol ogically confirmed diagnosis of MDS or nonproliferat ive CMML (ie, with white 
blood cell [WBC] <13,000/µL) at study  entry , based on one of the following:
French -American -British Classificat ions [2]:
Refractory  anemia wit h excess blasts (RAEB), defined as having 5% to 20% myelo blasts 
in the bone marrow.
CMML with 10% to 19% myelo blasts in the bone marrow and/or 5% to 19% blasts in the 
blood.
OR
WHO Classificat ions [3]:
RAEB- 1, defined as having 5% to 9% myelo blasts in the bone marrow.
RAEB- 2, defined as having 10% to 19% myelo blasts in t he bone marrow and/or 5% to 19% 
blasts in the blood.
CMML -2, defined as having 10% to 19% myelo blasts in the bone marrow and/or 5% to 19% 
blasts in the blood.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 47of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALCMML -1 (although CMML -1 is defined as having <10% myelo blasts in the bone marrow 
and/or <5% blasts in the blood, these patients may enro ll only if bone marrow blasts ≥5%).
12.All patients with MDS or CMML must also have one of the fo llowing Prognosti c Risk 
Categories at study  entry , based on the Revised Internat ional Prognostic Scoring System 
(IPSS -R) [4]:
Very  high (>6 points).
High (>4.5 -6 points).
Interm ediate (>3 -4.5 poi nts): a pati ent determined to be in the Intermediate Prognostic 
Risk Category  is only  allowabl e in the setting of ≥5% bone m arrow myelo blasts.
13.Patients wi th WHO -defined AML at study  entry , including leukemia secondary  to pri or 
chemotherapy or result ing from an antecedent hematologic disorder, who have failed to 
achieve CR or who have relapsed after prior therapy  and are not candidates for potentially 
curative treatment.
14.Patients with relapsed or refractory MDS at study entry, who have previously been treated wit h 
an hypo methylating agent.
15.For pati ents wi th hematol ogic malignancies, l aboratory  value requi rements per study  arms for 
eGFR, total bilirubin, and ALT are provided in the table below:
Treatment
ArmeGFR
(mL/min/1.73 m2)Total
Bilirubin ALT
Control ≥90 ≤ULN ≤ULN
Renal <30 ≤ULN ≤2.5 ×ULN
Mild hepatic ≥60 ULN <bilirubin ≤1.5 ×ULN
(not secondary to transfusions)Any
Moderate hepatic ≥60 1.5×ULN <bilirubin ≤3.0 ×ULN
(not secondary to transfusions)Any
ALT: alanine aminotransferase; eGFR: estimated glomerular filtration rate; ULN: upper limit of the normal range.
Refer to Section 9.4.16 for information regarding hepatic and renal function laboratory result requirements.
7.1.3 Patients With Advanced Solid Tumors
In addit ion to the inclusion criteria in Sect ion7.1.1 , each pat ient with advanced so lid tumors must 
also m eet the following inclusion criteria to be enrolled in the s tudy:
16.Adult patients who have a histologically  or cy tologically confirmed metastatic or locally  
advanced so lid tumor that is appropriate for treatment with pevonedistat in co mbination wit h 
either docetaxel  or carboplatin plus paclitaxel in Part B of this s tudy, or have progressed 
despite standard therapy , or f or whom  conventi onal therapy is not considered effect ive.
17.For pati ents wi th advanced so lid tumors, clinical laboratory values are specified below:
Hem oglobin ≥8g/dL. Pati ents may  be transfused to achi eve this value.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 48of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALFor patients to be treated with pevonedistat plus docetaxel in Part B, total bilirubin must be 
≤ULN.
ALT, AST, and ALP ≤2.5 ×ULN.
–For pati ents to be treated with pevonedistat plus docetaxel  in Part B, AST and ALT 
must be ≤1.5 ×ULN. Only patients with severe renal impairment may  be considered 
for this combination.
ANC ≥1500/mm3.
Platelet coun t ≥100,000/mm3.
Albumin ≥2.7 g/dL.
18.Com puteri zed tom ography  (CT) scan or m agnet ic resonance imaging (MRI) of the chest, 
abdo men, and pelvis wit hin 28 days of the first dose of study  drug.
19.For pati ents wi th advanced so lid tumors, laboratory value requirements per study arms for 
eGFR, total bilirubin, and ALT are provided in the table below:
Treatment
ArmeGFR
(mL/min/1.73 m2)Total
Bilirubin ALT
Renal <30 ≤ULN ≤1.5 ×ULN a
or
≤2.5 ×ULN b
Mild hepatic c≥60 ULN <bilirubin ≤1.5 ×ULN Any
Moderate hepatic c≥60 1.5×ULN <bilirubin ≤3.0 ×ULN Any
ALT: alanine aminotransferase; eGFR: estimated glomerular filtration rate; ULN: upper limit of the normal range.
Refer to Section 9.4.16 for information regarding hepatic and renal function laboratory result requirements.
a For patients who receive pevon edistat plus docetaxel only.
b For patients who receive pevonedistat plus carboplatin plus paclitaxel only.
c Patients with advanced solid tumors in the hepatic impairment arms will not receive combination treatment with 
pevonedistat and docetaxel.
7.2 Exclusion Criteria
7.2.1 All Patients
Patients m eeting any o f the following exclusio n criteri a are not to be enrolled in the study :
1.Any serious medical or psy chiatri c illness that could, in the invest igator’s opinio n, potenti ally 
interfere wi th the com pletion ofstudy  procedures or could limit expected patient survival to 
less than 6 months.
2.End-stage renal disease requiring hemodialysis at study  entry .
3.Gilbert syndrome.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 49of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL4.Treatment with any invest igational products or participat ion in any intervent ional studi es 
within 21 days before the first dose of any study  drug.
5.Known hypersensit ivity to pevonedistat or its excipients.
6.Active uncontrolled infect ion or severe infect ious di sease, such as severe pneumo nia, 
meningit is, or septicemia. Prophylactic treatment with ant ibiotics is allowed.
7.Major surgery  within 14 days before first dose or a scheduled surgery  during study  period; 
inserti on of  a venous access device (eg, catheter, port) is not considered major surgery .
8.Life-threatening illness unrelated to cancer.
9.Known HI V seroposi tive.
10.Known hepat itis B surface ant igen seroposit ive or known or suspected active hepat itis C 
infect ion. 
Note: Patients who have iso lated posi tive hepat itis B core antibody (ie, in the setting of 
negat ive hepat itis B surface antigen and negat ivehepati tis B surface ant ibody) must have an 
undetectable hepat itis B viral load.
11.Known hepat ic cirrhosis or severe pre -exist ing hepati c impai rment.
12.Known cardiopulmo nary disease defined as unstable angina, clinically significant arrhythmia, 
congest ive hear t failure (New York Heart Associat ion Class III or IV; see Appendix G) , and/or 
myocardial  infarction wit hin 6 months before first dose. However, patien ts with ischemic heart 
disease who have had acute coronary  syndrom e, my ocardial  infarct ion, or revascularization 
more than 6 months before screening and who are without cardiac symptoms may enroll. 
Patients wi th congest ive heart failure (New York Heart Ass ociation Class III or IV) or New 
York Heart Associat ion Class II with recent decompensat ion requiring hospitalizat ion within 
4weeks before screening are excluded.
13.Prolonged rate corrected QT interval ≥500 msec, cal culated according to inst itutional 
guidelines.
14.Treatment with strong CYP3A inducers (see Appendix M) within 14 days before the first dose 
of pevonedistat.
15.Female pat ients who are lactating and b reastfeeding or have a positive serum pregnancy  test 
during the screening period or a posit ive urine pregnancy test on Day 1 of Part A, before first 
dose of study  drug.
16.Female patients who intend to donate eggs (ova) during the course of this study or for 6months 
after receiving their last dose of study  drug(s).
17.Male patients who intend to donate sperm or father a child during the course of this study or for 
4months after receiving their last dose of study  drug(s).
18.Diagnosed or treated for a different malignancy within 2 years before rando mizat ion or 
previously diagnosed with a different malignancy  with any current evi dence of residual 
disease. Pati ents wi th nonmelano ma skin cancer or carcinoma in situ of any t ype are not 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 50of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALexcluded if they have undergone resection. Patients with AML who have a history  of MDS or 
CMML are not excluded, as MDS/CMML to AML is a natural progression for hematologic 
disease.
19.High bl ood pressure that cannot be controlled by  standard treatm ents.
20.Left ventricular eject ion fract ion (LV EF) <50% within 6 months pr ior to study enrollment. If a 
resul t within this t ime frame is unavailable, LVEF must be determined by echocardiography or 
multigated acquisit ion scan at screening.
21.Severe uncontrolled ventricular arrhyt hmias or torsade de pointe s; electrocardiographic 
evidence of acute ischemia or active conduction system abnormalit ies; or clinically significant 
arrhy thmia (as an example, well -controlled atrial fibrillat ion woul d not be an exclusio n 
whereas uncontrolled atrial fibrillat ion woul d be an exclusio n).
22.Severe symptomat ic pulmo nary hypertensi on requiring pharmaco logic therapy  or pati ents 
with chroni c respiratory  disease that requi res cont inuous oxy gen.
7.2.2 Patients With Hematologic Malignancies
Patients wi th hematol ogic malignancies meet ing any of the fo llowing addit ional exclusio n criteria 
are not to be enro lled in the study :
23.Acute promyelocyt ic leukemia as diagnosed by mo rphologic examination o f bone marrow, by 
fluorescent in situ hybridizat ion or cy togeneti cs of  peripheral  blood or bone m arrow, or by  
other accepted analysis.
24.Patients wi th AML wi th a WBC count ≥50,000/ μL. Patients who are cy toreduced wi th 
leukapheresis or with hydroxyurea may be enrolled if they otherwise meet the eligibilit y 
criteria.
25.Patients wi th either clinical  evidence of or history  of central  nervous system (CNS) 
involvement by  AML.
26.Known hypersensit ivity to azaci tidine or i ts excipients.
27.For pati ents wi th hematol ogic malignancies, PT or aPTT >1.5 ×ULN or active uncontrolled 
coagul opathy  or bl eeding disorder. Patients therapeuti cally ant icoagulated wi th warf arin, 
direct thrombin inhibitors, direct factor Xa inhibitors, or heparin are excluded fro m enro llment.
7.2.3 Patients With Advanced Solid Tumors
Patients wi th advanced so lid tumors meeting any of the fo llowing addit ional exclusion criteria are 
not to be enrolled in the study :
28.Prior treatm ent wi th radiation therapy  involving ≥25% of the hematopoiet ically active bone 
marrow.
29.Known hypersensit ivity or history of severe intolerance or toxicity to chemotherapeut ic agents, 
inclu ding known history  of severe hypersensit ivity reacti ons to docetaxel (polysorbate 
80-based formulat ions) for patients to be treated wit h pevonedistat in co mbinat ion with 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 51of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALdocetaxel; history of hypersensit ivity to carboplatin for patients to be treated with pevonedistat 
pluscarbopl atin plus paclitaxel; or history of severe hypersensit ivity to paclitaxel 
(Crem ophor -based formulat ions) for pati ents to be treated with pevonedistat with carboplat in 
plus paclitaxel.
30.CNS metastasis, except for patients who have re ceived prior treatment (radiat ion or resection) 
and have stable CNS disease (eg, stable MRI, no steroid requirement).
8.0 STUDY DRUG
8.1 Study Drug Administration
All protocol -specific criteria for administration o f study drug must be met and documented before 
drug administration. Study  drug will be administered only  to eli gible pat ients under the 
supervisio n of the invest igator or ident ified subinvestigator(s).
The amount of study drug (pevonedistat and/or azacit idine, docetaxel, or paclitaxel, as applicable) 
to be administered will be based on body  surface area (BSA). BSA will be calculated using a 
standard formula (see example in Appendix H) on Day 1 of Part Aand on Day 1 of each cycle in 
Part B if the patient experiences a >5% change in body weight from the weight used for the most 
recent BSA calculat ion.
On days when azacit idine is coadministered with pevonedistat, azacit idine is given first, followed 
by the pevonedistat IV infusio n.
Part A:
All eligible pat ients will receive a single dose of 20 mg/m2pevonedistat via a 1 -hour IV infusio n 
on Day 1. There will be no SOC agents administered or addit ional pevonedistat dosing during 
Part A.
Part B:
After complet ion of  Part A, all pat ients will have the opportunit y to continue into Part B.
Patients With Hematologic Malignancies
Patients wi th hematol ogic malignancies m ay receive pevonedistat on Day s1, 3, and 5 in 
combinat ion with azaci tidine (75 m g/m2) on Days 1 through 7 or Days 1 through 5, 8, and 9 in 
28-day cycles. Pati ents will  receive azaci tidine SC in Cycle 1. Azacit idine will be given SC or IV 
during Cycle 2 and beyo nd. On the day s both study  drugs are administered, azacit idine will be 
administered first, fo llowed by pevonedistat. During Cy cle1 of Part B, pl asma and urine PK 
samples for measurement of both pevonedistat and azacit idine will be co llected at predetermined 
time points or intervals on Day 3. Plasma PK samples for measurement of pevonedistat will also 
be co llected on Days 4 and 5 of Cycle 1. The schedule of PK sampling for patients with 
hematol ogic malignancies is provided in Appendix A ,Table B.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 52of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALPatients With Advanced Solid Tumors
Patients wi th advanced so lid tumors may receive pevonedistat in co mbination wit h docetaxel or 
with carboplat in plus paclitaxel on Day 1 and pevonedistat alone on Days 3 and 5 in 21 -day cycles. 
During Cycle 1of Part B, plasma PK samples for measurement of pevonedistat will be collected 
on Day s3, 4, and 5. The schedule o f PK sampling for patients with solid tumors is provided in 
Table D of Appendix A.
For pati ents wi th solid tum ors and severe renal impairment, the invest igator will select which 
chemotherapy (docetaxel or carboplatin plus paclit axel) each patient will receive in co mbination 
with pevonedistat based on his/ her m edical judgment and indicat ion provi ded in package inserts 
(USPI/Sm PC).
Starting Doses for Patients With Organ Impairment
Following sponsor and invest igator discussio n of safet y data from  Cycle 1, pati ents in the organ 
impairment arms who tolerate pevonedistat well at lower doses may be eligible for intrapatient 
dose escalat ion in Part B, starting in Cycle 2 or soon thereafter. The maximum dose of 
pevonedistat that may  be administered in combinatio n with azaci tidine or carbopl atin plus 
paclitaxel is 20mg/m2. The maximum  dose of pevonedistat that may  be administered in 
combinat ion with docetaxel is 25 mg/m2. Patients with advanced so lid tumors may also be eligible 
for intrapatient dose escalat ion of SOC agents, depending on the study  arm in which the y are 
enrolled. Starting doses and intrapatient dose escalation guidelines for patients with organ 
impairment are described in Table 8.a, Table 8.b, and Table 8.c.
Table 8.a Starting D oses for Patients With Mild Hepatic Impairment
MalignancyPevonedistat a
(mg/m2)Azacitidine b
(mg/m2)Paclitaxel c
(mg/m2) Carboplatin d
Hematologic 20 75 - -
Solid tumors 20 - 135 AUC4
AUC: area under the plasma concentration -time curve.
aThe maximum dose of pevonedistat that may be administered in combination with azacitidine or carboplatin plus 
paclitaxel is 20 mg/m2.
b The maximum dose of azacitidine that may be administered in combination with pevonedistat is 75 mg/m2.
cThe maximum do se of paclitaxel that may be administered in combination with pevonedistat and carboplatin is 
135mg/m2.
dFollowing sponsor and investigator discussion of the available safety data, patients who tolerate treatment well at the 
initially  assigned dose of ca rboplatin may be allowed to increase their dose to a maximum dose of AUC5 during 
Cycle2 or in subsequent cycles of treatment.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 53of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALTable 8.b Starting Doses for Patients With Moderate Hepatic Impairment
MalignancyPevonedistat a
(mg/m2)Azacitidine b
(mg/m2)Paclitaxel c
(mg/m2) Carboplatin d
Hematologic 10 75 - -
Solid tumors 10 - 90 AUC4
AUC: area under the plasma concentration -time curve.
aFollowing sponsor and investigator discussion of the available safety data, patients who tolerate treatment well at the 
initially  assigned dose of pevonedistat may be allowed to increase their dose in increments of 5 mg/m2per cycle 
starting in Cycle 2 (eg, pevonedistat at 15 mg/m2 on Days 1, 3, and 5 of Cycle 2). The maximum dose of pevonedistat 
that may  be administered in combination with azacitidine or carboplatin plus paclitaxel is 20 mg/m2.
b The maximum dose of azacitidine that may be administered in combination with pevonedistat is 75 mg/m2.
cThe maximum dose of paclitaxel that may be administered in combination with pevonedistat and carboplatin is 
90mg/m2.
dFollowing sponsor and investigator discussion of the available safety data, patients who t olerate treatment well at the 
initially  assigned dose of carboplatin may be allowed to increase their dose to a maximum dose of AUC5 during 
Cycle2 or in subsequent cycles of treatment. Intrapatient dose escalation of carboplatin is not to take place durin g the 
same cycle in which pevonedistat dose is escalated.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 54of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALTable 8.c Starting Doses for Patients With Severe Renal Impairment
MalignancyPevonedistat
(mg/m2)Azacitidine a
(mg/m2)Paclitaxel b
(mg/m2) Carboplatin cDocetaxel d
(mg/m2)
Hematologic 15 e75 - - -
Solid tumors f15 g- 135 AUC4
Solid tumors f15 g75
AML: acute myelogenous leukemia; AUC: area under the plasma concentration -time curve; CMML: chronic 
myelomonocytic leukemia; MDS: myelodysplastic syndromes; SOC: standard of care.
Note: Dose escalation of any SOC agent is not permitted in the same cycle as dose escalation of other SOC 
agents or of pevonedistat. Only 1 study drug may be escalated in a cycle.
a The maximum dose of azac itidine that may be administered in combination with pevonedistat is 75 mg/m2.
bFollowing sponsor and investigator discussion of the available safety data, patients who tolerate treatment well at the 
initially  assigned dose of paclitaxel may be allowed to increase their dose to a maximum dose of 175 mg/m2 in Cycle 2 
or in subsequent cycles.
cPatients who tolerate treatment well at the initially assigned dose of carboplatin may be allowed to increase their dose 
to a maximum dose of AUC5 in Cy cle2 or in su bsequent cycles.
d The maximum dose of docetaxel that may be administered in combination with pevonedistat is 75 mg/m2. Patients 
receiving pevonedistat plus docetaxel may have a maximum of 2 docetaxel dose modifications, with dose reductions 
to 60 mg /m2or 45mg/m2allowed.
ePatients with hematologic malignancies who tolerate treatment well at the initially assigned dose of pevonedistat 
may be allowed to increase their dose to a maximum of 20 mg/m2starting in Cycle 2.
fFor patients with solid tumors and severe renal impairment, the investigator will select which chemotherapy 
(docetaxel or carboplatin plus paclitaxel) that each patient will receive in combination with pevonedistat based on 
his/her medical judgment.
gPatients with advanced solid tumors wh o tolerate treatment well at the initially assigned dose of pevonedistat may be 
allowed to increase their dose in increments of 5 mg/m2per cycle starting in Cycle 2 (eg, pevonedistat at 20 mg/m2 on 
Days 1, 3, and 5 of Cycle 2). The maximum dose of pevoned istat that may be administered in combination with 
carboplatin plus paclitaxel is 20 mg/m2. The maximum dose of pevonedistat that may be administered in combination 
with docetaxel is 25 mg/m2.
Study  drugs will be administered per the instructions for dosing in Sect ion8.1.1 , Section 8.1.2 , 
andSection8.1.3 .
8.1.1 Instructions for Pevonedistat and Azacitidine Dosing
Patients will  receive pevonedistat diluted with 5% dextrose or 0.9% saline solut ion in a 250 mL 
bag via a 60 -minute IV infusio n per the informat ion provi ded in the Direct ions for Invest igational 
Drug Use document located in the Pharmacy Manual. Pevonedistat should be administered 
through central or peripheral venous access. The infusi on may be sl owed or stopped and restarted 
for any  associ ated infusio n-related reacti ons. All infusio n times must be recorded. The total time 
from drug reconsti tution to end of infusio n must not exceed 6 hours.
The ent ire content of the pevonedistat IV bag will be infused at a constant rate over 
60(±10) minutes. The start and end time of IV infusion should be recorded accurately, particularly 
when PK assessments are performed. To ensure that all the pevonedistat is administered, the 
infusio n line will be fl ushed wi th 0.9% saline sol ution or 5% dextrose immediately after 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 55of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALadministration. The vo lume used for line flushing is not considered a part of the vo lume of the 
pevonedistat IV bag to be documented.
On Days 1, 3, and 5, when both study drugs are administer ed, azacit idine will be administered first 
followed by pevonedistat. The infusio n of pevonedistat will begin between 15 and 60 minutes after 
completion of administration of azacit idine.
8.1.2 Instructions for Pevonedistat and Docetaxel Dosing
On Day 1 of each cy cle in Part B, docetaxel 75 mg/m2will be administered as a 1 -hour IV infusio n 
andpevonedistat will be administered as described in Sect ion8.1.1 . On Days 3 and 5, only 
pevonedistat will be given. The duration of each cycle will be 21 days. Refer to the most recent 
USPI/Sm PC for further details regarding docetaxel administration [13,20] .
Prem edicat ion to prevent docetaxel
-associated (hypersensit ivity or other) reactions is 
recommended according to inst itutional guidelines or l ocal practi ces. For exam ple, pati ents m ay 
be treated wi th dexamethasone (4 mg twi ce daily for 3 days), which should start 24 hours before 
docetaxel administration.
8.1.3 Instructions for Pevonedistat and Carboplatin Plus Paclitaxel Dosing
On Day 1 of each cy cle in Part B, paclitaxel will be given as an IV infusio n over approximately  
3hours, fo llowed by carboplat in as an approximately 30- minute IV infusio n. Pevonedistat will be 
administered as described in Sect ion8.1.1 . On Days 3 and 5, only pevonedistat will be given. The 
durati on of  each cycle will be 21 days.
Refer to the most recent SmPC/USPI for further details regarding carboplat in administration 
[14,15] .
If a patient’s GFR is est imated using serum creat inine measurements by the standardized 
isotope dilution mass spectrometry  method, the US Food and Drug Administration (FDA) 
recommends th at physicians consider capping the dose of carboplat in for desi red exposure 
(AUC) to avoid potential toxicit y due to overdosing. Using the Calvert formula described in 
the carboplatin label, the maximum doses can be calculated as fo llows:
Total  carbopl atindose (m g)
=(target AUC) (GFR +25) [Calvert formula]
Maximum carboplat in dose (mg) =target AUC (mg min/mL) (150 mL/min)
The maximum dose is based on a GFR estimate that is capped at 125 mL/min for patients with 
norm al renal funct ion. No hi gher est imated GFR values should be used.
For a target AUC =4, the maximum dose is 4 150= 600 mg.
For a target AUC =5, the maximum dose is 5 × 150 = 750 mg.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 56of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALRefer to the most recent SmPC/USPI for further details regarding paclitaxel administration 
[17,19] .
Prem edicat ion to prevent paclitaxel -associ ated (hypersensit ivity or other) reactions is 
recommended according to inst itutional guideli nes or l ocal practi ces. For exam ple, pati ents m ay 
be treated with either dexamethasone (10 mg) 24 hours before and on the day of paclitaxel dosing 
or methylpredniso lone immediately  before pacli taxel dosing.
8.2 Reference/Control Therapy
Not applicable.
8.3 Dose Mo dification Guidelines
8.3.1 Dose Modifications for Hematologic Toxicities
8.3.1.1 Pevonedistat
It is not anti cipated that pevonedi stat dose m odificati ons woul d be necessary  because of 
myelosuppressio n. However, if clinically indicated in the opinio n of the invest igator, the 
pevonedistat dose may be reduced by 1 dose level (eg, from 20 mg/m2to 15 mg/m2or 10 mg/m2). 
The pevonedistat dose may  be re-escalated to 15 mg/m2or 20 mg/m2at a subsequent cycle, if the 
toxicity has recovered to Grade ≤1 or the patient’s baseline.
Although leukostasis is not anticipated in this study, pevonedistat should be held for symptoms of 
leukostasis unt il the leukostasis is treated per institutional guidelines. Pevonedistat may be 
restarted when WBC count is <50,000/μL and fo llowing agreemen t by the sponsor’s proj ect 
clinician (or designee).
8.3.1.2 Azacitidine
Dose reduction or delays of azacit idine for hematologic toxicit ies (including fever and neutropenia) 
shoul d be strongly discouraged, as it may  impact pati
ent outcom e.
In Part B, combinat ion treatment with pevonedistat and azacit idine will be repeated every 28 days 
for pati ents wi th hematol ogic malignancies. For pati ents wi th Grade 4 neutropenia at risk of 
infect ion, particularly in a relapse/refractory setting, prophyla ctic administration of ant ibacterial or 
antifungal agents may be considered, as appropriate, per medical judgment of treating physician or 
per institutional guidelines. In addit ion, administration of granulocyte co lony stimulating factor 
(G-CSF) prior to a nd during study  may be considered as appropriate, per medical judgment of 
treating physician or per inst itutional guidelines.
For patients with Grade 4 neutropenia, particularly in a relapse/refractory setting, the start of a new 
treatm ent cycle m ay be del ayed if failure to recover counts is thought to be related to marrow 
replacement with blasts. For patients with delays in the init iation of a new cycle of treatment due to 
toxicity, for therapy  to resume, toxicit y consi dered rel ated to treatm ent m ust have resolved to the 
patient’s baseline values, or to a level considered acceptable by the invest igator after discussio n 
with the proj ect clinician or designee.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 57of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALInitiation of  the next cy cle of treatment may be delayed for up to 2 weeks. At the end of that time,
the patient should be re -evaluated to determine whether the criteria for retreatment have been met. 
Shoul d treatm ent need to be delayed for more than 2 weeks because of inco mplete recovery  from 
treatm ent-related toxicit y, then the azacit idine dose will be decreased to 50 mg/m2when treatment 
is resumed.
If the reduced dose is well tolerated and the toxicit y leading to dose reduction was Grade ≤3, has 
resolved, and does not reoccur, the dose may resume at the original dose level in the next cy cle 
after endo rsement by  the sponsor’s proj ect clinician (or designee).
A delay  in the ini tiation of a cycle by 4 weeks or greater because o f lack of recovery fro m 
treatm ent-related hematologic toxicit yto the pati ent’s baseline values ,or to a l evel considered 
acceptab le by the invest igator after discussio n with the proj ect clinician (or designee) that is not 
related to l eukemic infiltration ,will tri gger considerati on for discont inuat ion of the patient from 
the study . If hematol ogic toxi city has not resolved by  6weeks , the pati ent m ust be discont inued 
from the study .
If indicated, bone marrow evaluat ion will be performed to establish whether cont inued 
myelosuppressio n is related to persistent or progressing leukemic infiltrat ion.
8.3.1.3 Docetaxel, Carboplatin, and Paclitaxel
Dose m odificat ion gui delines for specific hematologic toxicit ies in pat ients with advanced so lid 
tumors receiving docetaxel or carboplat in/paclitaxel in Part B are presented in Table 8.d.
Patients wi th unreso lved toxicit ies of Grade >1 lasting 3 weeks or longer fro m the date of the next 
scheduled treatment will be discontinued fro m the study. For detailed dose modificat ion guidelines, 
see Section 8.3.2.3 .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 58of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALTable 8.d Dose Modification Guidelines for Specific Hematologic Toxicities in Patients 
With Advanc ed Solid Tumors
Pathologic Condition Severity Action on Study Drug
Hematologic:
ANCFebrile neutropenia Hold dosing on Day 1 of Cycles ≥2 up to 3 weeks until febrile 
neutropenia is resolved, then resume dosing as appropriate. 
Consider use of growth factor or reduce chemotherapy by 1 dose 
level, as appropriate.
ANC <1500 cells/ L on 
Day 1 of Cy cles≥2Initiation (Day 1) of Cycles ≥2 should be delayed for up to 
3weeks until ANC is ≥1500 cells/L. Consider use of growth 
factor or reduce chemotherapy by 1 dose level as appropriate.
Grade ≥3 neutropenia 
lasting >7daysInitiation (Day 1) of Cycles ≥2 should be delayed until ANC is 
≥1500 cells/L. Consider use of growth factor or reduce 
chemotherapy by 1 dose level as appropriate.
Hematologic:
PlateletsPlatelet count 
<100,000/ L on any 
dosing day of Cy cles≥2Dosing in Cycles ≥2 should be delayed for up to 3 weeks until 
platelet count is ≥100,000 cells/L. Dose of chemotherapy may 
be reduced by 1 dose level as appropriate.
Grade 4 
thrombocytopenia 
lasting >7 days or platelet 
count <25,000 cells/L at 
any timeDosing in Cycles ≥2 should be delayed until platelet count is 
≥100,000 cells/L (see Section 8.3.2.3 ). Dose of chemotherapy 
may be reduced by 1 dose level as appropriate.
Hematologic:
AnemiaGrade ≥1 No dose modification is allowed for anemia. Transfusion and/or 
erythropoietin may be given, as clinically indicated, for the 
treatment of anemia (see Section 8.7.1.1 ).
ANC: absolute neutrophil count.
8.3.2 Dose Modifications for Nonhematologic Toxicities
8.3.2.1 Pevonedistat
Pevonedistat Dose Adjustment Based on Serum Transaminases and Total Bilirubin
Transient ALT/AST elevat ions have been observed in so me pat ients (approximately 5% to 8% in 
patients wi th AML/MDS and approximately 20% in pat ients with so lid tumors) after pevon edistat 
dosing. For patients with increased liver funct ion tests (compared to baseline) on Day 3 or Day 5, 
pevonedistat dosing should be held; once the elevated AST or ALT returns to the patient's baseline 
level or better, and/or elevated bilirubin returns to patient’s baseline level or better, pevonedistat 
dose m ay be resumed.
Pevonedistat Dose Adjustment Based on Hypophosphatemia
If hypophosphatemia is Grade ≥3, study  drug treatment shoul d not be resum ed unt il the 
hypophosphatemia is Grade ≤2. Hy pophospha temia shoul d be eval uated (including severit y and 
etiology), monitored, and treated according to inst itutional guidelines.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 59of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALPevonedistat Dose Adjustment for Other Toxicities
For other Grade ≥2 nonhematologic toxicit ies potent ially related to pevonedistat, t he pevonedistat 
dose may be reduced from 20 mg/m2to 15 mg/m2or 10 mg/m2at the discret ion of the investigator 
as clinically indicated. If the toxicit y returns to Grade ≤1 or the patient’s baseline status, 
pevonedistat may be re -escalated to 15 mg/m2or 20 mg/m2at the next cy cle.
8.3.2.2 Azacitidine
Azacitidine Dose Adjustment Based on Renal Function and Serum Electrolytes (Mild or 
Moderate Hepatic Impairment and Control Arms Only)
For renal  toxicities, specifically elevated creatinine Grade >1, azacit idine shoul d be reduced in 
accordance with the prescribing informat ion [10] and/or inst itutional guidelines. Similarly , if 
unexplained elevat ions in serum  creat inine or bl ood urea ni trogen occur, the next cycle should be 
delayed until values return to normal or baseline values, and the dose should be reduced by 50% on 
the next treatment course.
If unexplained reductions in serum bicarbonate levels to <20 mEq/L occur, the azacit idine dose 
shoul d be reduced by 50% on the next course. The azacit idine dose m
ay be re -escalated back to 
75mg/m2at the next cycle if the toxicit y has recovered to Grade ≤1 or the patient’s baseline status.
8.3.2.3 Docetaxel, Carboplatin, and Paclitaxe l
Criteria for Beginning or Delaying a Subsequent Treatment Cycle
For individual pat ients experi encing specific toxi cities, treatm ent in each new cycle will be 
delayed unt il toxicit y is reduced to Grade ≤1, patient’s baseline, or to a level considered acce ptable 
by the investigator after discussio n with the proj ect clinician or designee.
If dosing with pevonedistat is held for toxicit y during any  given cycle, dosing m ay resume wi thin 
that sam e cycle when toxicit y is reso lved. Alternatively, dosing may be he ld until the next cycle. 
The start of the next cycle may also be delayed for up to 3 weeks to allow pat ients to recover fro m 
any safety concerns, so that pevonedistat may be administered in co mbinat ion with chemotherapy.
Day 1 dosing of any cycle in Part Bmay be delayed by  up to 2 days to accommodate inclement 
weather, holidays, vacat ions, or other administrative reasons.
Criteria for Dose Interruption During a Cycle
During treatment with SOC agents, the infusio n may be slowed or stopped and restarted for any 
associ ated infusio n-related reactions. The exact date and time of each addit ional sample collect ion 
and the actual start and stop times o f the infusio n shoul d be recorded accurately .
Criteria for Dose Reduction
Alopecia o f any duration will not lead to dose modificat ion or treatment delay.
Patients receiving pevonedistat plus docetaxel may have a maximum o f 2docetaxel dose 
modificati ons. Docetaxel  is initially dosed at 75 mg/m2, dose reductions up to 60 mg /m2and 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 60of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL45mg/m2may be considered (if applica ble) or pevonedistat may be modified as described in 
Secti on8.3.2.1 .
The decisio n to treat at a reduced dose level o f chemotherapy is at the discret ion of the invest igator. 
Discussi ons wi th the proj ect clinician or designee are encouraged.
Criteria for Discontinuation of Study Drug
Patients receiving pevonedistat plus docetaxel who require more than 2 dose m odificati ons of  
either docetaxel  or pevonedi stat will be discont inued fro m the study .
Patients receiving pevonedistat and carboplat in plus paclitaxel may have no more than 1 dose 
modificati on (if applicable) of chemotherapy  agents or of pevonedistat (see above). Patients who 
requi re addi tional dose modificat ions will be discont inued fro m the study .
Dose m odificat ion gui delines for specific nonhematologic toxicit ies in patients with advanced 
solid tumors are presented in Table 8.e. Treatment cannot be withheld for longer than 3 weeks for 
any toxicit y Grade >1.
Table 8.e Dose Modification Guidelines for Specific Nonhematologic Toxicities in 
Patients With Advanced Solid Tumors
Pathologic Condition Severity Action on Study Drug
Nausea, emesis, or 
diarrhea despite 
maximal prophylaxisGrade 3 On day s when both chemotherapy and pevonedistat are 
administered, hold dosing for up to 3 weeks or until the toxicity 
returns to Grade ≤1, then restart at the next lower dose of 
chemotherapy. On days when pevonedistat is given as a single 
agent, hold pevon edistat dosing for up to 3 weeks or until the 
toxicity returns to Grade ≤1 before dosing is resumed. Note : 
Ensure that optimal prophylaxis has been employed before dose 
reductio n. Supportive care should be considered per local 
institutional guidelines, as clinically indicated.
Neurotoxicity
(paclitaxel or
docetaxel only)Grade 2 Hold treatment until patient recovers to Grade 1 toxicity, then 
resume treatment at the next lower dose level. This will be a 
permanent dose reduction. Carboplatin or pevonedistat dose is 
not to be modified.
Allergic reaction
(paclitaxel or docetaxel 
onlyModerate symptoms Stop infusion. Give IV diphenhydramine 25 to 50 mg, IV 
dexamethasone 10 mg, and/or treatment per institutional 
guidelines. After recover y of symptoms, resume infusion at a low 
infusion rate. If no further symptoms occur, resume full dose rate 
until infusion is complete. If symptoms recur, stop infusion and 
discontinue patient from the study.
IV: intravenous.
8.3.3 Intrapatient Dose Escalation (Part B)
In Part B, following sponsor and investigator discussio n of the patient’s safet y and tolerabilit y data 
from Cycle 1, pati ents in the organ impairment arms who tolerate pevonedistat well at the init ially 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 61of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALassigned dose may be allowed to increase their dose of pevonedis tat in increments of 5 mg/m2 per 
cycle during Cycle 2 or in subsequent cy cles of treatm ent. Pati ents wi th advanced so lid tumors 
who tolerate init ial doses of SOC agents may also be allowed to increase their dose of SOC agents, 
depending on the allowances o f their study  arm and only in cycles in which their dose of 
pevonedistat is not increased. Starting doses and intrapatient dose escalat ion plans for study drugs 
in each organ impairment arm are presented in Table 8.a, Table 8.b, and Table 8.c.
8.4 Excluded Concomitant Medications and Procedures
Prohibited conco mitant therapi es include investigational agents, androgens, supraphysio logic 
doses of corti costeroi ds, ery thropoi etin, thrombopoiet in agonists (eg, eltrombopag and 
romiplostim), or chem otherapeutic agents active against hematologic malignancies or advanced 
solid tumors.
Results fr om Study C15011 indicated that itraconazole, a strong CYP3A/ P glycoprotein (P -gp) 
inhibitor, and fluconazo le, a moderate CYP3A inhibitor, had no clinically meaningful effects on 
pevonedistat PK. The effect of rifampin, a strong CYP3A inducer, on pevonedis tat PK was 
evaluated in Study P1015. The geometric mean 
AUC ∞of pevonedistat in the presence o f rifampin 
was 79% of that in the absence of rifampin (90% CI: 69.2%, 90.2%). The result indicated that 
coadministration of rifampin did not result in clinically meaningful alterat ion of pevonedistat 
systemic exposures in the context of 28% of inter -individual variabilit y in pevonedistat clearance. 
In order to i nterpret the effects of organ impairment on pevonedistat PK without potential 
confounding factors, strong CYP3A inhibitors and inducers remain prohibited in this study .
A physio logically  based PK (PBPK) m odel accounting for hepatic uptake and metabo lism of 
pevonedistat was developed to describe the PK of pevonedistat and the observed low sensit ivity to 
DDIs w ith strong CYP3A/P -gp inhibitor (itraconazole) and strong inducer (rifampin). The 
pevonedistat PBPK model indicates that the sy stemic exposure of pevonedistat was not sensit ive 
to the perturbations of enzyme act ivity when the hepatic uptake beco mes t he rat e-determining step 
of its clearance. Consi dering the minimum effect on P -gp inhibit ion and hepat ic uptake being the 
rate-determining step of pevonedistat clearance, the effect of breast cancer resistance protein 
(BCRP) inhibit ion on pevonedistat systemic c learance is not expected to be clinically meaningful. 
Therefore, exclusio n of BCRP inhibitors (eg, cy closporine) is not deemed warranted in clinical 
studi es of  pevonedistat and, as of Amendment 02, BCRP inhibitors are no longer included in the 
list of excl uded conco mitant m edicati ons.
Medicat ions that are generally excluded but are allowed with certain except ions are listed in 
Table 8.f(for the combinat ion pevonedistat plus SOC agents).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 62of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALTable 8.f Concomitant Medications Excluded While Receiving Study Treatment: 
Combination Pevonedistat Plus SOC agents
Therapy Comment/Exceptions
Acetaminophen and acetaminophen -containing products. Acetaminophen and acetaminophen -containing 
compounds may be used judiciously and should not 
exceed a dose of 2 g of acetaminophen in a 24 -hour 
period.
Systemic antineoplastic therapy, except for hydroxyurea. Hydroxyurea dosing prior to and during the study 
treatment phase may be used and adjusted to control the 
level of circulating blast counts to no lower than 
10,000/µL while on study treatment. The dosing of 
hydroxy urea and changes to dosing of hydroxyurea must 
be recor ded.
Strong CYP3A inhibitors and inducers
(see Appendix M)
Any investigatio nal agent for MDS, CMML, or AML, or 
commercially available agents used in MDS, CMML, or 
AML, including androgens, supraphysiologic doses of 
corticosteroids, erythropoietin, eltrombopag [Promacta], 
or romiplostim [Nplate].
AML: acute myelogenous leukemia; CMML: chronic myelomonocytic leukemia; MDS: myelodysplastic syndromes; 
SmPC: Summary of Product Characteristics; USPI: United States Prescribing Information.
This list is n ot all -inclusive; consult the docetaxel, carboplatin, azacitidine, or paclitaxel USPIs or SmPCs, as 
applicable, for additional information regarding precautions, warnings, and contraindications.
8.5 Permitted Concomitant Medications and Procedures
Medicat ions and procedures that are specifically permitted during the study are listed in Table 8.g.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 63of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALTable 8.g Concomitant Medications and Procedures Permitted During the Study
Therapy Comment
Antiplatelet agents (eg, aspirin, 
clopidogrel) and anticoagulantsMay be used in patients who develop a thrombosis while on study. Note that 
patients with active uncontrolled coagulopathy or who are therapeutically 
anticoagulated with warfarin, direct thrombin inhibitors, direct Xa inhibitors or 
heparin are excluded from enrollment as per Section 7.2.
Antiemetics May be administered according to institutional guidelines.
Antibacterial or antifungal agents For patients with Grade 4 neutropenia, (defined as ANC ≤500/µL for 7 days or 
with fever), particularly in relapse/refractory setting, at risk of infection, 
prophylactic treatment with antibiotics (eg, fluoroquinolone, ciprofloxacin), 
antifungals (eg, voriconazole, fluconazole, parconazole), and antiviral agents 
(eg, acy clovir, entecavir, tenofovir) should be i nitiated, and continued at least 
through Cycle 1, or per institutional guidance.
Myeloid growth factors 
(eg,G-CSF, GM -CSF)In general, the use of myeloid growth factors in patients with myeloid 
malignancies is discouraged and should be restricted. For patients with myeloid 
malignancy in CR, CRi, or marrow CR (MLFS), growth factors may be used in 
specific circumstances, per institutional guidelines and after discussion with the 
project clinician (or designee). Additionally, to avoid dose delays, patients who 
experience Grade 4 neutropenia (ANC <0.5 × 109/L) with or without fever may 
receive G -CSF or GM -CSF between days 28 through 42 after discussion and 
agreement with the project clinician (or designee).
Nephrotoxic medications, 
including nonsteroidal 
anti-inflammatory drugsCaution should be used with nephrotoxic concomitant medications (see 
Appendix K). Alternative concomitant nonnephrotoxic medicatio ns should be 
used whenever possible.
Platelet transfusion Permitted as medically necessary per institutional guidelines (eg, for platelets 
<10,000/ µLin the absence of clinical bleeding) ; see Section 8.7.
Red blood cell transfusion To be considered for all patients with anemia, especially those with hemoglobin 
values ≤8g/dL; see Section 8.7. When RBC transfusion is considered, it should 
be administered at least 1 day prior to dosing with pevonedistat. All incidences 
of transfusions (and units given) should be captured in the eCRF.
ANC: absolute neutrophil count; CR: complete response/remission; CRi: complete remission with incomplete blood 
count recover y; eCRF: electronic case report form; G -CSF: granulocyte colon y-stimulating factor; GM -CSF: 
granulocyte macrophage colony -stimulating fac tor; MLFS: morphologic leukemia -free state; RBC: red blood cell.
8.6 Precautions and Restrictions
Concomitant medicat ions and procedures that are excluded or must be used with caut ion are 
described in Section 8.4and Sect ion8.5, respectively.
Certain situat ions may warrant further caution, such as modifying the dose of study drug(s). Dose 
modificati on guidelines are provided in Sect ion 8.3.
Refer to the package insert for VIDAZA USPI [
10]or EU Sm PC [11] for precautions and 
restri ctions related to azacit idine use. Refer to the most recent SmPCs/USPIs for further details 
regarding admin istrati on of  docetaxel , carbopl atin, and paclitaxel.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 64of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALIt is not known what effects pevonedistat has on human pregnancy  or devel opment of the embry o 
or fetus. Therefore, female pat ients parti cipating in this study  shoul d avoi d becoming pregnant, 
and male pat ients shoul d avo id impregnating a female partner. Nonsterilized female pat ients of 
reproducti ve age group and male patients should use highly effect ive methods of contraception 
(see list provided in Appendix F) through defined periods during and after study  treatm ent as 
specified below.
Female pat ients must m eet one of the following criteria:
Be postmenopausal (see definit ion in Appendix E)  for at least 1 year before the screening visit, 
OR
Be surgi cally sterile, OR
Agree, if they are of childbearing potential, to practice 1 h ighly  effect ive method and 
1additional effect ive (barrier) method of contraception at the same time, fro m the time of 
signing of the informed consent form (ICF) through 6 months after the last dose of study drug 
(whichever is longer), OR
Agree to practice true abstinence, when this is in line wit h the preferred and usual lifest yle of 
the subject. Periodic abst inence (eg, calendar, ovulation, symptothermal, postovulat ion 
methods), withdrawal, spermicides only, and lactatio nal amenorrhea are not acceptable 
methods of contraception. Female and male condoms should not be used together.
Agree to not donate eggs (ova) during the course of this study  or for 6months after receiving 
their last dose of study  drug(s).
Female pat ients should be advised not to breastfe ed while undergo ing treatment with azacit idine.
Male patients, even if surgically  sterilized (ie, status postvasectomy) must agree to one of the 
following:
Practi ce effect ive barrier contracepti on during the ent ire study  treatm ent peri od and through 
4months after the last dose of study  drug, OR
Practi ce true abstinence, when this is in line wit h the preferred and usual lifest yle of the subject. 
Periodic abst inence (eg, calendar, ovulat ion, symptothermal, postovulat ion methods), 
withdrawal , spermicides only, and lactational amenorrhea are not acceptable methods of 
contraception. Female and male condo ms should not be used together.
Male patients must agree to not donate sperm or father a child during the course of this study or for 
4months after receivin g thei r last dose of study  drug(s).
Before starti ng treatm ent, m ale patients should be advised to seek counseling on sperm storage, 
and female patients should be advised to seek counseling on egg storage.
Nonclinical data suggest that male and female patie nts administered pevonedistat have a potential 
risk of infert ility.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 65of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL8.7 Management of Clinical Events
Patients who experience an AE with pevonedistat should be fo llowed cl osely  for a recurrence of 
similar or other AEs upon subsequent dosing of pevonedistat.
8.7.1 Combination Pevonedistat Plus Standard of Care Agents
Commo n AEs reported for patients receiving the combinat ion of pevonedistat with specific 
chemotherapeut ic agents are provided in the most recent IB. For the combination o f pevonedistat 
with SOC agents , follow the gui dance in the follo wing subsect ions of this protocol.
8.7.1.1 Guidance for Clinical Assessment and Management of Hemodynamic Compromise 
(All Patients)
It is essent ial that the patients receiving the combinat ion of pevonedistat and SOC agents are 
careful ly eval uated at screening and before each dose of study  drug for early  symptom s and signs 
of hemodynamic co mpromise and/or active infect ion. Particular attention should be given to fever, 
tachy cardi a, hypotensi on, orthostasis, tachypnea, recent nausea and vomiting, and clinical 
evidence of dehydrat ion. Pati ents who experience an untoward reaction with the combinat ion of 
pevonedistat and SOC agents shoul d be f ollowed cl osely on subsequent dosing.
For pati ents f or whom  there i s a concern of dehydration, the f ollowing gui dance for rehy dration 
before pevonedistat dosing may be considered: 500 mL/hr of 0.5 Nsaline given over 2 to4hours 
for a total  of 1 to 2 L of fluid as clinically appropriate; each infusion of IV fluids should be 
recorded in the electroni c case report forms (eCRFs).
For all pat ients with anemia, and especially for those with hemoglo bin values ≤8g/dL at screening 
or during the conduct of the study , RBC transfusio ns should be considered before pevonedistat 
dosing based on the risk of inadequate oxygenat ion, underlying cardiopulmo nary status, clinical 
judgment, and/or hospital guidelines. Similarly, for patients with clinically significant 
thrombocy topenia, especially  those wi th platel et count <10,000/µL, a platelet transfusio n shoul d 
be consider ed. Any RBC or platel et transfusio n must be recorded in the eCRFs.
Patients who experience signs and symptoms of hemodynamic compromise after pevonedistat 
dosing (eg, tachycardia, hypotensio n, orthostasis, changes in mental status, syncope, and dizziness) 
shoul d be f ollowed cl osely and managed wi th supporti ve care, including hospitalizat ion, as 
clinically indicated.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 66of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL8.7.1.2 Guidance for Management of Cytopenia and Infection (Patients with Hematologic 
Malignancies)
Cytopeni a is comm on in pat ients with MDS, CMML, and AML. Pati ents wi th baseline 
neutropeni a or th ose who have significant bone marrow invo lvement may be at particularly high 
risk. Pati ents receiving the combinat ion of pevonedistat and azacit idine are carefully  eval uated at 
screening and before each dose of study  drug for neutropenia and risk of infection and provided 
adequate prophylaxis as outlined below:
If indicated, bone marrow evaluat ion will be performed to establish whether cont inued 
myelosuppressio n is related to persistent or progressing leukemic i nfiltration. When deciding 
on dose m odificat ions for m anagement of myelosuppressio n, consider dose modificat ion of 
azacit idine first before modifications of pevonedistat. Pevonedistat is generally not associated 
with myelosuppression.
As general guidance for patients with, or who are expected to experience, significant 
protracted neutropenia (defined as ANC ≤500/µL for 7 days or with fever) who are therefore at 
high ri sk of infect ion, prophylact ic treatment with ant ibiotics should be in itiated as detailed in 
Table 8.g. Use of ant i - infective agents are to be captured in the eCRF.
In general, the use of myelo id growth factors is discou raged and should be restricted. For 
patients in CR, CRi, or marrow CR (morphologic leukemia -free state), growth factors may be 
used in specific circumstances, as detailed in Table 8.g.
8.7.1.3 Guidance Management of Leukostasis (Patients with Hematologic Malignancies)
Pevonedistat treatm ent shoul d be wi thheld for patients who develop symptoms of leukostasis. 
Treatment may include leukapheresis and hydroxyurea ad
ministration, per inst itutional guidelines. 
When the patient’s WBC count is <50,000/ L and symptoms are improved, pevonedistat 
treatm ent m ay be restarted after consult ing wit h the sponsor’s project clinician (or designee). 
Treatment with other chemotherape utic agents may continue as clinically indicated.
8.7.1.4 Guidance for Management of Extravasation (All Patients)
Based on nonclinical findings as detailed in the IB, pevonedistat is considered a nonvesicant drug. 
Although no published guidelines are available for extravasat ion of nonvesicants, the invest igator 
is encouraged to fo llow inst itutional guidelines. Some general advice in case of extravasat ion 
includes immediately stopping drug infusion and elevat ing the affected limb to minimize swelling.
8.7.1.5 Guidance for U se of Granulocyte -Colony Stimulating Factor (Patients w ith Advanced 
Solid Tumors)
Use of growth factors such as G -CSF in pat ients wit h advanced so lid tumors are permitted at the 
investigator’s discret ion.
8.8 Blinding and Unblinding
This is an open -label study .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 67of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL8.9 Description of Investigational Agents
Upon recei pt of drug supply , contents m ust be verified prompt ly and the proper contacts notified 
of any discrepancies or damages as described in the Study /Pharmacy Manual.
8.9.1 Azacitidine
Azacit idine may  be supplied by t he site from co mmercial sources, depending on regional 
availabilit y. Commercially  available azacit idine is supplied as lyophilized powder in 100 mg 
single- use vials. Refer to the Study /Pharm acy Manual  and the VIDAZA USPI [10] or EU Sm PC 
[
11], as applicable, for additional informat ion regarding azacit idine.
8.9.2 Pevonedistat
The drug product is labeled Pevonedistat (TAK -924/MLN4924) Inject ion for Sol ution for 
Infusio n.
Pevonedistat Inject ion for Sol ution for Inf usion will be supplied by  the sponsor as detailed in the 
Study /Pharm acy Manual .
Each Pevonedistat Inject ion for Sol ution for Infusion vial contains 50 mg or 44 mg pevonedistat, 
as free base, formulated with the following excipients: citric acid (anhydrous), trisodium citrate 
dihydrate, betadex sulfo butyl ether sodium (Capt isol), and water for i njecti on.
Details are available in the IB.
8.9.3 Docetaxel, Carboplatin, and Paclitaxel
Docetaxel, carboplatin, and paclitaxel are each obtained fro m commercial sources according to 
local pract ice standards and are provided as commercially available dose formulat ions. Addit ional 
details are provided in the USPI/SmPC for each agent.
8.10 Preparation, Reconstitution, and Dispensation
Parenteral  drug products should be inspected visually  for parti culate matter and disco loration 
before administration, whenever solution and container permit.
Before use, Pevonedistat Inject ion for Sol ution for Infusio n vials should be brought to ambient 
condi tions (15°C -30°C) by  removing the vials from the refrigerator and placing them at room 
temperature. Accelerated warming met hods, such as a water bath, must not be used. Pevonedistat 
Inject ion for Sol ution for Inf usion is stable at ambient temperature for 6 hours before dilution. If 
the drug product vial is not to be used within the 6 -hour timeframe, the vial should be returned to 
storage. Each vial is for single use only.
Each Pevonedistat Inject ion for Sol ution for Infusion vial contains no minally 5 mL (50 mg) or 
4.4mL (44 mg) pevonedistat, as free base. Before inject ing the drug product into the 250 mL IV 
bag containing a 5% dextrose or 0.9% saline so lution, calculate the vo lume of drug product that 
will be administered and remo ve this vo lume fro m the 250 mL IV bag containing a 5% dextrose or 
0.9% saline so lution (see Pharmacy Manual for details). Using sterile technique, wit hdraw the 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 68of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALappropriate volume of drug fro m the vial(s) and inject into the 250 mL IV bag containing a 5% 
dextrose or 0.9% saline so lution. The bag must be gent ly inverted repeatedly  to mix the contents. 
The prepared pevonedistat IV bag must be used within 6 hours if stored at room temperature or 
must be discarded. Alternat ively, the prepared IV bag is chemically stable and may be stored for 
up to 18 hours at 2°C to 8°C. After 18 hours of storage at 2°C to 8°C, the prepared IV bag must be 
used wi thin 3 hours upon coming to room temperature or must be discarded.
Discard bag, needle, and sy ringe in a proper bi ohazard container according to inst itutional 
guidelines.
Detailed reconst itution and dosage preparation instructions are provided in the Direct ions for Use
located in the Pharmacy  Manual .
Instructi ons for the preparation, reconstitution, and dispensat ion of azacit idine are provided in the 
VIDAZA USPI [10] or EU SmPC [ 11]. For instructi ons and precautions regarding preparation of 
docetaxel, carboplatin, and paclitaxel, refer to the applicable USPI/SmPC for each agent.
Pevonedistat is an ant icancer drug, and as with other potentially toxic co mpounds, caution should 
be exercised when handling pevonedistat.
8.11 Packaging and Labeling
Pevonedistat Inject ion for Sol ution for Inf usion will be provi ded in Uni ted States Pharm acopei a 
(USP) Ty pe I gl ass vials. Each USP Ty pe I gl ass vial no minally contains 5 mL or 4.4 mL of 
compounded sterile sol ution, sealed wi th a chl oro-butyl rubber stopper and oversealed wit h an 
aluminum  seal and a pl astic cap.
Azacit idine is available as lyophilized powder in 100 mg, single -use vials fro m co mmercial supply 
with commercial packaging and labeling. Azacit idine may  be sourced l ocally  by the clinical  sites 
when regulations allow for clinical site sourcing wit h approp riate labeling.
Docetaxel, carboplatin, and paclitaxel may be sourced locally by the clinical site when 
arrangements have been made and agreed to by the sponsor and when regulations allow for clinical 
site sourcing, appropri ate labeling, and com pliance wi th local and regi onal regulat ions. As 
requi red by l ocal regulat ions, any  modificati ons to the plan for drug supply or storage will be 
communicated to the invest igator and detailed in the Study Manual.
8.12 Storage, Handling, and Accountability
All invest igational supplies are to be kept in a secure area with controlled access.
Vials o f Pevonedistat Inject ion for Sol ution for Infusion are to be stored at 2°C to 8°C.
Details o f the storage and handling of azacit idine are provided in the VIDAZA USPI [10] or EU 
SmPC [
11]. For instructi ons and precauti ons regarding preparation of docetaxel, carboplat in, and 
paclitaxel, refer to the applicable USPI/SmPC for each agent.
8.13 Other Protocol -Specified Materials
Refer to the Pharmacy Manual.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 69of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL9.0 STUDY CONDUCT
This tri al will be conducted in com pliance wi th the protocol, Good Clinical Pract ice (GCP), 
applicable regulatory  requi rements, and Internat ional Council for Harmonisation (ICH) 
guidelines.
9.1 Study Personnel and Organizations
The contact informat ion for the sponsor’s project clinician for this study, the central  laboratory  and 
any addit ional clinical laboratories or vendors participat ing on the study may be found in the Study 
Manual(s). A full list of invest igators is available in the sponsor’s invest igator database.
9.2 Arrangements for Recruitment of Patients
Recrui tment and enro llment strategies for this study may include recruit ment from the 
investigator’s local practice or referrals from other physicians. If advert isements become part of 
the recruit ment strategy , they  will be reviewed by  the inst itutional review board 
(IRB)/independent ethics committee (IEC). It is not envisioned that prisoners (or other populat ions 
that might be subject to coercion or exploitation) will be enro lled into this study .
9.3 Treatment Group Assignments
No randomization or stratificat ion will be performed in this study. Patients will be assigned on the 
basis of their renal and hepat ic function.
Laboratory  value requirements per treatment arm for eGFR, total bilirubin, and ALT are provided 
in Table 9.aand  Table 9.bfor pati ents wi th hematologic malignancies and advanced so lid tumors, 
respectively .
Table 9.a Laboratory Value Requirements per Treatment Arm for eGFR, Total 
Bilirubin, and ALT (Patients With Hematologic Malignancies Only)
Treatment
ArmeGFR
(mL/min/1.73 m2)Total
Bilirubin ALT
Control ≥90 ≤ULN ≤ULN
Renal <30 ≤ULN ≤2.5 ×ULN
Mild hepatic ≥60 ULN <bilirubin ≤1.5 ×ULN
(not secondary to transfusions)Any
Moderate hepatic ≥60 1.5×ULN <bilirubin ≤3.0 ×ULN
(not secondary to transfusions)Any
ALT: alanine aminotransferase; eGFR: estimated glomerular filtration rate; ULN: upper limit of the normal range.
Refer to Section 9.4.16 for information regarding hepatic and ren al function laboratory result requirements.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 70of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALTable 9.b Laboratory Value Requirements per Treatment Arm for eGFR, Total 
Bilirubin, and ALT (Patients With Advanced Solid Tumors Only)
Treatment
ArmeGFR
(mL/min/1.73 m2)Total
Bilirubin ALT
Renal <30 ≤ULN ≤1.5 ×ULN a
or
≤2.5 ×ULN b
Mild hepatic c≥60 ULN <bilirubin ≤1.5 ×ULN Any
Moderate hepatic c≥60 1.5×ULN <bilirubin ≤3.0 ×ULN Any
ALT: alanine aminotransferase; eGFR: estimated glomerular filtratio n rate; ULN: upper limit of the normal range.
Refer to Section 9.4.16 for information regarding hepatic and renal function laboratory resul t requirements.
aFor patients who receive pevonedistat plus docetaxel only.
b For patients who receive pevonedistat plus carboplatin plus paclitaxel only.
c Patients with advanced solid tumors in the hepatic impairment arms will not receive combination tr eatment with 
pevonedistat and docetaxel.
Part A (all pat ients):
Patients in all arms will receive pevonedistat 20 mg/m2IV as a 1 -hour infusio n administered on 
Day 1.
Part B (patients with hematologic malignancies):
Starti ng in Cycle 1 of Part B, patients with hematologic malignancies and normal renal and hepat ic 
funct ion will receive 20 mg/m2pevonedistat on Days 1, 3, and 5 in combination wit h 75 mg/m2
azacit idine on Days 1 through 5, 8, and 9 in 28 -day cycles.
As of Amendment 02, the Control Arm of the study completed enro llment. Patients with advanced 
solid tumors with normal renal and hepat ic function will not be enro lled in the Control Arm.
Starti ng in Cycle 1 of Part B, patients with hematologic malignancies and severe renal impairment  
or mil d or m oderate hepati c impai rment will receive pevonedistat on Day s1, 3, and 5 in 
combinat ion with azaci tidine (75 m g/m2) on Days 1 through 7 or Days 1 through 5, 8, and 9 in 
28-day cycles. Pati ents will  receive azaci tidine SC in Cycle 1. Azacit idine will be given SC or IV 
during Cycle 2 and beyo nd. The starting doses for pevonedistat and azacit idine in pat ients with 
organ impairment are described in Sect ion8.1.
Part B (patients with advanced solid tumors):
For pati ents wi th solid tum ors, the invest igator will assign each pat ient to pevonedistat plus 
docetaxel or to pevonedistat plus carboplatin plus paclitaxel based on his/her medical judgment, 
and per informat ion provi ded in the package inserts for the SOC agents (docetaxel, paclitaxel, or 
carbopl atin) for indicat ions for use.
Starti ng in Cycle 1 of Part B, patients with advanced solid tumors and severe renal impairment or 
mild or moderate hepatic impa irment will receive docetaxel or carboplat in plus paclitaxel in 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 71of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALcombinat ion with pevonedistat on Day 1, and pevonedistat alone on Days 3 and 5 in 21 -day 
cycles.
The starting doses for pevonedistat, docetaxel, carboplat in, and paclitaxel in pat ients with 
advanced so lid tumors are described in Sect ion8.1.
9.4 Study Procedures
Refer to the schedule o f events (SOE) tables ( Appendix A)  for timing of assessments. Addit ional 
details are provided as necessary  in the sect ions that follow and in the Study  and Laboratory  
Manuals. When applicable, specific visit wind ows for study  procedures are provided in the 
footnotes to the study  schedule tables.
Nonessent ial protocol visits that do not require on -site sam ple collect ion and assessment may be 
completed via tel emedicine (video or phone conversation between the patien t and the treating 
physician, if allowed per inst itutional guidelines) in si tuations where a site visit cannot be 
conducted, such as in a coronavi rus disease 2019 ( COVID -19)pandemic. The reason for 
telemedicine (eg, COVID -19-related) and the assessments p erform ed are to be captured in the 
electroni c data capture (EDC).
9.4.1 Informed Consent
Each patient, or the patient’s legally acceptable representative, must provide written informed 
consent before any  study -requi red procedures are conducted, unless those proc edures are 
perform ed as part of the patient’s SOC.
Reconsent of Patients With Hematologic Malignancies Who Meet the Criteria for PD and 
Continue Study Treatment
Patients with HR MDS or HR CMML may be allo wed to continue study treatment if they meet the 
criteria for PD based only on bone marrow blast count (without AML transformat ion) if, in the 
clinical judgment of the invest igator, the patient is still receiving clinical benefit from this 
treatm ent, and the continuat ion is endorsed by the sponsor’s proj ect clinician (or designee). 
Patients with AML in this study may also be allowed to continue study treatment, even if they meet  
the criteria for PD based only  on bone marrow bl ast coun ts if, in the clinical judgment of the 
investigator, the patient is st ill receiving clinical benefit from this treatment, and the continuation 
is endorsed by  the sponsor’s project clinician (or designee). Patients who continue on study under 
these condit ions m ust be reconsented before continuing study  treatm ent.
9.4.2 Inclusion/Excl usion Confirmation
Confirmation of pat ient eligibilit y by the sponsor’s project clinician (or designee) is required prior 
to enrollment. During screening, a patient eligibilit y checklist must be completed and submitted by 
the invest igator for review and approval  by the sponsor or designee before the patient is enro lled. 
Com pletion of the eligibilit y checklist is necessary to verify that the patient has met all of the 
inclusio n and exclusio n criteria. Source documentation allows for independent verification that 
patient eligibilit y has been determined by  the proper m ethodol ogy. Unless specifically requested, 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 72of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALadditional source documentati on does not need to be submitted with the checklist for the 
assessment of eligibilit y related to the other inclusion and exc lusion criteria.
Refer to Section 9.4.16 for informat ion regarding hepatic and renal funct ion laboratory  resul t 
requi rements.
9.4.3 Patient Demographics
The date of birth, race, ethnicit y, and sex of the patient are to be recorded during screening.
9.4.4 Medical History
During screening, a complete medical history  will be com piled for each patient. The history  will 
emphasize the background and progress of the pat ient’s malignancy. For patients with 
hematol ogic malignancies , see Sect ion7.1.2 for definit ions rel evant to m edical history , including 
an assessment of bone m arrow m orphol ogy (see Secti on9.4.17.1 for addit ional details on bone 
marrow sample co llection and evaluat ion). For patients with advanced solid tumors, see 
Secti on7.1.3for definit ions rel evant to m edical history  and Secti on9.4.17.2 for details regarding 
evaluat ion of sites of disease by CT scan or MRI.
Inform ation regarding any  prior therapy  for treatment of the patient’s malignancy, including start 
and stop dates of eac h therapeut ic agent and response to therapy, will be co llected in the eCRF. In 
addition, all  blood transfusio ns related to the patient’s malignancy that the patient received within 
8weeks before enro llment will be recorded to document baseline transfusio ndependence.
9.4.5 Physical Examination
A co mplete physical examinat ion will be per formed per SOC at screening and at the EOS/ET visit. 
A symptom -directed physical examinat ion will be completed per SOC at the times specified in the
SOE (Appendix A), and as clinically indicated at the discret ion of the investigator.
9.4.6 Patient Height
Height will be measured only during screening.
9.4.7 Patient Weight
Weight will be measured during screening, within 3 days before Day 1 dosing in Part A, within 
3days before Day 1 dosing in all cycles in Part B, and at the EOS/ET visit. If the screening 
assessment was done within 3 days before Day 1 in Part A, an assessment at Day 1 inPart A will 
not be necessary .
The amount of study drug (pevonedistat and/or azacit idine, docetaxel, or paclitaxel, as applicable) 
to be administered will be based on BSA. BSA will be calculated using a standard formula (see 
example in Appendix H) on Day 1 in Part A and on Day 1 of each cycle in Part B if the pat ient 
experiences a >5% change in body  weight from  the wei ght used for the m ost recent BSA 
calculation.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 73of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALThe am ount of  carbopl atin to be administered will be based on exposure (AUC) (refer to 
Secti on8.1.3 for details of carboplat in dose calculations).
9.4.8 ECOG PS
ECOG PS will be assessed at the times specified in the SOE ( Appendix A). Ref er to Appendix D
for the PS grading scale.
9.4.9 Vital Signs
Vital signs, including diastolic and systolic blood pressure, heart rate, and body  temperature will 
be co llected as s pecified in the SOE 
(Appendix A) and as clinically  indicated at the discretion of 
the invest igator . When the timing of vital signs assessment coincides with the timing of a blood 
draw, vi tal signs will be com pleted before the collection of the blood sample, unless otherwise 
noted i n the SOE ( Appendix A ).
9.4.10 Pregnancy Test
A serum pregnancy test will be performed locally for women of childbearing potential at screening 
and wit hin 3 days before study  drug dosing on Day 1 in Part A. The results fro m these tests m ust 
be available and negative before the first d ose of study  drug i s administered.
In Part B, a serum pregnancy test will be performed for women o f childbearing potential wit hin 
3days before Day 1 of each cycle and at EOS/ET. The results from these tests must be available 
and negat ive before the study drug is administered on Day 1. If the Day 1 serum pregnancy results 
will not be available before dosing, a urine pregnancy test may be performed. Pregnancy tests ma y 
also be repeated during the study  if requested by  an IEC/IRB or if required by  local regul ations.
Women of childbearing potential are defined as any sexually active female subjects who meet the 
following criteria:
Those who have not undergone hysterectomy or bilateral oophorectomy.
Those who have not had natural menopause for 12 consecut ive months or l onger 
(ie,follicle -stimulat ing hormone [FSH] >40IU/L and no menopausal period for at least 
12consecutive months; loss o f menopausal periods following chemotherapy may  not rul e out 
childbearing potential).
9.4.11 Concomitant Medications and Procedures
All conco mitant m edicat ions and procedures (excluding transfusio ns) will be recorded fro m the 
time of the first dose of any study drug through 30 days (+10 days) after the last dose of any study 
drug(s). RBC and platelet transfusio ns will be recorded fro m 8weeks before enro llment through 
30days after the last dose of any study drug. See Section 8.4and Section 8.5for addi tional details 
regarding excluded and permitted concomitant medicat ions and procedures.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 74of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL9.4.12 AEs
Moni toring of AEs, serious and nonserious, will be conducted throughout the study as specified in 
the SOE. Refer to Section 10.0 for details regarding definit ions, documentation, and reporting of 
pretreatm ent events (PTEs), AEs, a nd SAEs.
9.4.13 Enrollment
Enrollment is achieved when the first dose of any study  drug has been administered.
Procedures for completion of the enrollment informat ion are described in the interact ive web 
response system and Study  Manual(s).
9.4.14 ECG
A 12 -lead ECG will be performed at screening, within 3 days of Day 1 of each cycle in Part B, and 
at the EOS/ET visit, as specified in the SOE ( Appendix A).
9.4.15 Clinical Labor atory Evaluations
Clinical laboratory  evaluat ions will be performed locally. Clinical laboratory evaluat ions will be 
perform ed as outlined in the following sect ions.
9.4.15.1 Clinical Chemistry, Hematology, and Urinalysis
As specified in the SOE ( Appendix A), the fo llowing sam ples will be obtained: blood samples for 
analysis o f hematology and clinical chemistry parameters shown in Table 9.c, Table 9.d, Table 9.e, 
and for coagulat ion parameters in Table 9.f; and urine samp les for analysis of the parameters 
shown in Table 9.g. Assessments may be performed more frequent ly if clinically indicated at the 
discreti on of  the in vestigator .
Table 9.c Hematology Tests
Hematology
Hematocrit
Hemoglobin
Leukocytes with differential, including percent circulating blasts
Neutrophils (ANC); ANC will be calculated from the leukocyte count with differential count; see Appendix I
Platelet (count)
ANC: absolute neutrophil count.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 75of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALTable 9.d Complete Serum Chemistry Panel
Complete Serum Chemistry Panel
Albumin
ALP
ALT
AST
Bilirubin (total)
BUN
Calcium
CO 2
Chloride Creatinine
Direct bilirubin
Glucose
Magnesium
Phosphate
Potassium
Sodium
Urate
ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN: blood urea 
nitrogen; CO 2: carbon dioxide.
Table 9.e Select Serum Chemistry Panel
Select Serum Chemistry Panel
ALP
ALT
ASTBilirubin (total)
BUN
Creatinine
ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN: blood urea 
nitrogen.
Table 9.f Coagulation Panel
Coagulation Panel
PT
INR
aPTT
aPTT: activated partial thromboplastin time ; INR: international normalized ratio; PT: prothrombin time .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 76of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALTable 9.g Urinalysis With Microscopic Analysis
Urinalysis
Bilirubin
Glucose
Ketones
Leukocytes
Nitrite
Occult bloodpH
Protein
Specific gravity
Turbidity  and color
Microscopic assessment of leukocytes, erythrocytes, 
bacteria, casts, and crystals
The fo llowing Modificat ion of Diet in Renal Disease Study  (MDRD) equation will be used to 
calculate eGFR (m drd.com ):
eGFR (mL/min/1.73 m2) = 175 × (Scr, std)-1.154×(Age)-0.203×(0.742 if female) ×(1.212 if African 
American).
9.4.16 Assessment of Hepatic and Renal Function for Treatment Group Assignment
Patients will be assigned to treatment arms on the basis of their renal and hepat ic function.
For assessment of hepat ic function (total  bilirubin and ALT), 2 blood samples will be required 
before the start of pevonedistat dosing on Day 1 of Part A. These 2 samples shoul d be obtained at 
least 48 hours apart, with the latest sample obtained no more than 48 hours before Day 1 and m ay 
be taken predose on Day 1. If the total  bilirubin and ALT measurements fro m the 2samples 
indicate the same liver funct ion category  forthe pati ent (i e, norm al, mild, or m oderate hepati c 
impairment), pevonedistat can be administered as scheduled. If the results of the 2 samples 
indicate different liver funct ion categori es, a thi rd sample m ust be obtained at l east 48 hours after 
the second sample. If  the resul ts of the 2 m ost recent m easurements (the second and third) denote 
the sam e liver funct ion category , the pati ent m ay be enrolled and should receive a single dose of 
pevonedistat on Day 1 in Part A, within 48 hours of the third sample. If the second and third 
measurements indicate different liver function categories, the patient will not be eligible for 
inclusio n in the study .
For assessment of renal funct ion, at least 2 blood samples will be collected to determine spot 
serum  creat inine for calculat ion of the eGFR according to the MDRD equation (see 
Secti on9.4.15.1 ). The sampling for spot serum creatinine should be done within 14 days of 
starting treatment, with the most recent measurement performed within 7 days o f starting 
treatm ent. The 2 measurements should both meet eligibilit y requirements based on the MDRD 
formula. If the 2 eGFR values do not both meet eligibilit y requi rement s, a thi rd measurement will 
be taken and the 2 most recent measurements (the second and third) will be averaged to assess 
renal funct ion status.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 77of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL9.4.17 Disease Assessment
9.4.17.1 Patients With Hematologic Malignancies
Disease assessments will be determined at time points indicated in the SOE based on local bone 
marrow aspirate blast counts and transfusio ns and laboratory  data. The invest igator’s assessment 
of disease status will be entered into the eCRF for each time point.
9.4.17.1.1 Bone Marrow  Aspiration and Bone Marrow  Biopsy
Atscreening and for study eligibilit y, a bone marrow aspirat ion and biopsy (performed locally) 
will be required to assess disease burden, cy togeneti cs, m olecular characteri zations, and cellular 
composition by  flow cy tometry. A bone m arrow biopsy  (in addi tion to bone marrow aspirate) is 
requi red only  at screening to confirm the diagnosis. However, a bone marrow biopsy  may be 
collected with bone marrow aspirate in accordance with inst itutional guidelines. If a biopsy  was 
done within 28 days pri or to enrollment , this archival biopsy  may be used and does not need to be 
repeated. If bone marrow biopsy is not collected routinely per country/inst itutional guidelines, it is 
not required.
9.4.17.1.2 Assessment of Disease Response
Assessment of disease response will be conducted only in Part B of the study. Response criteria are 
provi ded in Appendix J.  To determine disease response to pevonedistat treatment, the fo llowing 
proce dures will be done (see Table C in Appendix A): bone marrow aspirat ion to assess disease 
response at Cycle 2 on Day 22 (+6 days) and then every third cy cle afterward at any t ime between 
Day 15 and Day 28 until Cycle 11, provi ded that the disease assessment is available before Day 1 
of the fo llowing cycle. After complet ion of Cycle 11, bone m arrow aspi ration will be performed 
after com pletion of every  sixth cycle (or otherwise as clinically  indicated at the di screti on of  the 
investigator) after the patient’s previous scan at any t ime between Day 15 and Day 28, provi ded 
that the disease assessment is available before Day 1 of the fo llowing cycle.
Bone m arrow samples will be analyzed locally  at the clinical  site to:
Determine blast coun t on aspi rate sam ples: Samples will be evaluated locally  for blast count 
per institutional standard practice to inform disease burden assessment.
Analyze cy togeneti cs for IPSS -Rscore determination and disease response assessment for 
patients wi th HR MDS and CMML. Chromoso mal abnormalit ies and translocat ions that are 
routi nely assessed for the diagnosis of MDS and AML are included in the IPSS -R.
Addit ional bone m arrow aspi ration(s) may be done if warranted by  changes in peripheral blood 
counts, or otherwise as clinically  indicated at the discretion of the invest igator.
9.4.17.2 Patients with Advanced Solid Tumors
CT scans with IV contrast (unless medically contraindicated) or MRI of the chest, abdomen, and 
pelvis will be performed as entry  criteria. If the patient has had appropriate imaging scans 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 78of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALperform ed wi thin 28 days before the first dose of study  drug in Part A, the results of those scans 
may be used.
CT scans wit h IV contrast enco mpassing the known sites of disease will also be performed during 
the study  as specified in the SOE ( Appendix A) . A scan shoul d be taken at the EOS visit if a scan 
has not been completed within 28 days pri or to the EOS visit.
If a CT scan does not provide adequate imaging, MRI may be used to evaluate sites o f disease. For 
each site of disease, the imaging modalit y (CT scan or MRI) used at entry must be used throughout 
the study . Tum or response will be assessed by  the investi gator at these times using the RECIST 
guidelines (versio n1.1) as provi ded in Appendix J .
9.4.18 Biomarker, Pharmacodynamic, and PK Samples
9.4.18.1 Primary Specimen Collection
The primary  specimen collecti on is displayed in Table 9.h.
Table 9.h Primary Specimen Collection
Specimen Name in Procedure in SOE 
(Appendix A)Primary 
Specimen Description of Intended UseSample 
Collection
Plasma samples for pevonedistat protein 
binding aPlasma Unbound pevonedistat PK 
parametersMandatory
Plasma samples for pevonedistat PK Plasma PK measurements Mandatory
Plasma samples for azacitidine PK Plasma PK measurements Mandatory
Urine samples for pevonedistat PK Urine PK measurements Mandatory
Urine samples for azacitidine PK Urine PK measurements Mandatory
PK: pharmacokinetic(s); SOE: schedule of events.
a Samples for pevonedistat plasma protein binding measurement should be collected predose and at the end of 
infusion. The end of infusion sample will be used if bioanalytically feasible. If not feasible, the pre dose sample will 
also be used for pevonedistat plasma protein binding measurement.
9.4.19 PK Measurements
9.4.19.1 Blood Sampling
Blood sam ples f or the determination of plasma concentrations of pevonedistat will be collected 
from all patients during Part A and Part B (Cycle 1) of the study  at the timepoints specified in 
Appendix A, Table A, Table B, and Table D. Bl ood sam ples f or the determinat ion of plasma 
concentrations of azacit idine will be collected from patients with hematologic malignancies during 
Part B (Cy cle1) at the timep oints specified in Appendix A,  Tabl eB. The timing, but not the 
number, of PK blood samples may be changed if emerging data indicate that an alteration in the 
sampling scheme is needed to better characterize the PK of pevonedistat or azacit idine.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 79of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALThe exact date and time of each sample collect ion and the actual start and stop times of the infusio n 
shoul d be recorded accurately, wit h particular care given t o the recording of blood sampling t imes 
for pevonedistat that occur close to the infusio n.
To ensure that the measurements are representative of plasma exposure for pevonedistat, blood 
draws will be conducted in the arm opposite a patient’s IV infusio n. In the case that only a single 
arm is available, blood may be drawn as distal to the site for IV infusio n as feasible, and the site of 
blood draw should be documented.
Details regarding the preparation, handling, and shipping of samples are provided in the S tudy 
Manual.
If deemed appropriate, the blood samples co llected in this study may be addit ionally analyzed to 
determine the plasma concentrations of pevonedistat major metabo lites in humans.
The primary  object ive of PK sampling in this study is to measure pevonedistat concentrations in 
plasma. In addit ion, the end o f infusio n sample on Day 1 of Part A will be used for protein binding 
measurement to calculate unbound exposure of pevonedistat based on the measured total plasma 
concentrations and f u. If the en d of pevonedistat infusio n sample during Part A is not 
bioanalyt ically feasible for protein binding measurement, the predose sample taken on Day 1 of 
Part A, spiked with pevonedistat concentrations, will be used for pevonedistat plasma protein 
binding. The se PK samples may  also be used for the exploratory  measurement of plasma 
concentrations of metabo lites of  pevonedistat, if technically feasible and considered necessary for 
further understanding the metabo lism of pevonedistat in pat ients with cancer.
9.4.19.2 Urine Sampling
Urine output will be co llected fro m all pat ients during Part B (Cy cle1) of  the study  at the 
timepo ints specified in Appendix A,  Table B. Urin e samples will be analyzed for estimate of urine 
PK parameters of pevonedistat and (in patients with hematologic malignancies) azacit idine. The 
exact date and time of each sample co llection, and the volume o f urine collected, should be 
recorded accurately .
Detailed instructions on the procedure for collect ion, processing, storage, and shipment of the 
urine samples will be provided in the Study  Manual.
9.4.20 Pharmacodynamic Measurements
Not applicable to this study .
9.4.21 DNA Measurements
Not applicable to this study .
9.4.22 Banked Tumor Specimen Measurements
Not applicable to this study .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 80of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL9.5 Completion of Study Treatment (for Individual Patients)
Part A:
Patients will  be considered to have completed the protocol -specified treatment in Part A if they 
receive the single dose of pevonedistat.
Patients who have completed treatment in Part A and do not opt to continue into Part B will be 
considered to have completed study  treatm ent.
Part B:
Patients who con tinue to Part B will be considered to have completed study treatment if they 
complete at l east 12 cycles of treatment, discont inue treatment due to PD, or discontinue for any 
reason.
9.6 Completion of Study (for Individual Patients)
Part A:
Patients will  be considered to have completed the study  if they receive the Part A single dose of 
pevonedistat, provide samples for PK measurements (that will be used to provide data necessary 
for assessment of the effects of severe renal impairment or mil d or m oderate hepat ic impairment 
on pevonedistat PK), and co mplete the EOS visit. Note an EOS visit is needed in Part A only if the 
patient does not continue into Part B for any  reason (see SOE for Part A in Appendix A) .
Part B:
Patients who opt to continue into Part B will be considered to have completed the study if they 
have co mpleted study  treatm ent and the EOS vi sit or until  the sponsor terminates the study .
9.7 Discontinuation of Treatment With Study Drug and Patient Replacement
Patients who do not complete the protocol -specified dosing, PK, and safet y assessment in Part A 
may be considered nonevaluable and replaced.
Treatment with study  drug m ay be disco ntinued for any of the fo llowing reasons:
AE (see Section 10.1.2 ).
Protocol  deviat ion.
PD.
Note: Patients with hematologic malignancies may be allow ed to continue study  treatm ent if 
they meet the cri teria for PD on the basis of only  bone m arrow bl ast count (wi thout AML 
transformation in pat ients with HR MDS or HR CMML) if, in the clinical judgment of the 
investigator, the patient is st ill receiving clinical benefit from this treatment and the 
continuat ion is endorsed by the sponsor’s project clinician (or designee). Patients who meet the 
criteria for PD and continue on study  under these condi tions m ust be reconsented before 
continuing study  treatm ent.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 81of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALSymptom atic deteri oration.
Unsat isfactory  therapeuti c response.
Initiation of  hematopoi etic stem cell transplant.
Pregnancy (patient must be discontinued).
Study  terminated by  sponsor.
Withdrawal by the patient.
Lost to follow -up.
Other.
Once study  drug has been discont inued, all study  procedures outlined for the EOS visit will be 
completed as specified in the SOE. The primary  reason for study  drug di scont inuat ion will be 
recorded on the eCRF.
Patients who have achieved objective clinical benefit from co mbinat ion therapy  
(chemotherapy plus pevonedistat) and who have developed into lerance that is reasonably 
attributable to the chemotherapy after 2 or more cycles may cont inue on single -agent pevonedistat 
at the sam e dose and schedule upon request by  the inve stigator and agreem ent wi th the sponsor. 
The dose of single -agent pevonedistat may  be escalated to the maximum dose specified for the 
patient’s treatment arm , as described in Sect ion8.1.
Patients who are eligible may be able to continue to receive study drug; see Section 6.3.5 for PTA.
9.8 Withdraw al of Patients From Study
A pat ient may be wi thdrawn from  the study  for any  of the f ollowing reasons:
Lost to follow -up.
Study  terminated by  sponsor.
Withdrawal by pat ient.
Com pleted study .
Death.
Other.
PD.
Initiation of  hematopoi etic stem cell transplant.
The consequence of study  withdrawal  is that no new informat ion will be collected from the 
withdrawn pati ent and added to the exist ing data or any database.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 82of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL9.9 Study Compliance
Study  drug will be administered or dispensed only to eligible pat ients under the supervisio n of the 
investigator or ident ified subinvest igator(s). The appropriate study personnel will maintain records 
of study  drug recei pt and dispensing.
10.0 ADVERSE EVENTS
10.1 Definitions
10.1.1 Pretreatment Event Definition
A PTE i s any  untoward m edical o ccurrence in a patient or subject who has signed informed 
consent to participate in a study  but before administrati on of  any study  medicat ion; it does not 
necessarily have to have a causal relationship with study  participati on.
10.1.2 AE Definition
AE means any u ntoward medical occurrence in a patient or subject administered a pharmaceut ical 
product; the untoward medical occurrence does not necessarily have a causal relat ionship wit h this 
treatm ent. An AE can therefore be any unfavorable and unintended sign (inclu ding an abnorm al 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a m edicinal 
(invest igational) product whether or not it is related to the medicinal product. This includes any 
newly occurring event, or a previous condit ion that has increased in severit y or frequency since the 
administration of study  drug.
An abnormal laboratory  value will not be assessed as an AE unless that value leads to 
discontinuat ion or delay in treatment, dose modification, therapeutic intervent ion, or i s considered 
by the investigator to be a clinically significant change fro m baseline.
10.1.3 SAE Definition
SAE m eans any untoward medical occurrence that at any  dose:
Results in death.
Is life -threatening (refers to an AE in which the patient was at risk of deat h at the time of the 
event. It does not refer to an event that hypothetically might have caused death if it were more 
severe).
Requi res inpat ient hospi talizat ion or prolongat ion of an exist ing hospi talizat ion (see 
clarificati on in the paragraph in Sect ion10.2 on planned hospitalizat ions).
Results in persistent or significant disabilit y or incapacit y (disabilit y is defined as a substant ial 
disrupt ion of a person’s abilit y to conduct normal life funct ions).
Is a congenital anomaly/birth defect .
Is a medically important event . This refers to an AE that may  not resul t in death, be 
immediately  life threatening, or require hospitalization, but may be consid ered seri ous when, 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 83of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALbased on appropriate medical judgment, may  jeopardi ze the pati ent, requi re medical or 
surgi cal interventi on to prevent one of the outcomes listed above, or involves suspected 
transmissio n via a medicinal product of an infect ious agent. E xamples of such medical events 
include allergic bronchospasm requiring intensive treatment in an emergency room or at home, 
blood dyscrasias or convulsio ns that do not result in inpatient hospitalizat ion, or the 
development of drug dependency or drug abuse ; any o rganism, virus, or infect ious particle (eg, 
prion protein transmitt ing transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infect ious agent.
In thi s study , intensi ty for each AE, including any  lab abnormalit y, wil l be determined using the 
NCI CTCAE, versio n 5.0, effect ive 27 November 2017 [1].Clarificat ion should be made between 
an SAE and an AE that is considered severe in intensit y (Grade 3 or 4) because the terms serious
and severe are NOT synonymous. The general term severe is often used to describe the intensit y 
(severit y) of a specific e vent; the event itself, however, may be of relat ively minor m edical  
significance (such as a Grade 3 headache). This is NOT the same as serious , which is based on 
patient/event outcome or action criteria described above and is usually associated with events that 
pose a threat to a patient’s life or abilit y to functi on. A severe AE (Grade 3 or 4) does not 
necessarily need to be considered serious. For example, a WBC count of 1000/mm3to less than 
2000/mm3is considered Grade 3 (severe) but may  not be consider ed seri ous. Seri ousness (not 
intensity) serves as a guide for defining regulatory  reporting obligations.
10.2 Procedures for Recording and Reporting AEs and SAEs
All AEs spontaneously reported by  the pati ent or in response to an open question fro m study  
personnel or revealed by observation, physical examinat ion, or other diagnostic procedures will be 
recorded on the appropriate page of the eCRF (see Section 10.3 for the period of observation). Any 
clinically relevant deterioration in laboratory assessments or other clinical finding is considered an 
AE. When possible, signs and symptoms indicating a commo n underlying patho logy shoul d be 
noted as a si ngle comprehensive event.
Regardless of causalit y, SAEs and serious PTEs (as defined in Section 10.1)
 must be reported (see 
Secti on10.3 for the peri od of  observati on) by  the investi gator to the Takeda Global 
Pharmacovigilance department or designee within 24 hours of becoming aware of the event . This 
will be done by  transmi tting an EDC SAE report. If transmissio n of an EDC SAE report is not 
feasible, then a facsimile of the completed Takeda paper -based SAE form will be sent. A sample of 
the paper -based SAE form and processing direct ions are in t he Study  Manual. Inform ation in the 
SAE report or form must be consistent with the data provided on the eCRF.
If informat ion not available at the time of the first report becomes available at a later date, then the 
investigator will transmit a fo llow-up ED C SAE report (or a paper -based SAE form if an EDC 
SAE report is not feasible) or provide other documentation immediately wit hin 24 hours of receipt. 
Copi es of  any relevant data from the hospi tal notes (eg, ECGs, l aboratory  tests, di scharge 
summary, postmor tem resul ts) shoul d be sent to the addressee, if requested.
All SAEs and serious PTEs should be fo llowed up unt il reso lution or perm anent outcome o f the 
event. The timelines and procedure for follow -up reports are the same as those for the init ial report.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 84of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALPlanned hospital admissio ns or surgical procedures for an illness or disease that existed before the 
patient was enro lled in the trial orbefore study drug was given are not to be considered AEs unless 
the condi tion deteri orated in an unexpected manner dur ing the trial (eg, surgery was performed 
earlier or later than planned).
For both serious and nonserious AEs, the invest igator must determine both the severit y (toxi city 
grade) of the event and the relat ionship of the event to study drug administration. Fo r serious PTEs, 
the invest igator must determine both the severit y (toxi city grade) of the event and the causalit y of 
the event in relation to study  procedures.
Severit y (toxicit y grade) for each AE, including any lab abnormalit y, will be determined using t he 
NCI CTCAE, version 5.0, effect ive 27 November 2017 [1]. The criteria are provided in the Study 
Manual.
Relationship of the event to study drug administration (ie, its ca usality) will  be determined by the 
investigator responding y es (rel ated) or no (unrelated) to this quest ion: Is there a reasonable 
possibilit y that the AE is associated with the study  drug?
10.3 Monitoring of AEs and Period of Observation
AEs, both nonserious and seri ous, will  be monitored throughout the study  as fo llows:
AEs will be reported from the start of study  drug administrati on through 30 days (+10 days) 
after administrati on of  the l ast dose of study  drug and recorded in the eCRFs. AEs should be 
monitored until they are resolved or are clearly determined to be due to a patient’s stable or 
chronic condit ion or intercurrent illness(es).
SAEs will be reported as fo llows:
–Serious PTEs will be reported to the Takeda Global Pharmacovigilance department or 
designee fro m the time of the signing of the ICF up to first dose of study drug, and will also  
be recorded in the eCRF.
–Related and unrelated treatment -emergent SAEs and serious PTEs will be reported to the 
Takeda Gl obal Pharmacovigilance depart ment or designe e from the si gning of the ICF in 
Part A through 30 days (+10 days) after administration of the last dose of study  drug and 
recorded in the eCRF. After this period, only related SAEs must be reported to the Takeda 
Global Pharm acovigilance department or desi gnee. SAEs shoul d be m onitored until they  
are resolved or are clearly determined to be caused by  a pati ent’s stable or chronic 
condi tion or intercurrent illness(es).
10.4 Procedures for Reporting Drug Exposure During Pregnancy and Birth Events
If a woman beco mes pregnant or suspects that she is pregnant while participat ing in this study, she 
must inform the invest igator immediately and permanent ly discont inue study  drug. The sponsor 
must also be contacted immediately by sending a completed pregnancy form to the Takeda Globa l 
Pharmacovigilance department or designee. The pregnancy  must be fo llowed for the final 
pregnancy outcome.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 85of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALIf a female partner of a male patient becomes pregnant during the male pat ient’s participat ion in 
this study , the sponsor m ust also be c ontacted immediately by  sending a com pleted pregnancy  
form to the Takeda Global Pharmacovigilance department or designee. Every  effort shoul d be 
made to fo llow the pregnancy  for the final pregnancy  outcom e.
10.5 Procedures for Reporting Product Complaints or Me dication Errors (Including 
Overdose)
A product complaint is a verbal, written, or electronic expression that implies dissat isfaction 
regarding the identit y, strength, puri ty, quali ty, or s tabilit y of a drug product. Individuals who 
ident ify a potential pro duct complaint situat ion shoul d immediately report this via the phone 
numbers or email addresses provided below.
A medicat ion error is a preventable event that involves an ident ifiable pat ient and l eads to 
inappropriate medicat ion use, which may  resul t in patient harm . Whereas overdoses and 
underdoses const itute medication errors, doses missed inadvertent ly by a pat ient do not. 
Individuals who ident ify a potential medicat ion error (including overdose) situation should 
immediately  report thi s via the phone n umbers or email addresses provided below.
Call Center Phone Number Email Fax
Dohmen Life 
Science Services1-844-662-8532
Non–toll-free number: 1 -510-740-1273 GlobalOncologyMedinfo
@takeda.com 1-800-881-6092
Product complaints and medicat ion errors in and of themselves are not AEs. If a product complaint  
or a m edicat ion error results in an SAE, the SAE should be reported.
10.6 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspect ed unexpected serious adverse react ions 
(SUSARs) and any other applicable SAEs to regulatory  authori ties, including the European 
Medicines Agency ,investigators, and IRBs and IECs, as applicable, in accordance wit h national 
regul ations in the countries whe re the study  is conducted. Relat ive to the first awareness of the 
event by/or further provisio n to the sponsor or sponsor’s designee, SUSARs will be submitted to 
the regulatory  authori ties as expedi ted reports wi thin 7 days for fatal  and life -threatening e vents 
and within 15 days for other serious events, unless otherwise required by nat ional regulat ions. The 
sponsor will also prepare an expedited report for other safet y issues where these might materially 
alter the current benefit -risk assessment of an inv estigational medicinal product or that would be 
sufficient to consider changes in the investigat ional medicinal product’s administration or in the 
overall conduct of the trial. The invest igational site also will forward a copy  of all expedited 
reports to h is or her IRB or IEC in accordance wit h national regulat ions.
11.0 STUDY- SPECIFIC COMMITTEES
Sponsor Safety Assessment
Safety data will be reviewed and assessed periodically by a glo bal pharmacovigilance team and a 
cross -functional safet y management team throug hout the conduct of the study . These 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 86of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALcross -functional reviews will include a global safety lead from the study  team , and other 
representation fro m other departments at Takeda such as Clinical Research, Pharmacovigilance, 
Biostati stics, Clinical Pharmaco logy, and Clinical Operations.
12.0 DATA HANDLING AND RE CORDKEEPING
The full details o f procedures for data handling will be documented in the data management plan. 
If selected for coding, AEs, medical history , and concurrent condit ions will be coded using the 
Medical Dict ionary for Regulatory  Activities (MedDRA). Drugs will be coded using the WHO 
Drug Dict ionary.
12.1 eCRFs
Com pleted eCRFs are required for each patient who signs an ICF.
The sponsor or its designee will supply invest igative sites with access to eCRFs and will make 
arrangements to train appropriate site staff in the use of the eCRF. These forms are used to transmit  
the informat ion collected in the performance of this study  to the sponsor, contract research 
organi zation (CRO) partners, and regulatory  authorities. Invest igative sites must complete eCRFs 
in English.
After complet ion of the entry  process, com puter l ogic checks will be run to ident ify such i tems as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site.
Any change of, modificat ion of, or addit ion to the data on the eCRFs should be made by the 
investigator or appropriate site personnel . Corrections to eCRFs are recorded in an audit trail that 
captu res the old informat ion, the new information, ident ificat ion of the person making the 
correcti on, the date the correction was made, and the reason for the change.
The principal invest igator must review the eCRFs for completeness and accuracy and must sign 
and date the appropriate eCRFs as indicated. Furthermore, the principal invest igator must retain 
full responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs .
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by study monitors. The sponsor (or designee) will be permitted to review the subject’s medical and 
hospi tal records pertinent to the study to ensure accuracy of the eCRFs. The co mpleted eCRFs are 
the sole property  of the sponsor and should not be made available in any form to third parties, 
except for authorized representatives of appropriate governmental healt h or regulatory authorities, 
without wri tten permissio n of the sponsor.
12.2 Record Retention
The invest igator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion logof all 
participat ing subjects, medical records, temporary media such as thermal -sensit ive paper, source 
worksheets, all original signed and dated ICFs, subject authorization forms regarding the use of 
personal healt h informat ion (if separate from the ICFs ), electroni c copi es of  eCRFs including the 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 87of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALaudit trail, and detailed records of drug disposit ion to enable evaluat ions or audits from regulatory 
authori ties and the sponsor or its designees. Any source documentation printed on degradable 
thermal-sensit ivepaper shoul d be photocopi ed by the site and filed with the original in the 
subject’s chart to ensure long -term legibilit y. Furthermore, ICH E6 Section 4.9.5 requi res the 
investigator to retain essent ial docum ents specified in ICH E6 (Section 8) unt il at l east 2 years 
after the last approval of a market ing applicat ion for a specified drug indicat ion being investigated 
or, if an applicat ion is not approved, until at least 2 years after the invest igation is discont inued and 
regul atory  authori ties are notified . In addi tion, ICH E6 Secti on4.9.5 states that the study  records 
shoul d be retained unt il an amount of time specified by applicable regulatory requirements or for a 
time specified in the clinical study  site agreement between the invest igator and sponsor.
Refer to the clinical study  site agreement for the sponsor’s requirements for record retention. The 
investigator should contact and receive written approval fro m the sponsor before disposing of any 
such documents.
13.0 STATISTICAL METHODS
13.1 Statistical and Analyt ical Plans
Analyses will be primarily  descriptive in nature. No formal statist ical hypothesis testing will be 
perform ed. A statistical analysis plan will be prepared and finalized before database lock. This 
docum ent will provi de further details regarding t he definit ion of analysis variables and analysis 
methodol ogy to address all study  objectives.
Summary  tabulat ions will be presented to display  the number of observations, mean, standard 
deviat ion, median, minimum, and maximum for cont inuous variables alo ngwith the number and 
percentage (calculated using nonmissing values) per category for categorical data, unless specified 
otherwi se.
13.1.1 Analysis Sets
Safety population will include pat ients who receive at least 1 dose of study drug. The safet y 
popul ation will be used for all safet y analyses.
PK population will include pat ients who:
–Com plete the protocol -specified pevonedistat dosing and PK assessment in Part A and/or 
protocol -specified pevonedistat and/or azacitidine dosing and PK assessment in Cycle 1 of 
Part B.
–Do not receive any excluded conco mitant m edicat ions through the completion o f Part A.
–Have sufficient concentration -time data to permit reliable est imation of PK parameters.
Response -evaluable populat ion: patients who receive at least 1 dose of study dr ug, have a 
baseline disease assessment, and have at least 1 postbaseline disease assessment will be used 
for analyses of response.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 88of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL13.1.2 Demographics and Other Baseline Characteristics
Dem ographic and baseline characterist ics will be summarized in a descript ive fashion, including 
sex, age, race, ethnicit y, wei ght, hei ght, BSA, organ funct ion category  (ie, normal, severe renal  
impairment, or mild or moderate hepat ic impairment), baseline disease characterist ics, and other 
param eters as appropriate.
13.1.3 Efficacy Analys is
Efficacy measures will include disease response and duration of disease response. Analysis o f all 
efficacy  measures will  be descri ptive. Disease response in AML will be based on the ORR 
(CR + PR) using the Revised Recommendations of the International Worki ng Group (IWG) for 
Diagnosis, Standardi zation of Response Criteria, Treatment Outcomes, and Reporting Standards 
for Therapeutic Trials in AML [5].
For AML patients, all CR includes both CR and CRi.
Disease response in pat ients with MDS or CMML will be based on the best overall response 
(CR
+PR+HI) as determined by the invest igator using the revised IWG response criteria for 
MDS (detailed in Appendix J) [6].
Disease response to pevonedistat in co mbinat ion wit h docetaxel or carboplat in plus paclitaxel will 
be based on the best overall response as determined by the invest igator using RECIST version 1.1 
guidelines ( Appendix J) .
The durati on of  response will be defined in all pat ients with disease response as the time between 
the first documentation of response and the first documentation of PD or death if no prior PD is 
docum ented. Responders without disease progression will be censored at the last clinical 
assessment of response.
13.1.4 PK Analysis
Individual and mean pevonedistat plasma concentration -time data fo llowing a single dose of 
pevonedistat during the PK assessment in Part A will be plotted and listed by organ function group. 
Individual and mean pevonedistat and/or azacit idine pl asma concentration -time data fo llowing 
multiple-dose administration during Cy cle1 of Part B will be plotted and listed by organ funct ion 
group and by  dose levels. Pl asma pevonedistat and/or azacitidine PK parameters for each patient 
will be calculated using nonco mpart mental analy sis m ethods. Unbound values of pevonedistat 
Cmax, AUC last, AUC ∞and AUC in individual patients will be calculated as the product of the 
patient’s pevonedistat f uand the total values of C max, AUC last, AUC ∞and AUC , respectively. 
Descript ive statistics will be presented for pevonedistat PK parameters (C max, AUC last, AUC ∞, 
AUC , CL, t 1/2z, CL R, fu, and unbound values of C max, AUC last, AUC ∞and AUC ) by organ 
funct ion and dose levels. Descript ive statist ics will be presented for azacitidine PK parameters 
(Cmax, Tmax, AUC , CL/F, t 1/2z, and CL R by organ funct ion and dose levels.
The analysis for the effects of organ impairment on pevonedistat PK will be based on unbound 
pevonedistat plasma exposure (AUC) fo llowing a single dose of pevonedistat in Part A. To assess 
the effects of severe renal impairment or mild or moderate hepatic impairment on pevonedistat PK 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 89of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL(unbound AUC lastand AUC ∞), an analysis o f variance (ANOVA) on the natural log- transformed 
PK parameters will be performed for severe renal impairment (R enal Arm) versus the norm al 
group (Control Arm), mild hepat ic impairment (Mild Hepat ic Ar m) versus the normal group 
(Control  Arm ), and m oderate hepatic impairment (Moderate Hepatic Arm) versus the normal 
group (Control Arm). The ANOVA results will be used to estimate the ratios of least -squares 
geom etric means (severe renal impairment vs normal, mild hepat ic impairment vs normal, and 
moderate hepat ic impairment vs normal) and corresponding 90% CIs for pevonedistat unbound 
AUC. The PK -evaluable populat ion will be used for these analyses.
13.1.5 Pharmacodynamic Analysis
Not applicable.
13.1.6 PK/Pharmacodynamic Analysis
Not applicable.
13.1.7 Immunogenicity Analyses
Not applicable.
13.1.8 Safety Analysis
A safet y analysis will be conducted separately for Part A and Part B. The safety pop ulation will be 
used for the safet y analysis. Safet y will be evaluated on the basis of the incidence of AEs, severit y 
and t ype of AEs, and by changes from baseline in the pat ient’s vital signs, weight, and clinical 
laboratory  values using the safet y popul ation. Exposure to the study  drugs and reasons for 
discontinuat ion will  be tabulated.
A treatment -emergent adverse event (TEAE) in Part A is defined as any AE that occurs after 
administration of the single dose of study  treatm ent in Part A and up through 30 days after the 
single dose of study  drug in Part A for patients who do not continue into Part B; or up through 
Part B Cycle 1 Day 1 (predose) for pati ents who continue into Part B.
A TEAE in Part B is defined as any AE that occurs after administration of the first dose of study  
treatm ent in Part B and up through 30 days after the last dose of study drug in Part B.
AEs will be tabulated according to MedDRA by System Organ Class, High -Level Term , and 
Preferred Term and will include the fo llowing categori es:
TEAEs.
Drug -related TEAEs.
Treatment -emergent Grade 3, 4, and 5 AEs (presented by  grade and overall).
Treatment -emergent drug -related Grade 3, 4, and 5 AEs (presented by grade and overall).
The m ost comm only reported TEAEs (i e, those events reported by  ≥10% of  all pat ients).
SAEs.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 90of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALDrug -related SAEs.
A listing of TEAEs result ing in study  drug di scont inuat ion will be provided.
The m ost comm only reported TEAEs (i e, those events reported by  ≥10% of all pat ients) will be 
tabul ated by  System  Organ Class and Preferred Term . Tabul ation also will be provided that 
enumerates AEs by  maximum  intensity. Deaths, SAEs, and AEs result ing in study  drug 
discontinuat ion will  be tabulated.
Descript ive statistics for the actual values of clinical laboratory parameters (and change fro m 
baseline in clinical laboratory  param eters) will be presented for all scheduled measurements over 
time. Mean laboratory  values over time will be plo tted for key  laboratory  parameters.
Shift tables for laboratory parameters will be generated to show changes in NCI CTCAE grade 
from baseline to the worst postbaseline value. Graphical displays of key safety parameters, such as 
scatter pl ots of  baseline versus worst postbaseline values, may  be used to understand the 
pevonedistat safet y profile.
Graphical displays will be used to show vital sign parameters over time separately for Part A and 
for Part B.
All conco mitant m edicat ions collected from screening throughout the study  period will  be 
classified to Preferred Terms according to the WHO Drug Dict ionary.
Addit ional safet y analyses may be performed to enumerate rates of toxicit ies and to further define 
the safet y profile of pevonedistat.
13.2 Interim Analysis
No interim analysis is planned.
13.3 Determination of Sample Size
The sample size calculat ion is based on the number of patients required to adequately characterize 
the PK of pevonedistat in the impaired organ functio n groups (severe renal impairment or mild or 
moderate hepat ic impairment) in comparison to the control group. Based on these considerations, 
the expected sample size is approximately 9 for the control group (normal renal and hepat ic 
funct ion) and 9 to 12 patients in each of the 3 organ impairment arms. Patients who are considered 
nonevaluable may be replaced. The sample size of approximately 9 patients specified as being 
requi red for the PK -evaluable populat ion in each group in Part A is based on ty pical  sample sizes 
utilized in organ impairment PK studies in cancer patients, rather than on specific statist ical 
considerations. Wit h a sample size of 9patients per group, if the ratio of geometric means 
(impaired organ funct ion vs control) of AUC ∞is X, the associated 90% CI is expected to be 
(0.688X, 1.45X) based on the %CV in pevonedistat AUC ∞ of 43.8% (Study C15011).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 91of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL14.0 QUALITY CONTROL AND QUALITY ASSURANCE
14.1 Study Site Monitoring Visits
Moni toring visit s to the study  site will  be made peri odically  during the study  to ensure that all 
aspects of the protocol are fo llowed. Source documents will be reviewed for verificat ion of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The invest igator and inst itution guarantee access to source documents by  the sponsor or i ts 
designee (CRO) and by  the IRB or IEC.
All aspects of the study and its documentation will be subject to review by the sponsor or designee 
(as long as blinding is not jeopardized) including, but not limited to, the invest igator’s binder, 
study  medicat ion, subject medical records, informed consent documentation, documentation of 
subject authorizat ion to use personal healt h information (if separate fro m the ICFs), and review of 
eCRFs and associated source documents. It is important that the investigator and other study  
personnel are available during the monitoring visit s and that sufficient time is de voted to the 
process.
In the event a monitor cannot visit the site in a timely manner due to the COVID -19 pandemic, 
alternat ive monitoring approaches, such as remote source data verificat ion (SDV) and remote 
source data review (SDR), may be used to ensure data qualit y and integri ty and m aintain pat ient 
safet y. Alternative m onitoring approaches should be used only  where all owed by  the l ocal health 
authori ty and privacy  laws and where permitted by the IRB/IEC.
14.2 Protocol Deviations
The invest igator should not d eviate fro m the protocol , except where necessary  to eliminate an 
immediate hazard to study subjects. Should other unexpected circumstances arise that will require 
deviat ion from protocol -specified procedures, the investigator should consult with the sponso r or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exempt ions (a prospectively approved deviat ion) from the inclusio n or exclusio n criteria.
The site should document all protocol deviat ions in the su bject’s source documents. In the event of 
a significant devi ation, the si te shoul d notify  the sponsor or i ts desi gnee (and IRB or EC, as 
requi red). Si gnificant devi ations include, but are not limited to, those that invo lve fraud or 
misconduct, increase the health risk to the subject, or confound interpretation of the primary stud y 
assessment.
The sponsor will assess any protocol deviat ion; if it is likely to affect to a significant degree the 
safet y and ri ghts of  a subject or the reliabilit y and robustness of the data generated, it may be 
reported to regulatory  authori ties as a seri ous breach of GCP and the protocol.
14.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also m ay be subject to qualit y assurance audi ts by  the sponsor or des ignees. In this 
circumstance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory  samples are collected, 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 92of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALwhere the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the US FDA, the United Kingdo m [UK] Medicines and 
Healthcare products Regu latory Agency  [MHRA], the Pharmaceut icals and Medical Devices 
Agency of Japan [PMDA]). If the study site is contacted for an inspect ion by a regulatory body, the 
sponsor should be notified immediately. The investigator and inst itution guarantee access for 
qualit y assurance auditors to all study  documents as described in Section 14.1.
15.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted wi th the h ighest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declarat ion of Helsinki, 
and the ICH Harmonised Tripartite Guideline for GCP. Each invest igator will conduct the s tudy 
according to applicable local or regional regulatory requirements and align his or her conduct in 
accordance with the responsibilit ies of the investigator that are listed in Appendix C. The 
principles of Helsinki are addressed through the protocol and through appendices containing 
requi rements for informed consent and invest igator responsibilities.
15.1 IRB and/or IEC Approval
IRBs and IECs must be const ituted according to the applicable state and federal/local requirements 
of each participat ing regio n. The sponsor or designee will require documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect parti cipat ion in this study , written notification regarding his or her abstinence fro m 
voting must also be obtained. Those American sites unwilling to provide names and tit les of all 
members because of privacy and conflict of interest con cerns should instead provide a 
Federalwide Assurance number or comparable number assigned by the US Department of Health 
and Human Services.
The sponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocol ’s review and approval. This protocol, the IB, a copy  of the ICF, and, if 
applicable, subject recruit ment materials and adverti sements and other documents required by all 
applicable laws and regulations must be submitted to a central or local IRB or IEC fo r approval. 
The IRB’s or IEC’s written approval o f the protocol and subject informed consent must be 
obtained and submitted to the sponsor or designee before commencement of the study , ie, before 
shipment of the sponsor -supplied drug or study -specific scre ening act ivity. The IRB or IEC 
approval  must ref er to the study  by its exact protocol  title, number, and versio n date; ident ify 
versio ns of other documents (eg, ICF) reviewed; and state the approval date. If required by country 
or regi onal regulat ions or p rocedures, approval from the com petent regulatory  authori ty will be 
obtained before commencement of the study  or impl ementati on of  a substant ial amendment. The 
sponsor will notify the site of act ivation status once the sponsor has confirmed the adequacy of site 
regul atory  docum entati on and, when applicable, the sponsor has received permissio n from the 
competent authori ty to begin the tri al. Until  the si te receives notification o f activat ion status, n o 
protocol  activit ies, including screening, may  occur.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 93of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALSites must adhere to all requirements stipulated by  their respect ive IRB or IEC. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the ICF, recruit ment 
materi als intended for viewing by  subjects, l ocal safety reporting requi rements, reports and 
updates regarding the ongoing review of the study  at intervals specified by the respect ive IRB or 
IEC, and submissio n of the invest igator’s final status report to the IRB or IEC. All IRB and IEC 
approval s and rel evant docum entati on for these items must be provided to the sponsor (or 
designee).
Subject incentives should not exert undue influence for participat ion. Payments to subjects must 
be approved by the IRB or IEC and sponsor.
15.2 Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The ICF, subject authorizat ion form (if applicable), and subject 
inform ation sheet (if applicable) describe the planned and permitted uses, transfers, and 
disclosures of the subject’s personal and personal healt h informat ion for purposes of conducting 
the study . The ICF an d the subject informat ion sheet (if applicable) further explain the nature of 
the study , its obj ectives, and potential risks and benefits, and the date informed consent is given. 
The ICF will detail the requirements of the participant and the fact that he or she i s free to 
withdraw at any  time wi thout giving a reason and without prejudice to his or her further medical 
care.
The invest igator is responsible for the preparation, content, and IRB or IEC approval of the ICF 
and, if applicable, the subject author ization form. The ICF, subject authorizat ion form (if 
applicable), and subject informat ion sheet (if applicable) must be approved by both the IRB or IEC 
and the sponsor before use.
The ICF, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) 
must be written in a language fully co mprehensible to the prospective subject. It is the 
responsibilit y of the invest igator to explain the detailed elements of the ICF, subject authorizat ion 
form (if applicable), and subject informa tion sheet (if applicable) to the subject. Informat ion 
shoul d be given in both oral  and wri tten form  whenever possible and in the manner deemed 
appropriate by the IRB or IEC. If the subject is not capable of rendering adequate written informed 
consent, the n the subject’s legally acceptable representative may provide such consent for the 
subject in accordance wit h applicable laws and regulat ions.
The subject, or the subject’s legally acceptable representative, must be given ample opportunit y to 
(1) inquire a bout details of the study  and (2) deci de whether to participate in the study . If the 
subject, or the subject’s legally acceptable representative, determines that he or she will participate 
in the study , then the ICF and subject authorizat ion form  (if appli cable) m ust be si gned and dated 
by the subject, or the subject’s legally acceptable representative, at the time of consent and before 
the subject enters into the study . The subject or the subject’s legally  acceptable representative 
shoul d be instructed to sign using their legal names, not nicknames, using a ballpo int pen wi th 
either blue or black ink. The investigator must also sign and date the ICF and subject authorizat ion 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 94of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL(if applicable) at the time of consent and before the subject enters into the study ; however, the 
sponsor may allow a designee of the invest igator to sign to the extent permitted by applicable law.
Once signed, the original ICF, subject authorizat ion form (if applicable), and subject informat ion 
sheet (if applicable) will be stored in th e investigator’s site file. The investigator must document 
the date the subject signs the informed consent in the subject’s medical record. Copies of the 
signed ICF, the signed subject authorizat ion form (if applicable), and subject informat ion sheet (if 
applicable) shall be given to the subject.
All revised ICFs must be reviewed and signed by relevant subjects or the relevant subject’s legally 
acceptable representative in the same manner as the original informed consent. The date the 
revised consent was ob tained should be recorded in the subject’s medical record, and the subject 
shoul d receive a copy  of the revised ICF.
Patients wi th PD based only  on bone marrow bl asts counts m ay be allowed to remain on study , 
after di scussio n between the invest igator and project clinician or designee, if it is judged that they 
are deriving clinical benefit fro m doing so. Patients who meet the criteria for PD and continue on 
study  under these condit ions m ust be reconsented before continuing study  treatm ent.
15.3 Subject Confident iality
The sponsor and designees affirm and upho ld the principle of the subject’s right to protection 
against invasio n of privacy. Throughout this study , a subject’s source data will be linked to the 
sponsor’s clinical study  database or documentation only via a unique ident ificat ion number. As 
permitted by all applicable laws and regulat ions, limited subject attributes, such as sex, age, or date 
of birth, and subject init ials may be used to verify the subject and accuracy o f the subject’s unique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requi res the investigator to permit its monitor or designee’s monitor, representatives fro m any 
regul atory  authori ty (eg, US FDA, UK MHRA, Japan PMDA ), the sponsor’s designated auditors, 
and the appropriate IRBs and IECs to review the subject’s original medical records (source data or 
docum ents) including, but not limited to, laboratory test resul t reports, ECG reports, admissio n and 
discharge summarie s for hospi tal admissio ns occurring during a subject’s study participation, and 
autopsy  reports. Access to a subject’s original medical records requires the specific authorizat ion 
of the subject as part of the informed consent process (see Sect ion15.2).
Copi es of  any subject source documents that are provided to the sponsor must have certain 
ident ifying personal informat ion rem oved, eg, subject nam e, address, and other ident ifier fields 
not collected on the subject’s eCRF.
15.4 Publication, Disclosure, and Clinical Trial Registration Policy
15.4.1 Publication
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the invest igator from the study . During and after the study , only  the sponsor m ay make study  
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 95of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALinform ation available to other study  invest igators or to regulatory  agencies, except as required by  
law or regul ation. Except as otherwise allowable in the clinical st udy site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and advert isements, is the sole responsibilit y of the sponsor.
The sponsor may publish any d ata and informat ion fro m the study (including data and informatio n 
generated by  the invest igator) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production an d 
review of the document. All publicat ions and presentations must be prepared in accordance with 
this secti on and the clinical study  site agreement. In the event of any discrepancy between the 
protocol  and the clinical study  site agreement, the clinical st udy site agreement will  prevail.
15.4.2 Clinical Trial Registration
To ensure that information on clinical trials reaches the public in a timely manner and to comply 
with applicable laws, regulations, and guidance, Takeda will, at a minimum, register intervent ional 
clinical trials it sponsors anywhere in the world on ClinicalTrials.gov or other publicly accessible 
websites on or before start of study , as defined byTakeda policy / s tandards. Takeda contact 
inform ation, along wi th invest igator’s cit y, state (for Amer icas investigators), country , and 
recrui ting status will be registered and available for public viewing.
As needed, Takeda and invest igator/site contact information may be made public to support 
participant access to trials via registries. In certain situa tions/registri es, Takeda m ay assist 
participants or potential part icipants in finding a clinical trial by  helping them  locate tri al sites 
closest to thei r homes by providing the investigator name, address, and phone number via 
email/phone or other methods preferred by  callers requesting trial informat ion. Once subjects 
receive invest igator contact informat ion, they may call the site requesting enrollment into the trial. 
The invest igative sites are encouraged to handle the trial inquiries according to their established 
subject screening process. If the caller asks addit ional quest ions beyo nd the topic of trial 
enrollment, they should be referred to the sponsor.
Any invest igator who objects to Takeda providing this informat ion to callers must provide Takeda 
with a wri tten noti ce request ing that their informat ion not be listed on the registry site.
15.4.3 Clinical Trial Results Disclosure
Takeda will post the results of clinical trial son ClinicalTrials.gov for the US and 
clinicaltrialsregister.eu for studies conducted in the EU, and other publicly accessible websites 
(including the Takeda corporate site) and registries, as required by Takeda policy/ standard s, 
applicable laws, and/or regulations.
15.4.3.1 Data Sharing
The sponsor is committed to responsible sharing of clinical d ata wi th the goal  of advancing 
medical science and improving pat ient care. Qualified independent researchers will be permitted 
to use data collected from pat ients during the study to conduct addit ional scient ific research, which 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 96of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALmay be unrelated to the stu dy drug or the patient’s disease. The data provided to external 
researchers will not include informat ion that i dentifies pat ients personally.
15.5 Insurance and Compensation for Injury
Each subject in the study  must be insured in accordance with the regulations applicable to the site 
where the subject is participat ing. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study  insurance against the risk o f injury to clinical study subjects. 
Refer to the clinical study  site agreement regarding the sponsor’s policy on subject compensat ion 
and treatment for injury . If the invest igator has questions regarding this po licy, he or she should 
contact the sponsor or sponsor’s designee.
16.0 REFERENCES
1.Commo n Termino logy Criteria for Adverse Events (CTCAE) Version 5.0. U.S. Department of 
Health and Human Services, Nat ional Inst itutes of Health, National Cancer Inst itute. 
November 2017.
2.Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposal s for 
the classificati on of  the myelodysplast ic syndro mes. Brit ish Journal of Haematology 
1982;51(2):189 -99.
3.Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 
revisio n of the World Healt h Organizat ion (WHO) cl assificat ion of myelo id neoplasms and 
acute l eukemia: rati onale and important changes. Blood 2009;114(5):937 -51.
4.Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia -Manero G, So le F, et al. Revised 
internat ional prognostic scoring system for myelodysplast ic syndromes. Blood 
2012;120(12):2454 -65.
5.Cheson BD, Bennett JM, Kopecky  KJ, Buchner T, Willman CL, Estey  EH. Revised 
recommendat ions of the International Working Group for di agnosis, standardizat ion of 
response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute 
myelo id leukemia. J Clin Onco l 2003;21(24):4642 -9.
6. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al . 
Clinical applicat ion and proposal for modificat ion of the International Working Group (IWG) 
response criteria in myelodysplasia. Blood 2006;108(2):419- 25.
7.Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, et al. Phase Ib study of 
pevoned istat, a NEDD8 -activat ing enzyme inhibit or, in combinat ion with docetaxel , 
carbopl atin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. Invest New 
Drugs 2019;37(1):87 -97.
8.Faessel H, Nemunait is J, Bauer TM, Lockhart AC, Faller DV, Sedarati  F, et al . Effect of 
CYP3A inhibitors on the pharmacokinet ics of pevonedistat in patients with advanced so lid 
tumours. Br J Clin Pharmaco l 2019;85(7):1464 -73.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 97of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL9.Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, et al. Pevonedistat, a 
first-in-class NEDD8- activat ing enzyme (NAE) inhibitor, combined wit h azacit idine, in 
patients wi th AML. Bl ood 2018;131(13):1415 -24.
10.Vidaza (azacit idine) for inject ion. Prescribing Informat ion. Summit, NJ: Celgene Corporation, 
2018.
11.Vidaza (azaci tidine). Summary  of Product Characteri stics. Uxbridge: Celgene Ltd, 2018.
12.Von Hoff DD, Slavik M, Muggia FM. 5 -Azacyt idine. A new ant icancer drug with 
effect iveness in acute myelogenous leukemia. Ann Intern Med 1976;85(2):237 -45.
13.TAXOTERE (docetaxel) 20 mg/0.5 mL concentrate and so lvent for solution for infusio n 
[Summary of Product Characterist ics]. Sm PC. Antony  Cedex, France: Avent is Pharma S.A., 
November, 2005.
14. CARBOPLATIN - carboplat in inject ion, solut ion [package insert]. Princeton, NJ: Sandoz In c, 
2011.
15.Carbopl atin 10 mg/mL concentrate for infusio n (Summary o f Product Characteristics). SmPC. 
East Sussex, United Kingdo m: TEVA UK Limited, 26 April, 2016.
16.Naughton CA. Drug -induced nephrotoxicit y. Ameri can Family Physician 2008;78(6):743-50.
17.ABRAXANE (paclitaxel) 5 mg/mL powder for suspensio n for infusio n [Summary  of Product 
Characteristics]. SmPC. Uxbridge, United Kingdom: Celgene Europe Ltd, January  2013.
18.Xiaofei Z, Vaishampayan U, Mahalinqam D, Harvey R, Chung K, Sedarati F, et al. A Phase 1 
Study  to Eval uate the Effects of Rifampin, a Strong CYP3A Inducer, on Pharmacokinet ics of 
Pevonedistat in Patients with Advanced Malignancies. EHA Learning Center 2020;25:PB1983. 
PB1983.
19.PACLITAXEL [package insert]. Lake Forest, IL: Hospira, Inc, 2007.
20.TAXOTERE (docetaxel) [package insert]. Bridgewater, NJ 08807: Sanofi -Avent is, 2014.
21.Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicit y and 
response criteria of the Eastern Cooperative Onco logy Group. Am erican Journal  of Clinical  
Onco logy 1982;5(6):649 -55.
22.The Cri teria Co mmit tee of  New York Heart Associat ion. Nom enclature and Criteria for 
Diagnosis of Diseases of the Heart and Great Vessels. 9 ed. Boston, MA: Little, Brown & Co; 
1994.
23.Eisenhauer EA, The rasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response 
evaluat ion criteria in solid tum ours: revi sed RECIST gui deline (versio n 1.1). Eur J Cancer 
2009;45(2):228 -47.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 98of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL24.du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A ran domized clinical trial 
of cisplat in/paclitaxel versus carboplatin/paclitaxel as first -line treatment of ovarian cancer. J 
Natl Cancer Inst 2003;95(17):1320- 9.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 99of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALAppendix ASOE
SOE for Part A: Single -Agent Pevonedistat and PK (All Patients)
ProcedureScreeningaPK PeriodEOS/
ET Days Day 1 Day 2 Day 3 Day 4 b
Window (+10 days)
Informed consent x
Inclusion/exclusion criteria cx
Demographics x
Medical history x
Complete physical examination x x
Symptom -directed phy sical examinationdx e
Height x
Weight fx x ex
Vital signsgx x x
ECOG PS x x ex
12-lead ECG x x
Pregnancy test hx x ex
Hematology ix x ex
Coagulation x
Complete chemistry panel jx x ex
Urinalysis kx x
Pevonedistat IV infusion x l
Plasma sample for pevonedistat PK (see Table A) x x x x
Plasma sample for pevonedistat protein binding (see Table A) x
Bone marrow aspiration/biopsy and investigator disease 
assessment for patients with hematologic malignancies onlymx
Tumor assessment for solid tumors by RECIST, version 1.1nx x o
Monitoring of concomitant medications and procedures Recorded from the first dose of any study drug through 30 days (+10) days after the last dose of any study drug.
RBC and platelet transfusion documentation Recorded from 8 weeks before enrollment through 30 days after the last dose of any study drug.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 100of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALProcedureScreeningaPK PeriodEOS/
ET Days Day 1 Day 2 Day 3 Day 4 b
Window (+10 days)
AE/SAE reporting Recorded from the first dose of any study drug through 30 days (+10) days after the last dose of any stu dy drug.
AEs should be monitored until they are resolved or are clearly determined to be due to a patient’s stable or chronic 
condition or intercurrent illness(es). 
SAEs will be reported from signing of the ICF through 30 days after the last dose of any study drug.
AE: adverse event; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AML: acute myelogenous leukemia; AST: aspartate aminotransferase; BSA: body surface area; 
BUN: blood urea nitrogen; CT: computerized tomography; ECG: electrocardiogram; ECOG PS: E astern Cooperative Oncology Group performance status; eGFR: estimated 
glomerular filtration rate; EOS: end of study; ET: early termination; ICF: informed consent form; IV: intravenous(ly); LVEF: left ventricular ejection fraction; MDRD: Modification 
of Die t in Renal Disease; PK: pharmacokinetic(s); RBC: red blood cells; RECIST: Response Evaluation Criteria in Solid Tumors; SAE: serious adverse event; SC: subcutaneous(ly); 
SOE: schedule of events; WBC: white blood cell.
An EOS visit is needed in Part A only if for any reason the patient does not continue into Part B.
aUnless otherwise noted, the screening visit must occur within 28 days before the day of the first dose of study drug on Day 1.
bPatients may start Part B 4 to 7 days after the pevonedistat dos e in Part A.
cConfirmation of patient eligibility by the sponsor’s project clinician (or designee) is required prior to enrollment. A patie nt eligibility checklist must be completed and submitted by 
the investigator for review and approval by the sponsor or designee prior to patient enrollment. For assessment of hepatic function, 2 blood samples (total bilirubin and ALT), will be 
required before the start of pevonedistat dosing on Day 1. These 2 samples should be obtained at least 48 hours apart, with the latest sample obtained no more than 48 hours before 
Day1 and may be taken predose on Day 1. If the total bilirubin and ALT measurements from the 2 samples indicate the same liver function category for the patient (ie, normal, mild, 
or moderate hepatic imp airment), pevonedistat can be administered as scheduled. If the results of the 2 samples indicate different liver function categories, a third sample must be 
obtained at least 48 hours after the second sample. If the results of the 2 most recent measuremen ts (the second and third) denote the same liver function category, the patient may be 
enrolled and should receive a single dose of pevonedistat on Day 1 within 48 hours of the third sample. If the second and third measurements indicate different liver func tion 
categories, the patient will not be eligible for inclusion in the study. For assessment of renal function, at least 2 blood samples will be collected to determine spot serum creatinine for 
calculation of the eGFR according to the MDRD equation (see Se ction 9.4.15.1 ). The sampling for spot serum creatinine should be done within 14 days of starting treatment, with the 
most recent measurement perfor med within 7 days of starting treatment. The 2 measurements should both meet eligibility requirements based on the MDRD formula. If the 2 eGFR 
values do not both meet eligibility requirements, a third measurement will be taken and the 2 most recent measure ments (the second and third) will be averaged to assess renal function 
status. LVEF must be <50% within 6 months prior to study enrollment. If a result within this time frame is unavailable, LVEF must be determined by echocardiography or multigated 
acquisi tion scan at screening.
dThe symptom -directed physical examination will be conducted within 3 days before dosing on Day 1. The symptom -directed physical examination may be performed at other visits 
during Part A of the study at the discretion of the inves tigator.
eExcept for measurement of WBC count, procedures conducted during the screening period that are performed within 24 hours of Day 1 can also be used as the predose Day 1 
evaluation and do not need to be repeated. If dosing falls on a Monday, the c ollection window may be extended to collect samples on a previous Friday, with the exception of the 
hepatic and renal function assessments.
fWeight will be measured during screening and within 3 days before Day 1 dosing for calculating BSA. BSA will be ca lculated using a standard formula (see example in Appendix H) 
on Day 1.
gVital signs, including diastolic and systolic blood pressure, heart rate, and body temperature will be obtained at screening. On Day 1, vital signs are to be measured predose 
(20minutes [±10 minutes]) before the infusion of pevonedistat, 30 minutes (±10 minutes) after the start of the pevonedistat infusion, and 30 min (±10 minutes) after the completion 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 101of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALof the pevonedistat infusion. When the timing of vital signs assessment coincides with the timing of a blood draw, vital sign s will be measured before bloo d sample collection. Vital 
sign measurements will be taken with the patient in the supine (after 3 -5 minutes in this position) or sitting position (after 3 -5 minutes in this position). Either oral or axial body 
temperature may be used, but the same method for measuring body temperature (oral or axial) should be used consistently for the same patient throughout the study.
hA serum pregnancy test will be performed for women of childbearing potential at screening and within 3 days before study drug dosing on Day1. The results from these tests must 
be available and negative before the first dose of study drug is administered.
iHematology samples will be collected during screening and within 3 days before infusion/administration with study drug on Day 1. Pleas e note: The sample for WBC count must be 
drawn before dosing on Day 1. For patients with hematologic disease, WBC count must be <50,000/μL before administration of pevonedistat; hydroxyurea may be used to control the 
level of WBCs to no lower than 10,000/μ L while on pevonedistat. An additional sample will be taken on Day 1 at 4 hours after the completion of pevonedistat infusion.
jSamples for the full clinical chemistry panel will be collected predose on Day 1. In addition, samples will be taken on Day 1 at 4hours after the completion of pevonedistat infusion 
(see Table 9.d).
kUrinalysis will be analyzed locally. See Section 9.4.15.1 . for additional details.
lAll eligible patients will receive a single dose of 20 mg/m2pevonedistat via a 1 -hour IV infusion on Day 1. Plasma PK samples will be col lected at a series of predetermined time 
points up to 72 hours (Day 4) following the single dose of pevonedistat. There will be no SOC agents or additional pevonedistat dosing in Part A.
m At screening and for study eligibility, a bone marrow aspiration an d biopsy (performed locally) will be required to assess disease burden, cytogenetics, molecular characterizations, 
and cellular composition by flow cytometry. A bone marrow biopsy (in addition to bone marrow aspirate) is required only at sc reening to confi rm the diagnosis. However, a bone 
marrow biopsy may be collected with bone marrow aspirate in accordance with institutional guidelines. If a biopsy was done wi thin 28 days before enrollment, this archival biopsy 
may be used and does not need to be repeated . If a bone marrow biopsy is not collected routinely per country/institutional guidelines, it is not required.
nRadiological imaging (CT scan or magnetic resonance imaging) of chest, abdomen, and pelvis are required as entry criteria for this study to ass ess the status of the patient’s 
underlying disease. If the patient has had appropriate imaging scans performed within 28 days before the first dose of study drug in Part A, the results of those scans may be used.
oAn EOS/ET CT scan does not need to be com pleted/repeated if a scan was performed within the previous 28 days.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 102of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALTable A Part A: Pevonedistat Plasma PK Sampling Schedule –Pevonedistat Single -Dose PK (All Patients)
Pevonedistat Plasma PK Sample Day 1 Day 2 Day 3 Day 4
Predose x a,c
End of pevonedistat infusion x b,c
30 minutes (± 5 minutes) postinfusion of pevonedistat xd
1hour (± 15 minutes) postinfusion of pevonedistat xd
2hours (±20 minutes) postinfusion of pevonedistat x d
3hours (±20 minutes) postinfusion of pevonedistat x d
4hours (±30 minutes) postinfusion of pevonedistat x d
6hours (±30 minutes) postinfusion of pevonedistat x d
8hours (±30 minutes) postinfusion of pevonedistat x d
24hours (±1 hour) postdose of pevonedistat x e
48hours (±1 hour) postdose of pevonedistat x e
72hours (±1 hour) postdose of pevonedistat x e
IV: intravenous(ly); PK: pharmacokinetics.
aThe predose sample is to be collected within 1 hour before pevonedistat infusion.
bThe sample is to be collected at the end of pevonedistat infusion (immediately before stopping the IV infusion). The infusion takes approximately 1 hour.
cSamples for pevonedistat plasma protein binding measurement should be collected predose and at the end of infusion. The end of infusion sample will be used if bioanalytically 
feasible. If not feasible, the predose sample will also be used for pevonedistat plasma protein binding measurement.
dThe time of sample collection is to be based on the time of c ompletion of pevonedistat infusion.
eThe time of sample collection is to be based on the time of initiation of pevonedistat infusion.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 103of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALSOE for Part B: Treatment Cycle 1 (28 -Day Cycle) Through EOS (Patients With Hematologic Malignancies Only)
DayCycle 1 and Subsequent Cycles (28 days)
EOS/ET Day 1 Day 3 Day 4 Day 5 Day 8 aDay 15 aDay 22
ProcedureWindow (±1day) (±3day) (±3days) (+10 days) b
Symptom -directed phy sical 
examinationcx
Complete physical examination x
Weight x dx
Vital signsex x x x
ECOG PS fx x
12-lead ECGgx x
Pregnancy test hx x
Hematology ix x x x x x x
Complete chemistry panel x x
Select chemistry panel jx x x x x
Urinalysis kx x
Plasma sample for pevonedistat PK 
(Cycle 1 only, see Table B)x x x
Plasma sample for azacitidine PK 
(Cycle 1 only, see Table B)x
Urine sample for pevonedistat PK 
(Cycle 1 only, see Table B)x
Urine sample for azacitidine PK 
(Cycle 1 only, see Table B)x
Bone marrow aspiration/biopsy and 
investigator disease assessmentSee the Bone Marrow Collection and Assessment Schedule (Table C).
Pevonedistat IV infusion lDays 1, 3, and 5 of each cycle.
Azacitidine IV or SC administration lDays 1 -7 or Day s1-5, 8, and 9 of each cycle.
Monitoring of concomitant 
medications and proceduresRecorded from the first dose of any study drug through 30 days (+10) days after the last dose of any study drug.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 104of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALDayCycle 1 and Subsequent Cycles (28 days)
EOS/ET Day 1 Day 3 Day 4 Day 5 Day 8 aDay 15 aDay 22
ProcedureWindow (±1day) (±3day) (±3days) (+10 days) b
RBC and platelet transfusion 
documentationRecorded from 8 weeks before enrollment through 30 days after the last dose of any study drug.
AE/SAE reporting Recorded from the first dose of any study drug through 30 days (+10) days after the last dose of any study  drug.
AEs should be monitored until they are resolved or are clearly determined to be due to a patient’s stable or chronic conditio n or intercurrent 
illness(es).
SAEs will be reported from signing of the ICF through 30 days after the last dose of a ny study drug.
AE: adverse event; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BSA: body surfa ce area; BUN: blood urea nitrogen; COVID -19: 
coronavirus disease 2019; ECG: electrocardiogram; ECOG PS: Eastern Cooperative Oncology Group performance status; EOS: end of study; ET: early termination; IV: 
intravenous(ly); PK: pharmacokinetic(s); RBC: red blood cells; SAE: serious adverse event; SC: subcutaneous(ly); SOE: schedule of events; WBC: whi te blood cell.
Study completion is defined as completion of study treatment and the EOS visit.
Nonessential protocol visits in Part B that do not require on -site sample collection and assessment may be completed via telemedicine (video or phone conversation between the 
patient and the treating physician, if allowed per institutional guidelines) in situations where a site visit cannot be conducte d, such as in a COVID -19 pandemic. The reason for 
telemedicine (eg, COVID -19 related) and for the assessments performed are to be c aptured in the electronic data capture.
aHematology samples and select chemistry panels will be collected on Days 8 (±1 day) and 15 (±1 day) in Cycle 1 and in any cycle in which intrapatient dose escalation of any study 
drug occurs.
b The EOS/ET visit wil l occur 30 days (+10 days) after the last dose of study drugs or before the start of subsequent antineoplastic therapy, if that occurs sooner.
cThe symptom -directed physical examination will be conducted within 3 days before dosing on Day 1 of each treatm ent cycle. The symptom -directed physical examination may be 
performed at other visits during the treatment cycle at the discretion of the investigator.
dWeight will be measured within 3 days before Day 1 dosing in each cycle, for calculating BSA. BSA will be calculated using a standard formula (see example in Appendix H) on 
Cycle1 Day 1, and on Day 1 of subsequent cycles if the patient experiences a >5% change in body weight from the weight used for the most recent BSA calculation.
eVital signs, including diastolic and systolic blood pressure, heart rate, and body temperature will be collected predose (30 minutes [±10 minutes]) before the infusion of pevonedistat 
and 30 minutes (±10 minutes) after the start of the pevonedistat infusion on Days 1, 3, and 5 o f each cycle, at EOS/ET, and as clinically indicated at the discretion of the investigator. 
On Cycle 1 Day 1, vital signs are to be measured predose (20 minutes [±10 minutes]) before the infusion of pevonedistat, 30 minutes (±10 minutes) after the start of the pevonedistat 
infusion, and 30 min (±10 minutes) after the completion of the pevonedistat infusion. Vital sign measurements will be taken with the patient in the sup ine (after 3 -5minutes in this 
position) or sitting position (after 3 -5minutes in this position). Either oral or axial body temperature may be used, but the same method for measuring body temperature (oral or axi al) 
should be used consistently for the same patient throughout the study.
fECOG PS will be performed within 3 days before the be ginning (Day 1) of each treatment cycle and at the EOS/ET visit.
gA 12 -lead ECG will be performed Day 1 predose of every cycle and at EOS/ET. Predose assessment may be performed up to 3 days in advance if necessary. ECGs may be obtained 
as clinically indi cated at the discretion of the investigator. ECG assessments are to be performed with the patient supine and rested for 5 minutes.
hA serum pregnancy test will be performed for women of childbearing potential within 3 days before Day 1 of each cycle and a t EOS/ET. The results from these tests must be 
available and negative before the study drug is administered on Day 1. If the Day 1 serum pregnancy results will not be available before dosing, a urine pregnancy test may be 
performed.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 105of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALiHematology samples wi ll be collected before infusion with study drug(s) on Days 1, 3, and 5, and on Day 22 of each cycle, and at EOS/ET. Samples may be drawn up to 1day before 
dosing. If dosing falls on a Monday, the collection window may be extended to collect samples on the previous Friday. Additional collections on Days 8(±1day) and 15(±1day) will 
be performed in Cycle 1 or in any cycle in which study drug dose is escalated. Please note: The sample for WBC count must be drawn before each dose on Days 1, 3, and 5. WBC 
count must be <50,000/μL before administration of pevonedistat; hydroxyurea may be used to control the level of WBCs to no lowe r than 10,000/μL while on pevonedistat.
jThe select chemistry panel will be collected predose on Days 3 and 5 and on Day 22 of eac h cycle. For Days 3 and 5, samples may be drawn up to 1 day before dosing. If dosing falls 
on a Monday, the collection window may be extended to collect samples on the previous Friday. Additional collections on Days 8(±1day) and 15 (±1day) will be perfo rmed in 
Cycle1 or in any cycle in which study drug dose is escalated. The select chemistry panel will include the following: BUN, creatinine, total bilirubin, ALP, AST, and ALT.
k Urinaly sis will be analyzed locally. See Section 9.4.15.1 . for additional details.
lFollowing a 4 -to 7-day washout period after single -dose pevonedistat administration in Part A, starting on Day 1 patients will receive pe vonedistat on Days 1, 3, and 5 in 
combination with azacitidine (75 mg/m2) on Days 1 through 7 or Days 1 through 5, 8, and 9 in 28 -day cycles. Patients will receive azacitidine SC in Cycle 1. Azacitidine will be given 
SC or IV during Cycle 2 and beyond. On Days 1, 3, and 5, when both study drugs are administered, azacitidine will be administered first, followed by pevonedistat. The pe vonedistat 
infusion may be slowed or stopped and restarted for any associated infusion -related reactions. Following sponsor an d investigator discussion of the available safety data, patients who 
tolerate treatment well at the initially assigned dose of pevonedistat may be allowed to increase their dose during Cycle 2 or in subsequent cycles of treatment. Eligible patients may 
continue to receive treatment in Part B until they experience symptomatic deterioration or disease progression, treatment is discontinued for another reason, or un til the study is 
stopped by the sponsor. See Section 8.0for details of study drug administration.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 106of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALTable B Part B: Azacitidine and Pevonedistat Plasma and Urine PK Sampling Schedule in Cycle 1 (Patients With 
Hematologic Malignancies Only)
Day Dosing aAzacitidine Plasma PK Pevonedistat Plasma PKUrine PK for Azacitidine and 
Pevonedistat
Azacitidine Pevonedistat Timepoint Sample Timepoint Sample Timepoint
3 x Predose x bPredose bx bPredose c
x (start infusion) 5minutes (±5 minutes) x d
0–2hours postdose interval g15minutes (±5 minutes) x d
30minutes (±10 minutes) x d
45minute s (±10 minutes) x d
x (end infusion) 1hour (±10 minutes) x d,eEnd of pevonedistat infusion x e,f
1.5hours (±10 minutes) x d,e30minutes (±5 minutes) x e,h
2hours (±20 minutes) x d,e1hour (±15 minutes) x e,h
3hours (±20 minutes) x d,e2hours (±20 minutes) x e,h
4hours (±30 minutes) x d,e3hours (±30 minutes) x e,h
2-4hours postdose interval g
5hours (±30 minutes) x d,e4hours (±30 minutes) x e,h
7hours (±30 minutes) x d,e6hours (±30 minutes) x e,h4-6hours postdose interval g
8hours (±30 minutes) x h6–8hours postdose interval g
4 24hours (±1 hour) x i
5 48hours (±1hour) x i, j
IV: intravenous; PK: pharmacokinetic(s); SC: subcutaneous(ly).
aFordays when azacitidine is coadministered with pevonedistat, azacitidine will be given first, followed by pevonedistat infusion .
bThe predose plasma sample is to be coll ected within 10 minutes before the start of azacitidine administration.
cPatients should be asked to void completely in a container approximately 30 minutes before administration of the first dose of study drug. An aliquot of this spot urine specimen will
be a predose urine sample. Detailed instructions on the procedure for collection, processing, storage, and shipment of the ur ine samples will be provided in the Study Manual.
dSamples should be collected after azacitidine SC administration.
eThese samples are collected to measure both azacitidine and pevonedistat plasma concentrations.
f The sample is to be collected at the end of pevonedistat infusion (immediately before stopping the IV infusion). The pevonedi stat infusion takes approximatel y 1hour.
g Postdose intervals are based on completion of azacitidine SC administration.
hThe time of sample collection is to be based on the time of completion of pevonedistat IV infusion on Day 3.
iThe time of sample collection is to be based on the ti me of initiation of pevonedistat IV infusion on Day 3.
jThe sample is to be collected before the combination dose administration on Day 5.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 107of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALTable C Bone Marrow Collection and Assessment Schedule (Patients with Hematologic Malignancies Only)
Assessment ScreeningCycle 2
Day 22
(+6 Days)Cycle 5
(Between
Days 15-28)Cycle 8
(Between
Days 15-28)Cycle 11
(Between
Days 15-28)Subsequent Cycles
(Between Days 15-28);
Every 6 Cycles Thereafter Relapse
Bone marrow blast count x ax bx bx bx bx bx
Cytogenetics cx x x x x x x
eCRF: electronic case report form; FISH: fluorescence in situ hybridization.
All samples will be collected and analyzed locally.
aAt screening and for study eligibility, a bone marrow aspiration and biopsy (performed locally) will be required to assess di sease burden, cytogenetics, molecular characterizations, 
and cellular composition by flow cytometry. A bone marrow biopsy (in addi tion to bone marrow aspirate) is required only at screening to confirm the diagnosis. However, a bone 
marrow biopsy may be collected with bone marrow aspirate in accordance with institutional guidelines. If a biopsy was done wi thin 28 days before enrollmen t, this archival biopsy 
may be used and does not need to be repeated. If bone marrow biopsy is not collected routinely per country/institutional guid elines, it is not required.
bA bone marrow aspirate for blast count (to determine disease response) will b e performed on Day 22 (+6 days) of Cycle 2, and between Days 15 and 28 of Cycle 5, Cycle 8, 
Cycle11, and then every 6 cycles afterward or otherwise as clinically indicated at the discretion of the investigator. Results must be available before dosing star ts in the next cycle.
cCytogenetics analysis will be done at the clinical site: a bone marrow aspirate sample will be tested according to institutio nal guidelines in a cytogenetics laboratory routinely used 
by the site. Analyses should be done by karyotyp e, and by  FISH if possible. Results will be collected in the eCRF.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 108of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALSOE for Part B: Treatment Cycle 1 (21 -Day Cycle) Through EOS (Patients with Advanced Solid Tumors Only)
DayCycle 1 and Subsequent Cycles (21 days)
EOS/ET Day 1 Day 3 Day 4 Day 5 Day 8 aDay 15 a
Procedure Window (±3day) (±3day) (+10 days) b
Symptom -directed phy sical 
examinationcx
Complete physical examination x
Weight x dx
Vital signsex x x x
ECOG PS fx x
12-lead ECGgx x
Pregnancy test hx x
Hematology ix x x x x x
Complete chemistry panel x x
Select chemistry panel jx x x x
Urinalysis kx x
Plasma sample for pevonedistat 
PK (Cycle 1 only, see Table D)x x x
Tumor assessment for solid 
tumors by RECIST, version 1.1l To be completed within 28 days before dosing in Part B, end of Cycle 2, Cycle 5, and every 6 cycles thereafter. x
Pevonedistat IV infusion mDays 1, 3, and 5 of each cycle.
Chemotherapy IV infusion mDay1 of each cycle.
Monitoring of concomitant 
medications and proceduresRecorded from the first dose of any study drug through 30 days (+10) days after the last dose of any study drug.
RBC and platelet transfusion 
documentationRecorded from 8 weeks before enrollment through 30 days after the last dose of any study drug.
AE/SAE reporting Recorded from the first dose of any study drug through 30 days (+10) days after the last dose of any study drug.
AEs should be monitored until they are resolved or are clearly determi ned to be due to a patient’s stable or chronic condition or intercurrent 
illness(es).
SAEs will be reported from signing of the ICF through 30 days after the last dose of any study drug.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 109of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALAE: adverse event; ALP: alkaline phosphatase; ALT: alanine amino transferase; AST: aspartate aminotransferase; BSA: body surface area; BUN: blood urea nitrogen; 
CT:computerized tomography; ECG: electrocardiogram; ECOG PS: Eastern Cooperative Oncology Group performance status; EOS: end of study; ET: early terminati on; 
ICF: informed consent form; IV: intravenous(ly); MRI: magnetic resonance imaging; PK: pharmacokinetic(s); RBC: red blood cells; RECIST: Response Evaluation Criteria in Solid 
Tumors; SAE: serious adverse event; SOE: schedule of events
Study  completion is defined as completion of study treatment and the EOS visit.
Nonessential protocol visits in Part B that do not require on -site sample collection and assessment may be completed via telemedicine (video or phone conversation between the 
patient and the tr eating physician, if allowed per institutional guidelines) in situations where a site visit cannot be conducted, such as in a COVID -19 pandemic. The reason for 
telemedicine (eg, COVID -19 related) and for the assessments performed are to be captured in the electronic data capture (EDC).
aHematology samples and select chemistry panels will be collected on Days 8 (±1 day) and 15 (±1 day) in Cycle 1 and in any cycle in which intrapatient dose escalation of any study 
drug occurs.
b The EOS/ET visit will occur 3 0days (+10 days) after the last dose of study drugs or before the start of subsequent antineoplastic therapy, if that occurs sooner.
cThe symptom -directed physical examination will be conducted within 3 days before dosing on Day 1 of each treatment cycle . The symptom -directed physical examination may be 
performed at other visits during the treatment cycle at the discretion of the investigator.
dWeight will be measured within 3 days before Day 1 dosing in each cycle, for calculating BSA. BSA will be calcu lated using a standard formula (see example in Appendix H) on 
Cycle1 Day 1, and on Day 1 of subsequent cycles if the patient experiences a >5% change in body weight from the weight used for the most recent BSA calculation.
eVital signs, including diastolic and systolic blood pressure, heart rate, and body temperature will be collected predose (30minutes [±10 minutes]) before the infusion of pevonedist at 
and 30 minutes (±10 minutes) after the start of the pevonedistat infusion on Days 1, 3, and 5 of each cycle, at EOS/ET, and as clinically indicated at the discretion of the investigator. 
On Cycle 1 Day 1, vital signs are to be measured predose (20 minut es [±10 minutes]) before the infusion of pevonedistat, 30 minutes (±10 minutes) after the start of the pevonedistat 
infusion, and 30 min (±10 minutes) after the completion of the pevonedistat infusion. Vital sign measurements will be taken with the patient in the supine (after 3 -5minutes in this 
position) or sitting position (after 3 -5minutes in this position). Either oral or axial body temperature may be used, but the same method for measuring body temperat ure (oral or axial) 
should be used consistently for the same patient throughout the study.
fECOG PS will be performed within 3 days before the beginning (Day 1) of each treatment cycle and at the EOS/ET visit.
gA 12 -lead ECG will be performed Day 1 predose of every cycle and at EOS/ET. Predose assessm ent may be performed up to 3 days in advance if necessary. Additional ECGs may 
be obtained as clinically indicated at the discretion of the investigator. ECG assessments are to be performed with the patie nt supine and rested for 5 minutes.
hA serum pregna ncy test will be performed for women of childbearing potential within 3 days before Day 1 of each cycle and at EOS/ET. The results from these tests must be 
available and negative before the study drug is administered on Day 1. If the Day 1 serum pregnancy results will not be available before dosing, a urine pregnancy test may be 
performed.
iHematology samples will be collected before infusion with study drug(s) on Days 1, 3, and 5, and EOS/ET. Samples may be drawn up to 1 day before dosing. If dosing falls on a 
Monday, the collection window may be extended to collect samples on the previous Friday. Additional collections on Days 8 (±1 day) and 15 (±1 day) will be performed in Cycle 1 
or in any cycle in which study drug dose is escalated.
jThe select chemistry panel will be collected predose on Days 3 and 5 and will include the following: BUN , creatinine, total bilirubin, ALP, AST, and ALT. On Days 3 and 5 samples 
may be drawn up to 1 day before dosing. If dosing falls on a Monday, the collection window may be extended to collect samples on the previous Frid ay. Additional collections on 
Days 8(±1day) and 15 (±1 day) will be performed in Cycle 1 or in any cycle in which study drug dose is escalated.
k Urinaly sis will be analyzed locally. See Section 9.4.15.1 . for additional details.
lTumor assessment will be performed before the start of the study and at the completion of Cycle 2, Cycle 5, and every 6 cycles thereafter in Part B. Patients will undergo CT (with 
IV contrast, except for pa tients with an allergy to contrast agents), MRI, x -ray, and/or bone scanning to monitor and assess disease progression. If the anatomic region cannot be 
adequately imaged by CT, MRI may be used instead; see Section 9.4.17.2 . An EOS/ET CT scan does not need to be completed/repeated if a scan was performed within the previous 
28days. Response will be determined according to RECIST version 1.1.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 110of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALmThe inve stigator will select which chemotherapy (docetaxel or carboplatin plus paclitaxel) that each patient will receive in combinat ion with pevonedistat. Following a 4 -to 7-day 
washout period after single -dose pevonedistat administration in Part A, starting on Cycle 1 Day 1, patients will receive pevonedistat and chemotherapy agents on Day 1 and 
pevonedistat alone on Days 3 and 5 in 21 -day cycles. The infusion of pevonedistat may be slowed or stopped and restarted for any associated infusion -related reactions. F ollowing 
sponsor and investigator discussion of the available safety  data, patients who tolerate treatment well at the initially assig ned dose of pevonedistat may be allowed to increase their dose 
during Cycle 2 or in subsequent cycles of treatment. The ch emotherapeutic agent may be dose reduced because of toxicities in accordance with Section 8.3.2.3 . See Section 8.0for the 
details of study drug administration.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 111of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALTable D Part B: Pevonedistat Plasma PK Sampling Schedule in Cycle 1 (Patients with Advanced Solid Tumors)
Day Dosing Pevonedistat Plasma PK
Pevonedistat Timepoint Sample
3 Predose ax a
x (start infusion)
x (end infusion) End of pevonedistat infusion x b
30minutes (±5 minutes) x c
1hour (±15 minutes) x c
2hours (±20 minutes) x c
3hours (±30 minutes) x c
4hours (±30 minutes) x c
6hours (±30 minutes) x c
8hours (±30 minutes) x c
4 24hours (±1 hour) x d
5 48hours (±1 hour) x d
IV: intravenous; PK: pharmacokinetic(s).
aThe predose plasma sample is to be collected within 10 minutes before the start of pevonedistat infusion.
b The sample is to be collected at the end of pevonedistat infusion (immediately before stopping the IV infusion). The pevonedistat infusion takes ap proximately 1 hour.
cThe time of sample collection is to be based on the time of completion of pevonedistat IV infusion on Day 3.
dThe time of sample collection is to be based on the time of initiation of pevonedistat IV infusion on Day 3.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TA K-924/MLN4924)
Study No. Pevonedistat -1016 Page 112of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALAppendix BStudy Diagrams
D: Day ; IV: intravenous; PK: pharmacokinetic; SC: subcutaneous
In Part A, patients will receive a singe IV dose of pevonedistat for PK assessment. In Part B, patients with hematologic 
malignancies will receive an IV infusion of pevonedistat on Days 1, 3, and 5 in combination with 75 mg/m2 
azacitidine on Days 1 -7 or Days 1 –5, 8, and 9 in a 28 -day treatment period. Patients will receive azacitidine SC during 
Cycle 1 of Part B (PK assessment period). Azacitidine will be administered SC or IV during Cycle 2 and beyond. Part 
Bmay start 4 –7 days after the dose of pevonedistat administered in Part A. Intrapatient dose escalation may start in 
Cycle 2 or in subsequent cycles.
See Section 8.1 for details of study drug administration.0- 8hr 24hr 48hr 72hr 0- 8hr 24hr 48hr
D1 D2 D3 D 4 D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D 28
urine*
Pevonedistat dose Azacitidine dose
sample collection for PK *Urine collection for PKPart B
[4-7 days]Part A [WASHOUT]
PEVONEDISTAT
Days 1 through 5, 8 and 9 
AZAC ITIDINE OR
Days 1 through 7 PEVONEDISTAT
20mg/m2
SCREENING 
(28 days)PEVONEDISTAT -1016   PART A: SINGLE DOSE PEVONEDISTAT AND PART B: PEVONEDISTAT IN 
COMBINATION WITH AZACITIDINE (PATIENTS WITH HEMATOLOGIC MALIGNANCIES)
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TA K-924/MLN4924)
Study No. Pevonedistat -1016 Page 113of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALAppendix CResponsibilities of the Investigator
Clinical research studies sponsored by  the sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions. The responsibilit ies imposed on invest igators by  the FDA are 
summarized in the Statement of Investigator (Form FDA 1572), which m ust be com pleted and 
signed before the invest igator may participate in this study .
The invest igator agrees to assume the fo llowing responsibilit ies by signing a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff who will assist in the protocol.
3.If the invest igator/institution retains the services of any individual or party to perform 
trial-related duti es and funct ions, the invest igator/inst itution shoul d ensure that this individual 
or party  is qualified to perform those trial -related duti es and funct ions and should implement 
procedures to ensure the integrit y of the tri al-related duti es and funct ions performed and any 
data generated.
4.Ensure that study -related procedures, including stu dy-specific (nonroutine/nonstandard panel) 
screening assessments, are NOT performed on potent ial subjects before the receipt of written 
approval  from relevant governing bodies/authorit ies.
5.Ensure that all co lleagues and emplo yees assist ing in the conduct o f the study are informed of 
these obligat ions.
6.Secure prior approval o f the study and any changes by an appropriate IRB/IEC that conform to 
21 CFR Part 56, ICH and local regulatory  requi rements.
7.Ensure that the IRB/IEC will be responsible for init ial revie w, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to subjects. Make at least y early reports on the progress of the study  to the 
IRB/IEC, and issue a final report wi thin 3 months of study  com pletion.
8.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
regul ations, are m et.
9.Obtain valid informed consent from each subject who participates in the study , and docum ent 
the date of con sent in the subject’s medical chart. Valid informed consent is the most current 
versio n approved by the IRB/IEC. Each ICF should contain a subject authorizat ion section that 
describes the uses and disclosures of a subject’s personal informat ion (including personal 
healt h informat ion) that will take place in connect ion with the study. If an ICF does not include 
such a subject authorizat ion, then the investigator must obtain a separate subject authorizatio n 
form from each subject or the subject’s legally acce ptabl e representative.
10.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital records, laboratory  resul ts, etc, and maintain these data for a minimum o f 
2years fo llowing notificat ion by the sponsor th at all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TA K-924/MLN4924)
Study No. Pevonedistat -1016 Page 114of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALcontact and receive written approval fro m the sponsor before disposing o f any such 
docum ents.
11.Allow possible inspe ction and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
12.Maintain current records of the receipt, administratio n, and disposit ion of sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the sponsor.
13.Report adve rse reacti ons to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TA K-924/MLN4924)
Study No. Pevonedistat -1016 Page 115of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALAppendix DECOG Scale for Performance Status
Grade Description
0 Normal activity. Fully active, able to carry on all predisease performance without restriction.
1 Symptoms but ambulatory. Restricted in physically strenuous activity, but ambulatory and able to 
carry  out work of a light or sedentary nature (eg, light housework, office work).
2 In bed <50% of the time. Ambulatory and capable of all self -care, but unable to carry out any work 
activities. Up and about more than 50% of waking hours.
3 In bed >50% of the time. Capable of only limited self -care, confined to bed or chair more than 50% of 
waking hours.
4 100% bedridden. Completely disabled. Cannot carry on any self -care. Totally confined to bed or 
chair.
5 Dead.
Source: Oken, 1982 [21].
ECOG: Eastern Cooperative Oncology Group.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TA K-924/MLN4924)
Study No. Pevonedistat -1016 Page 116of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALAppendix E Definition of Postmenopausal
A postm enopausal  state is defined as no menses for 12 months without an alternat ive medical 
cause. A high FSH level in the postmenopausal range may be used to confirm a postmenopausal 
state in women not using hormonal contraception or hormonal replacement therapy . However, in 
the absence of 12 months of amenorrhea, a single FSH measurement is insuffic ient. Please refer to 
the following source for addit ional informat ion: European Heads of Medicines Agencies Clinical 
Trial Facili tation Group; see 
hma.eu/filea dmin/datei en/Human_Medicines/01- About_HMA/Working_Groups/CTFG/2014_09
_HMA_ CTFG_Contraception.pdf.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TA K-924/MLN4924)
Study No. Pevonedistat -1016 Page 117of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALAppendix FAcceptable Methods of Contraception Considered Highly Effective
Birth control  methods that can achieve a failure ra te of less than 1% per year when used 
consistent ly and correctly  are considered to be highly  effect ive. Such methods include the 
following:
Combined (estrogen and progestogen –containing) hormonal contraception associated with 
inhibit ion of ovulation a:
–Oral.
–Intravaginal.
–Transdermal.
Progestogen -only hormonal contracepti on associ ated wi th inhibit ion of ovulation a:
–Oral.
–Injectable.
–Implantable. b
Intrauterine device. b
Intrauterine hormone -releasing system. b
Bilateral tubal occlusio n. b
Vasectomized part ner. b,c
Sexual abst inence. d
Methods Considered Less Highly Effective
Acceptable birth control methods that result in a failure rate of more than 1% per y ear include the 
following:
Progestogen -only oral horm onal contracepti on, where inhibit ion of ovulatio n is not the 
primary  mode of  action.
Male or female condo m with or wi thout spermicide. e
Cap, diaphragm, or sponge with spermicide. e
aHormonal contraception may be susceptible to interaction with the investigational medicinal product, which may 
reduce th e efficacy of the contraception method.
bContraception methods that, in the context of this guidance, are considered to have low user dependency.
cVasectomized partner is a highly effective birth control method provided that partner is the sole sexual pa rtner of the 
woman of childbearing potential participant of the study and that the vasectomized partner has received medical 
assessment of the surgical success.
dIn the context of this guidance, sexual abstinence is considered a highly  effective method on ly if defined as refraining 
from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of 
sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual 
lifesty le of the subject.
eA combination of male condom with either cap, diaphragm, or sponge with spermicide (double -barrier methods) is 
also considered an acceptable, but not a highly effective, birth control method.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TA K-924/MLN4924)
Study No. Pevonedistat -1016 Page 118of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALAppendix GNew York Heart Association Classification of Cardiac Disease
The fo llowing tabl e presents the New York Heart Associat ion classification of cardiac disease 
[22].
Class Functional Capacity Objective Assessment
I Patients with cardiac disease but without resulting limitations of physical 
activity . Ordinary  physical activity  does no t cause undue fatigue, palpitation, 
dyspnea, or anginal pain.No objective evidence of 
cardiovascular disease
II Patients with cardiac disease resulting in slight limitation of physical activity. 
They  are comfortable at rest. Ordinary physical activity results in fatigue, 
palpitatio n, dy spnea, or anginal pain.Objective evidence of 
minimal cardiovascular 
disease
III Patients with cardiac disease resulting in marked limitation of physical 
activity . They  are comfortable at rest. Less than ordinary activit y causes 
fatigue, palpitation, dyspnea, or anginal pain.Objective evidence of 
moderately severe 
cardiovascular disease
IV Patients with cardiac disease resulting in inability to carry on any physical 
activity  without discomfort. Symptoms of heart failure or the anginal 
syndrome may  be present even at rest. If any physical activity is undertaken, 
discomfort is increased.Objective evidence of 
severe cardiovascular 
disease
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TA K-924/MLN4924)
Study No. Pevonedistat -1016 Page 119of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALAppendix HBSA Calculation
BSA shoul d be calculated using a standard formula. An example formula fo llows:
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TA K-924/MLN4924)
Study No. Pevonedistat -1016 Page 120of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALAppendix IFormula for ANC Calculation
ANC =total leukocy te count ×total percentage of neutrophils (segmented neutrophils +band 
neutrophils)
Example:
If total  leukocyte count =4.3× 103/L; segmented neutrophils =48%; band neutrophils = 2%
Then:
ANC = 4300 × (0.48 +0.02) = 4300 × 0.5=ANC of 2150
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TA K-924/MLN4924)
Study No. Pevonedistat -1016 Page 121of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALAppendix J Response Criteria for MDS, CMML, AML, and Solid Tumors
Response Criteri a for Altering Natural History of MDS and CMML
Category Response Criteria
CR Bone marrow: ≤5% myeloblasts with normal maturation of all cell lines a
Persistent dysplasia will be noted a
Peripheral blood b
Hgb ≥11 g/dL
Platelets ≥100 109/L
Neutrophils ≥1.0109/L
Blasts 0%
PR All CR criteria if abnormal before treatment except:
Bone marrow blasts decreased by ≥50% over pretreatment but still >5%
Cellularity and morphology not relevant
Marrow CR Bone marrow: ≤5% myeloblasts and decrease by ≥50% over p retreatment
Peripheral blood: any HI responses (see Table, below) will be noted separately, in addition to 
marrow CR
Stable disease Failure to achieve at least PR, but no evidence of progression for >8 weeks
If a patient has <50% increase in blast count from pretreatment, then this is stable disease and 
the patient should remain on study
Failure Death during treatment or PD (as defined below), or progression to AML or a more advanced 
MDS or CMML FAB/WHO subtype than pretreatment
Relapse after CR or 
PRAt least o ne of the following:
Return to pretreatment bone marrow blast percentage
Decrement of ≥50% from maximum remission/response levels in granulocytes or platelets
Note: Transient cytopenias during chemotherapy courses should not be considered relapse , 
as long as they recover to the previous levels
Reduction in Hgb concentration by ≥1.5 g/dL or transfusion dependence
Cytogenic response Complete
Disappearance of the chromosomal abnormality without appearance of new ones
Partial
At least 50% reduction o f the chromosomal abnormality 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TA K-924/MLN4924)
Study No. Pevonedistat -1016 Page 122of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALCategory Response Criteria
Progressive disease 
(PD)Note: Transient cytopenias during chemotherapy courses should not be considered PD, as 
long as they recover to the previous levels; progression based on blood values should not be 
considered at all u ntil after the post -Cycle 4 marrow draw
If a patient has ≥50% increase in blast count from pretreatment (without AML 
transformation) but is still deriving benefit from this treatment (eg, improvement in 
peripheral blood counts), the patient may continue on study as agreed by the investigator and 
the sponsor’s project clinician (or designee)
For patients with:
Less than 5% blasts: ≥50% increase in blasts to >5% blasts.
5%-9% blasts: ≥50% increase to >10% blasts.
10%-19% blasts: ≥50% increase to >20% blasts.
20%-30% blasts.
Any of the following:
At least 50% decrement from maximum remissio n/response in granulocytes or platelets.
Reduction in Hgb by ≥2 g/dL.
New transfusion dependence.
To convert hemoglobin from grams per deciliter to grams per liter, multiply grams per deciliter by 10.
AML: acute myelogenous leukemia; CMML: chronic myelomonocytic leukemia; CR: complete response/remission; 
DFS: disease -free survival; FAB: French -American -British; Hgb: hemoglobin; HI: hematologic improvement; MDS: 
myelodysplasti c syndromes; PFS: progression -free survival; PR: partial response/remission; WHO: World Health 
Organization.
aDysplastic changes should consider the normal range of dysplastic changes.
bTransient cytopenias during repeated chemotherapy courses should not be considered as interrupting durability of 
response, as long as they recover to the improved counts of the previous course.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TA K-924/MLN4924)
Study No. Pevonedistat -1016 Page 123of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALResponse Criteria for HI for MDS and CMML
HI aResponse Criteria (Responses Must be At Least 8 Weeks in Duration)
Erythroid response (pretreatment, <11 
g/dL)Hgb increase by ≥1.5 g/dL
Relevant reduction of units of RBC transfusions by an absolute number of at 
least 4 RBC transfusions/8 weeks compared with the pretreatment 
transfusion number in the previous 8 weeks. Only RBC tra nsfusions given 
for a Hgb of ≤9.0 g/dL pretreatment will count in the RBC transfusion 
response evaluation.
Platelet response (pretreatment, 
<100 109/L)Absolute increase of ≥30109/L for patients starting with >20 109/L 
platelets
Increase from <20 109/L to >20 109/L and by  at least 100% 
Neutrophil response (pretreatment, 
<1.0109/L)At least 100% increase and an absolute increase >0.5 109/L
Progression or relapse after HI bAt least o ne of the following:
At least 50% decrement from maximum response levels in granulocytes 
or platelets.
Reduction in Hgb by ≥1.5 g/dL.
Transfusion dependence.
To convert hemoglobin levels from grams per deciliter to grams per liter, multiply grams per deciliter by 10.
CMML: chronic myelomonocytic leukemia; Hgb: hemoglobin; HI: hematologic improvement; 
MDS: myelodysplastic syndromes; RBC: red blood cell.
aPretreatment counts will be the average of screening and Cycle 1 Day 1 predose samples.
bIn the absence of another explanation, such as acute infection, a cou rse of chemotherapy, gastrointestinal bleeding, 
hemoly sis, and so forth. The 2 kinds of erythroid and platelet responses should be reported overall as well as by the 
individual response pattern.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TA K-924/MLN4924)
Study No. Pevonedistat -1016 Page 124of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALResponse Criteria for AML
Category Response Criteria
Morphologic complete 
remission (CR)A CR designation requires that the patient achieve the morphologic leukemia -free state and 
have an ANC of more than 1000/µL and platelets of ≥100,000/µL. A morphologic 
leukemia -free state requires less than 5% blasts in an aspirate sample with marrow spicules 
and with a count of at least 200 nucleated cells. Hemoglobin concentration or hematocrit has 
no bearing on remission status, although the patient must be independent of transfusions. 
There should be no residual evide nce of extramedullary leukemia.
Morphologic complete 
remission with 
incomplete blood 
count recover y (CRi)After chemotherapy, some patients fulfill all of the criteria for CR except for residual 
neutropenia (<1000/µL) or thrombocytopenia (<100,000/µL).
Cytogenetic CR Reversion to a normal karyotype at CR or CRi.
Partial remission (PR) This designation requires all of the hematologic values for a CR but with a decrease of at 
least 50% in the percentage of blasts to 5% to 25% in the bone marrow aspirate. Thus, if the 
pretreatment bone marrow blast percentage was 50% to 100%, the percentage of blasts must 
decrease to a value between 5% and 25%; if the pretreatment blast percentage was 20% to 
less than 49%, they must decrease by at least half to a value of m ore than 5%. A repeat bone 
marrow aspiration after several weeks may be required to distinguish between a PR and 
increased blasts caused by bone marrow regeneration. A value of ≤5% blasts may also be 
considered a PR if Auer rods are present.
Progressive d isease 
(PD)Because the IWG criteria for AML do not provide a standardized definition for PD [5], PD is 
defined in this protocol as one of the follow ing:
>50% increase in bone marrow blasts from baseline value to >30% blasts.
>50% increase in circulating blasts from baseline value to >30% blasts in peripheral 
blood (in the exceptional case when bone marrow examination is not possible).
Development of b iopsy-proven extramedullary disease, or new sites of extramedullary 
leukemia.
Relapse after CR Relapse after CR is defined as a reappearance of leukemic blasts in the peripheral blood 
or >5% blasts in the bone marrow not attributable to any other cause (eg, bone marrow 
regeneratio n after consolidation therapy). In the setting of recent treatment, if there are no 
circulating blasts and the bone marrow contains 5% to 20% blasts, a repeat bone marrow 
performed at least a week later is necessary to distingui sh relapse from bone marrow 
regeneratio n.
AML: acute myelogenous leukemia; ANC: absolute neutrophil count; IWG: International Working Group.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TA K-924/MLN4924)
Study No. Pevonedistat -1016 Page 125of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALResponse Criteria for Target and Nontarget Lesions in Solid Tumors
Evaluation of Target Lesions
CR Disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must 
have reduction in short axis to <10 mm.
Partial 
responseAt least a 30% decrease from baseline in the sum of diameters of target lesions, taking as reference the 
baseline sum of diameters.
PD At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on 
study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase 
of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or 
more new lesions is also considered progression.
SD Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for PD, 
taking as reference the smallest sum of diameters w hile o n study.
Evaluation of Nontarget Lesions
CR Disappearance of all nontarget lesions and normalization of tumor marker level. All lymph nodes must 
be nonpathological in size (<10 mm short axis). 
Non-CR/ 
Non-PD Persistence of one or more nontarget lesion(s) or/and maintenance of tumor marker level above the 
normal limits.
PD Appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.
Source: Eisenhauer, 2009 [23].
CR: complete response/remission; PD: progressive disease; SD: stable disease.
Overall Disease Response Criteria for Target and Nontarget Lesions in Solid Tumors
Target Lesions Nontarget Lesions New Lesions Overall Response
CR CR No CR
CR Non-CR/Non -PD No Partial response
CR Not evaluated No Partial response
PR Non-PD or not all evaluated No Partial response
SD Non-PD or not all evaluated No SD
Not all evaluated Non-PD No Inevaluable
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
Source: Eisenhauer, 2009 [23].
CR: complete response/remission; PD: progressive disease; SD: stable disease.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TA K-924/MLN4924)
Study No. Pevonedistat -1016 Page 126of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALAppendix KDrugs Associated With Nephrotoxicity
The drugs listed in the table below are permitted to be used during the conduct of this study  but 
shoul d be used wi th cauti on.
Drugs Associated With Nephrot oxicity
Analgesics Cardiovascular agents
Nonsteroidal anti -inflammatory drugs Angiotensin -converting enzyme inhibitors, angiotensin 
receptor blockers
Antidepressants/mood stabilizers Clopidogrel (Plavix), ticlopidine (Ticlid)
Lithium Contrast dye
Antimicrobials Diuretics
Acyclovir (Zovirax) Loops, thiazides
Aminoglycosides Triamterene (Dyrenium)
Amphotericin B (Fungizone; deoxycholic acid 
formulation more so than the lipid formulation) Herbals
Beta lactams (penicillins, cephalosporins) Chinese herbals with aristolochic acid
Foscarnet (Foscavir) Others
Ganciclovir (Cytovene) Allopurinol (Zyloprim)
Pentamidine (Pentam) Gold therapy
Quinolones Haloperidol (Haldol)
Rifampin (Rifadin) Pamidronate (Aredia)
Sulfonamides Phenytoin (Dilantin)
Vancomycin (Vancocin) Quinine (Qualaquin)
Antiretrovirals Zoledronate (Zometa)
Adefovir (Hepsera), cidofovir (Vistide), tenofovir 
(Viread)
Indinavir (Crixivan)
Calcineurin inhibitors
Cyclosporine (Neoral)
Tacrolimus (Prograf)
Source: Modified from Naughton, 2008 [16].
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TA K-924/MLN4924)
Study No. Pevonedistat -1016 Page 127of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALAppendix LHematologic Toxicity of Carboplatin Alone and in Combination With 
Paclitaxel
In 2prospectively rando mized, controlled studies conducted by  the Nati onal Cancer Insti tute of  
Canada Clinical Trials Group and the Southwest Onco logy Group, 789 chemotherapy -naïve 
patients wi th advanced ovarian cancer were treated with carboplat in or cisplat in in combinat ion 
with cycl ophosphamide every  28days for 6 courses before surgical re -evalua tion. See the table 
below for the hematologic adverse experiences of patients treated with carboplatin in co mbinat ion 
with cycl ophosphamide.
Hematologic Adverse Experiences of Patients With Ovarian Cancer Treated With 
Carboplatin in Combination With Cyclop hosphamide
Adverse Experience Laboratory ValueNCIC CTG Study
% Patients
(N=447)SWOG Study
% Patients
(N=342)
Bone marrow
Thrombocytopenia <100,000/mm370 59
<50,000/mm341 22
Neutropenia <2000 cells/mm397 95
<1000 cells/mm381 84
Leukopenia <4000 cells/mm398 97
<2000 cells/mm368 76
Anemia <11 g/dL 91 88
<8 g/dL 18 8
Infections 14 18
Bleeding 10 6
Transfusions 42 25
Source: Carboplatin US Package Insert 2011 [14].
NCIC CTG: National Cancer Institute of Canada Clinical Trials Group; SWOG: Southwest Oncology Group.
In a rando mized clinical study, 798 patients wi th ovarian c ancer were treated with eit her cisplatin 
plus paclitaxel or paclitaxel plus carboplatin therapy  at 3-week intervals for 6 courses. See the 
table bel ow for the hematol ogic adverse experiences of patients treated with 
paclitaxel/carboplat in.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 128of 134
Protocol Incorporating Amend ment 4 27 May 2021
CONFIDENTIALHematologic Toxicities and Associated Supportive Care in Patients With Advanced Ovarian Cancer Stratified by Treatment 
Arm and Toxicity Grade
NCI CTC Grade, % Difference ain the Proportions 
of Patients With Grades 3/4 
Toxicity, % Paclitaxel+Carboplatin Arm Cisplatin+Paclitaxel Arm
Toxicity Set N 0 1 2 3 4 N 0 1 2 3 4 E 95% CI
Hemogl obin C 2209 29.1 49.4 20.1 1.3 0.1 2095 33.6 49.5 16.1 0.8 0.0 -0.6 -1.3 to 0.0
P 388 9.0 40.7 44.3 5.4 0.5 382 14.7 44.2 37.2 3.9 0.0 -2.0 -5.1 to 1.1
Platelets C 2193 71.9 19.9 5.2 2.5 0.5 2082 93.4 6.2 0.2 0.2 0.0 -2.9 -3.6 to -2.1
P 388 43.3 31.2 12.6 10.1 2.8 382 78.3 19.4 1.3 1.0 0.0 -11.8 -15.3 to -8.4
Transfusions pRBCs 
aC 1868 94.3 -- -- 5.7 -- 1766 97.2 -- -- 2.8 -- -2.9 -4.2 to -1.6
P 383 81.7 -- -- 18.3 -- 370 89.5 -- -- 10.5 -- -7.7 -12.7 to -2.8
Leukocytes (WBC) C 2200 37.0 22.6 29.3 10.8 0.3 2073 56.4 23.3 17.3 2.9 0.0 -8.1 -9.6 to -6.6
P 388 13.4 16.0 38.7 30.4 1.5 382 31.4 35.1 32.7 10.5 0.3 -21.2 -26.8 to -15.6
Neutrophils C 1842 56.9 12.9 12.8 12.4 5.0 1864 70.9 10.6 9.8 6.4 2.3 -8.7 -10.8 to -6.5
P 371 31.3 12.9 18.9 21.6 15.4 373 48.0 13.1 16.9 15.0 7.0 -14.9 -21.4 to -8.5
Febrile neutropenia C 2228 98.3 -- -- 1.7 0.0 2110 99.3 -- -- 0.7 0.0 -0.9 -1.6 to -0.3
P 388 92.0 -- -- 8.0 0.0 384 96.4 -- -- 3.6 0.0 -4.3 -7.6 to -1.1
Supportive care: 
antibiotics bC 1868 98.3 -- -- 1.7 -- 1768 97.9 -- -- 2.1 -- 0.4 -0.5 to 1.3
P 383 93.2 -- -- 6.8 -- 370 90.5 -- -- 9.5 -- 2.7 -1.2 to 6.6
Supportive care: 
G-CSF bC 1868 94.0 -- -- 6.0 -- 1767 98.2 -- -- 1.8 -- -4.2 -5.5 to -3.0
P 383 85.6 -- -- 14.4 -- 370 95.4 -- -- 4.6 -- -9.8 -13.9 to -5.7
Source: du Bois, 2003 [24].
The symbol “ --” denotes “not defined.”
C:maximum grade over all courses; G -CSF: granulocyte colony stimulating factor; E: estimate; N: number of courses in set C and number of patients in set P; NCI CTC: National 
Cancer Institute Common Toxicity Criteria; P: maximum grade over all courses within a patient; pRBCs: packed red blood cells; WBC: white blood cell.
aDifferences are calculated by subtracting the paclitaxel+carboplatin arm proportion from the cisplatin+paclitaxel arm proportion; statistically significant differences in proportions 
between the 2 treatment arms are in bold font. All percentages are rounded to 1 decimal place; therefore, the estimates may differ by ±1 from the difference of the percentages of the 
treatment arm columns.
bTransfusion of pRBCs and use of antibiotics and G -CSF were not assessed for the last treatment cycle within a patient. Use of antibiotics and use of G -CSF are graded in the same 
fashion as transfusion of pRBCs. Use of antibiotics/application of G -CSF is coded as a toxicity of Grade 3; a Grade 0 is applied otherwise.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 129of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALAppendix M Excluded Strong CYP3A Inhibitors and Inducers
Use of strong CYP3A inhibitors and inducers listed in the table below should be avo ided during 
pevonedistat therapy  unless otherwi se noted in the protocol.
In Vivo Inhibitors and Inducers of CYP3A
Strong Inhibitors Strong Inducers
Clarithromycin Carbamazepine
Idelalisib Phenytoin
Itraconazole Phenobarbital
Ketoconazole Primidone
Nefazodone Rifabutin
Posaconazole Rifampin
Telithromy cin Rifapentine
Voriconazole St. Jo hn’s wort
CYP: cytochrome P450.
Strong CYP3A inhibitors and inducers should only be excluded during the Part A and Cycle 1 of Part B of the study 
where the pevonedistat pharmacokinetic measurements are conducted.
This is not an exhaustive list; refer to the following source: 
https://www.fda.gov/drugs/drug -interactions -labeling/drug-development -and-drug-interactions -table -substrates -inhi
bitors -and-inducers.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 130of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALAppendix NProtocol History
Amendment History:
Date Amendment No. Amendment Type Region
27 May  2021 4 Substantial Global
04 November 2020 3 Substantial Global
29 June 2020 2 Substantial Global
25 February 2019 1 Substantial Global
07 November 2018 Initial protocol Not applicable Global
Rationale for Amendment 3
This document describes the changes in reference to the protocol incorporating Amendment 3 The 
primary  reason for this amendment is to incorporate changes requested by glo bal health authorities. 
Inaddition, this amendment permit s alternative clinical site monitoring approaches, if needed, and 
where allowed by the local healt h authorit y, privacy laws, and permitted by the inst itutional review 
board/ethi cs co mmittee (IRB/IEC). These changes to altern ative monitoring procedures are 
intended to minimize the impact of the coronavirus disease- 2019 (COVID -19) pandemic while 
ensuring data qualit y and integrit y.
In thi s amendment, minor grammat ical, editorial, formatting, and administrative changes not 
affec ting the conduct of the study  are included for clarification and administrative purposes only.
Protocol Amendment 3
Summary of Changes Since the Last Version of the Approved Protocol
Description of Each Change and Rationale Sections Affected by Change
Description Rationale Location
1.Add use of strong cytochrome 
P450 (CYP)3A inducers within 
14 days of baseline to the list of 
exclusion criteria.
2.Add stro ng CYP3A inducers 
and inhibitors to the list of 
excluded concomitant 
medications.Although strong CYP3A inhibito rs 
and inducers did not have clinically 
meaningful impact on pevonedistat 
systemic exposures based on results 
from Studies C15011 and 
Pevonedistat -1015, strong CYP3A 
inhibito rs and inducers remain 
prohibited in this study in order to 
interpret the effects of organ 
impairment on pevonedistat PK 
without potential confounding 
factors.
Change made in response to 
protocol review by global health 
autho rities.Section 2.0STUDY SUMMARY
Section 4.1.3.1 Clinical 
Pharmacokinetics
Section 4.1.5 Potential for DDIs
Section 7.2Exclusion Criteria
Section 8.4Excluded Concomitant 
Medications and Procedures , 
including Table 8.fConcomitant 
Medications Excluded While 
Receiving Study Treatment: 
Combination Pevonedistat Plus 
SOC agents
Appendix MExcluded Strong 
CYP3A Inhibitors and Inducers
3.Provide alternative clinical site 
monitoring approaches due to 
the COVID -19 pandemic.To ensure data quality and integrity 
and maintain patient safety during 
the COVID -19 pandemic.Section 14.1 Study Site Monitoring 
Visits
Appendi x ASOE Table B 
Footnotes
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 131of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALProtocol Amendment 3
Summary of Changes Since the Last Version of the Approved Protocol
Description of Each Change and Rationale Sections Affected by Change
Description Rationale Location
4.Revised the timeframe of 
contraception (and donation of 
eggs) in women of childbearing 
potential from 4 months to 
6months.Change made in response to 
protocol review by global health 
autho rities.Section 2.0STUDY SUMMARY
Sectio n7.1Inclusion Criteria
Section 7.2Exclusion Criteria
Section 8.6Precautions and 
Restrictions
5.Added patients with previously 
untreated hematologic 
malignancies not suitable for 
inductio n therapy  to inclusion 
criteria.Clarified to make Inclusion Criteria 
section consistent with Overview of 
Study Design section.Section 2.0STUDY SUMMARY
Section 7.1Inclusion Criteria
6.Updated azacitidine dosing to 
permit subcutaneous (SC) or 
intravenous (IV) dosing during 
Cycle2 and beyond in Part B.
7.Updated aza citidine dosing 
schedule to permit dosing on 
Days 1 through 7 or Days 1 
through 5, 8, and 9 in 28 -day 
cycles in Part B.Clarified that azacitidine 
administration by SC and IV routes 
is permissible as per the United 
States Prescribing Information 
(USPI) and Summary of Product 
Characteristics (SmPC) and has 
been studied in Study C15009.Section 2.0STUDY SUMMARY
Section 6.1Overview of Study 
Design
Section 8.1Study Drug 
Administration
Section 8.1.1 Instructions for 
Pevonedistat and Azacitidine 
Dosing
Section 9.3Treatment Group 
Assignments
Appendix ASOE Table A 
Footnote l
Appendix ASOE Table B 
Footnote a
Appendix BStudy Diagrams
8.Updated eligibility criterion to 
emphasize the role of patient ’s 
legally  acceptable 
representative for voluntary 
written consent.Clarified potential role of the 
patient ’s legally acceptable 
representative for consistency with 
existing language in 
Section 15.2 Subject Information, 
Informed Consent, and Subject 
Authorization.Section 2.0STUDY SUMMARY
Section 7.1Inclusion Cr iteria , #9
Section 9.4.1 Informed Consent
9.Updated protocol amendment 
history  sections .Change made to reflect the current 
format being used by the sponsor.Section 1.3Protocol Amendment 3 
Summary of Changes
Appendix NProtocol Histor y
RATIONALE FOR AMENDMENT 2
The primary reasons for Amendment 2 were to include patients with moderate hepatic impairment 
in the study  and to all ow enrollment of pat ients with advanced so lid tumors with severe renal 
impairment or mild or moderate hepat ic impairme nt. These changes expanded participat ion in the 
organ impairment arms o f the study  without com promising the safet y of the study  parti cipants or 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 132of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALthe primary objectives o f the study. For patients with so lid tumors to be enro lled in this study, the y 
must have had hist ologi cally or cy tologically confirm ed m etastati c or l ocally  advanced solid 
tumor(s), appropriate for treatment with one of the 2 combinat ion therapies in Part B (docetaxel or 
carbopl atin/paclitaxel), that had progressed despite standard therapy. Patients w ith solid tumors 
for who m convent ional therapy was not considered effect ive were also eligible for enro llment. As 
patients wi th combined abnorm alities of transaminases and alkaline phosphatase should not be 
treated with docetaxel [20], it was to only  be administered to patients in the severe renal 
impairment arm.
Other modificat ions to the study  design incl uded r emoving the determinat ion of the maximum 
tolerated dose (MTD) and recommended phase 2 dose (RP2D) of pevonedistat in co mbinat ion 
with azaci tidine in pat ients with organ impairment in Part A and adding assessment of the 
pharmacokinet ics (PK) and safet y of pevonedistat in combinat ion with azacit idine in these specific 
patient popul ations in Part B. In addit ion, an evaluation of the safet y of pevonedistat in 
combinat ion with car boplatin plus paclitaxel in pat ients with mild or moderate hepatic impairment, 
or in combination wit h carboplat in plus paclitaxel or with docetaxel in pat ients with severe renal 
impairment, was to be performed in Part B of the study .
Minor grammat ical, editorial, formatting, and administrative changes not affect ing the conduct of 
the stu dy were included for clarificat ion and administrative purposes only
.
Changes in Amendment 2
1.Include patients with advanced solid tumors in the single -dose pevonedistat PK assessment in 
Part A and, if eligible, continue treatment with pevonedistat in combin ation with standard of 
care (SOC) chemotherapy  (docetaxel  or carbopl atin plus paclit axel) in Part B.
2.Include patients with moderate hepatic impairment in the assessment of pevonedistat PK in 
patients wi th organ im pairment.
3.Remove dose escal ation phase and determinat ion of MTD/RP2D for pevonedistat in 
combinat ion with azaci tidine in pat ients with hematol ogic malignancies ( myelodysplast ic 
syndro mes [MDS], chronic myelo monocy tic leukemia [ CMML], and acute myelogenous 
leukemia) fro m Part A.
4.Add secondary  object ives to assess the PK of pevonedistat and azacit idine in co mbinat ion 
treatm ent in patients with hematologic malignancies/organ impairment and to assess the PK of 
pevonedistat in pat ients with advanced solid tumors/organ impairment receiving combinat ion 
treatment with SOC agents.
5.Revise starting dose, maximum dose, and intrapatient dose escalat ion rules for each of the 
organ impairment arms in the study .
6.Add dose m odificat ion guidelines for patients with advanced so lid tumors treated with 
pevonedistat in combination wit h SOC agents.
7.Revise guidelines for pevonedistat dose adjust ment based on serum transaminases, total 
bilirubin, and other toxicit ies.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 133of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIAL8.Add guidance for management of cy topenia and infect ion for pati ents wi th hematol ogic 
malignancies and for u se of granulocyte -colony stimulat ing factor in pat ients with advanced 
solid tumors.
9.Add inclusio n and exclusio n criteria for pati ents wi th advanced so lid tumors.
10.Revise laboratory  values requi red for enrollment to incl ude pati ents wi th moderate hepati c 
impairment.
11.Add inclusio n criterion to indicate that all pat ients should have an expected survival o f at least 
3months from  the date of enrollment in the study .
12.Clarify  that medical  history  and di agnosis -related inclusion criteria for patients with 
hematol ogic malignancies must be met at study entry .
13.Add exclusio n criterion for pati ents di agnosed or treated for a different malignancy wit hin 
2years before enrollme nt or previously  diagnosed wi th a different m alignancy  with any 
current evidence of residual disease (excluding prior MDS or CMML).
14.Add exclusio n criterion for pati ents wi th end-stage renal disease requiring hemodialysis.
15.Add exclusio n criterion for pati ents wi th Gilbert syndrom e.
16.Remove use of strong cy tochrom e P450 (CYP)3A inducers wit hin 14 days of baseline fro m 
list of exclusio n criteria and rem ove strong CYP3A inducers and known breast cancer 
resistance protein inhibitors fro m the list of excluded conc omitant medications.
17.Clarify  and add exclusio n criteria for patients wi th cardi ovascular condi tions.
18.Update the number of patients to be enrolled in the study and increase the number of study sites 
to approximately 25 to 30 sites.
19.Update vi al volume and di lution instructions for pevonedistat to include a vial vo lume of 
4.4mL and a diluent of 0.9% saline so lution.
20.Increase study  durati on to 3.5 years.
21.Clarify  timing for collect ion of plasma samples for measuring pevonedistat protein binding.
22.Specify  that ad verse events should be monitored unt il they are resolved or are clearly 
determined to be due to a patient’s stable or chronic condit ion or intercurrent illness(es).
23.Specify  that nonessent ial protocol  visits that do not require on -site sample collecti on and
assessment m ay be com pleted via tel emedicine.
RATIONALE FOR AMENDMENT 1
The primary  reason for Amendment 1 was to remove eligibilit y criteria relevant to the absolute 
neutrophil count (ANC), platelets, and hemoglo bin to be consistent with other studies in the 
pevonedistat program. Patients with hematologic malignancy ( acute myelo id leukemia [ AML] and 
myelodysplast ic syndromes [MDS]) suffer fro m cytopenia and/or anemia related to their 
underlying illness, particularly in a relapse/refractory  setti ng. The sp onsor had also considered 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Pevonedistat (TAK -924/MLN4924)
Study No. Pevonedistat -1016 Page 134of 134
Protocol Incorporating Amendment 4 27 May 2021
CONFIDENTIALfeedback fro m the study  invest igators indicat ing that certain eligibilit y criteria may represent 
major hurdles for enrolling pat ients with underlying hematol ogic di sease (AML and MDS) in 
urgent need of treatment. Therefore, change s were made to the original protocol to modify  these 
restri ctions without compromising patient safet y and to make further clarificat ions regarding study 
execution. Sections relat ing to the definit ion of dose -limiting toxicit ies (DLTs) and dose 
modificati onguidelines were also revised to correlate with the aforement ioned changes.
Minor grammat ical, editorial, formatting, and administrative changes not affect ing the conduct of 
the study  are included for clarificat ion and administrative purposes only.
Changes in Amendment 1
1.Correct the study  title to rem ove “relapsed/refractory ” (also rem ove wording elsewhere in the 
protocol  as appropri ate to the study ) and clarify  study  phase as 1/1b.
2.Delete requi rements for ANC ≥1000/mm3, platelet count ≥75,000/mm3, and hem oglobin 
≥8g/dL fro m the inclusion criteria.
3.Delete Grade 4 neutropenia and Grade 4 thrombocy topenia from  DLTs for hematologic 
toxicity.
4.Revise dose modificat ions.
5.Revise the table of Conco mitant Medi cations and Procedures Permitted During the Study .
6.Clarify  treatm ent group assignments by adding the laboratory  value requi rements per 
treatm ent arm .
7.Correct header in laboratory  table by adding “Complete” to Serum Chemistry .
8.Correct header in laboratory  table from  “Select Serum  Chemistry ” to “Coagulation Panel .”
9.Clarify  the assessment of hepat ic and renal funct ion prior to enrollment.
10.Increase the number of study  sites to support pati ent enrollment.
11.Update footn otes in Schedule of Events tables for clarification.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
 
 
 
ELECTRONIC SIGNATURES  
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 
 
 
 
 
090101d6810bb995Amendment 4 to A Phase 1/1b Study of Pevonedistat in Combination With Select Standard of Care Agents in
Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myelogenous
Leukemia, or Advanced Solid Tumors With Severe Renal Impairment or Mild or Moderate Hepatic Impairment
Clinical Science Approval 01-Jun-2021 15:31 UTC
Clinical Pharmacology Approval 01-Jun-2021 16:23 UTC
Clinical Science Approval 01-Jun-2021 16:26 UTC
Biostatistics Approval 01-Jun-2021 16:43 UTC
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use